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Biological systems show a high level of  complexity.
For years single-target drugs have been successful and many pathologies have been 
considered cured and eradicated. As a matter of fact, the biological complex 
ecosystem was using the single-target chemical drugs information to evolve and 
find its own shortcuts. 
This is the case of antibiotic resistance. Planktonic bacteria evolve generating 
biofilm communities that are able to gambol antibiotic aggression and possibly 
evade the host immune system mechanisms. 
Synergistic solutions are needed to reactivate a virtuous balance in host’s favor: 
these solutions must be able to cooperate and eventually boost the host immune 
system, which has a naturally-embedded synergistic modus operandi; they must 
produce a reduced number of inconvenient metabolites, and they should exert a 
multifunctional activity.
Antimicrobial peptides seem to convey the features required as they deploy a 
multifunctional antimicrobial set of measures, complying with the host immune 
system and offering regenerative effects on tissues.
On the other end, ozone has been investigated for its bactericidal capacity and for 
its potential to reactivate depressed immune systems.
As this experimental study accounts for, the administration to bovine mastitis of a 
blending of platelet concentrate, rich in antimicrobial peptides, with oxygen/ozone 
mix in oil vehicle suggests the importance of further investigation and evidence of 








The aim of this study was to evaluate the potential of some treatments that are 
typically used in regenerative medicine and apply them to some veterinary relevant 
states.
Both stem cells and platelet concentrate were investigated.
As for the first, an application to horse injuries led to the paper reported in Chapter 
9.
The second was administered to bovine mastitis and its enhancement with 
ozonated oil showed very interesting results.
Chapters 3 to 8 report the fascinating research of a new viable interpretation of 
bovine mastitis, in relation to antibiotic resistance, and, hopefully, a new type of 
effective treatment seems to be discovered.
Due to the complexity of the problem and to the many variables involved, these 
results express a hint for further experimental trials.
Chapter 3 outlines the strict relation between tissue damage and mastitis worsening, 
the demonstrated dependence between antibiotic resistance and the malicious 
presence of bacterial biofilm, the regenerating and antimicrobial activity of platelet 
concentrate and the beneficial properties of  ozone and ozonated oil.
Chapters 4 and 5 describe the experimental trials, which took place between 
December 2011 and May 2014.
Chapter 6 discusses the most recent scientific evidence trying to find a significance 
for the collected results.
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3. State of  the Art
3.1 Mastitis
Mastitis has a complex aethiology and is the most costly disease in dairy cattle.
Decreased milk production, loss of lactating cows or quarters, spreading of 
microbial agents throughout the livestock and consequent proliferation of the 
disease are the main problems related to the phenomenon.
Mastitis is defined as an inflammatory reaction of the mammary gland that is 
usually caused by a microbial infection (Zhao, 2008). It is reported that mammary 
tissue damage reduces the number and activity of epithelial cells and consequently 
contributes to decreased milk production (Zhao, 2008).
Mastitis usually occurs primarily in response to intramammary bacterial infection, 
but also to intramammary mycoplasmal, fungal, or algal infections. Mechanical 
trauma, thermal trauma, and chemical insult predispose the gland to intramammary 
infection. Occurrence of mastitis depends on the interaction of host, agent, and 
environmental factors and, once occurred, worsening of microbial aggression, 
arising of mammary tissue damage and decreasing milk production set up a 
negative loop, hard to reverse. 
For this reason, early diagnosis and fast effectiveness of therapy are fundamental to 
control losses.
Bovine mammary glands are exposed to diverse bacteria throughout lactation and 
in non-lactating periods. Pathogens commonly isolated from mastitic milk can be 
classified as noncontagious (most are environmental) and contagious 
microorganisms. The former include Streptococcus uberis, Streptococcus 
dysgalactiae, Escherichia coli, and coagulase-negative staphylococcus species, 
whereas the latter include Staphylococcus aureus and Streptococcus agalactiae. The 
teat and streak canal are the first line of defense of the mammary gland. The 
keratin lining in the streak canal provides a physical and chemical barrier against 
bacterial penetration (Capuco, 1992). Bacteria may escape the natural defense 
mechanisms by multiplication along the streak canal (especially after milking), or by 
propulsion into the teat cistern by vacuum fluctuations at the teat end during 
milking. The infection occurs after bacteria gain entrance to the mammary gland 
via the teat canal. After bacteria overcome the anatomical defense, they must evade 
the cellular and humoral defense mechanisms of the mammary gland to establish 
disease (Sordillo, 2002). If the infection is not eliminated, bacterial levels in the 
mammary gland eventually rise to a level at which they begin to damage the 
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mammary epithelium. As infection persists, the number of somatic cells in milk 
continues to increase and, concomitantly, tissue damage is worsened. The alveoli in 
the gland start to lose structural integrity and the blood-milk barrier is breached. 
This allows extracellular fluid to enter the gland and mix with the milk. Visible 
changes in the milk and the udder start to occur. These can include external 
swelling, reddening of the gland, and clotting and wateriness of the milk. By 
definition, this is the start of  clinical symptoms (Zhao, 2008).
In brief, bovine mammary epithelial cells can be damaged during mammary 
inflammation by:
1) release of a range of cellular and extracellular products from bacterial 
pathogens; 
2) lysosomal enzymes and oxidative products released from phagocytes during 
phagocytosis of  invading organisms, and 
3) proteases from blood and cytokines released during the immune response.
Particular attention must be paid to tissue damage, which occurs through two 
distinct types of cell death, apoptosis and necrosis: these may be distinguished by 
morphological, biochemical, and molecular changes in dying cells and are both 
reported in association to the presence of microorganisms, such as E. coli and S. 
aureus (Zhao, 2008).
In very severe cases of Escherichia coli inflammation, the infection progressed via 
the ductile system to produce a limited inflammatory reaction but with an extensive 
involvement of the secretory tissue. In its most severe form with uncontrolled 
bacterial multiplication, all lactiferous sinus epithelia were lost, interstitial tissue 
became hemorrhagic, and often the animal died of toxemia within a few hours of 
infection (Zhao, 2008).
On the other hand, it is also reported that Staph. aureus. exhibited less milk 
synthesis and secretion, due to necrosis of the secretory tissues, as evidenced by 
more interalveolar stroma and involuting alveolar epithelium and less alveolar 
luminal space compared with uninfected contralateral controls. Moreover, these 
changes were associated with replacement of secretory tissue with non-secretory 
tissue (Zhao, 2008). 
3.1.1. Involvement of  neutrophils in tissue damage 
Following detection of pathogen invasion into the mammary gland, macrophages 
and epithelial cells release chemoattractants. These agents trigger the migration of 
leukocytes, mainly PMN, from the blood toward the mammary gland and increase 
their proportions from a basal level of 5 to 25% to approximately 90% of total 
cells in the milk. These PMN are considered as the second line of defense of the 
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mammary gland. The presence of functional PMN is crucial to the host defense 
against bacterial pathogens (Zhao, 2008).
The main functions of PMN are to engulf pathogens and destroy them via 
oxygen-dependent and oxygen-independent systems. At the same time, PMN can 
potentially harm the mammary gland. The exact mechanism by which PMN 
damage bovine epithelial cells during mastitis is still not fully understood. 
Neutrophils may promote tissue injury and disturb mammary function, via reactive 
oxygen metabolite generation (i.e., the respiratory burst) and granular enzyme 
release (i.e., degranulation) (Zhao, 2008).
3.1.2. Involvement of  bacteria in tissue damage
There is increasing evidence that pathogens use various mechanisms to impinge 
upon cell death pathways. A number of pathogens are armed with an array of 
virulence determinants, which interact with key components of a host cell’s death 
pathways or interfere with regulation of transcription factors monitoring cell 
survival. These virulence factors induce cell death by a variety of mechanisms, 
which include:
1) pore-forming toxins, which interact with the host cell membrane and permit the 
leakage of  cellular components; 
2) toxins that express their enzymatic activity in the host cytosol; 
3) effector proteins delivered directly into host cells by a highly specialized type-III 
secretory system; 
4) super-antigens that target immune cells, and
5) other modulators of host cell death. Much progress has been made in 
understanding the role of apoptosis and necrosis in response to bacterial 
infection (Zhao, 2008).
3.1.3. Involvement of  plasma proteins and cytokines in tissue damage
At the onset of mastitis, increased permeability of the blood-milk mammary 
epithelial barrier leads first to an influx of serum constituents, such as plasminogen 
and numerous other enzymes, and second to a massive recruitment of somatic 
cells, in particular, PMN. Milk contains two proteinase systems derived from blood, 
one of which is involved in dissolving blood clots (i.e., plasmin) and the other in 
defense against invasive microorganisms (i.e., lysosomal proteinases of somatic 
cells). Whereas plasmin is the principal proteinase in good-quality milk, other 
proteinases, including cathepsins and elastase, are probably also active, particularly 
as the somatic cell count of milk increases. This is supported by the observation 
that the protease activities of plasmin and mastitic milk differ. In addition, 
mammary epithelial cells also express certain matrix metalloproteasen and serine 
proteases, which are involved in the activation of plasminogen to plasmin. How 
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much plasmin contributes to tissue damage during mastitis is debatable. Mammary 
epithelial cell viability depends on attachment to the extra cellular matrix, so it is 
reasonable to postulate that extra cellular matrix degradation is involved in tissue 
damage and cell death during mastitis (Zhao, 2008).
Very little work has been conducted to determine the role of cytokines in the 
regulation of tissue damage during mastitis. Cytokines recruit PMN that function 
as phagocytes at the site of infection and sometimes induce apoptosis in a variety 
of cell types, including bovine endothelial cells and human mammary epithelial 
cells. Levels of these cytokines increase during E. coli mastitis, and it is tempting to 
assume that they also induce apoptosis in bovine mammary epithelial cells. A range 
of cytokines are also known to promote a wide variety of functions of PMN, 
including adhesion, surface receptor expression, free radical production, and release 
of lysosomal constituents. Therefore, the effects of cytokines on tissue damage are 
more likely to be mediated through recruitment and activation of PMN (Zhao, 
2008).
3.1.4. Protective role of  cathelicidins in mammary tissue (Whelehan, 2014) 
Recently, it is also shown that constitutive cathelicidin expression in the mammary 
gland suggests a possible role for these host defence peptides its protection.
Cathelicidins comprise a major group of host-defence peptides. Conserved across a 
wide range of species, they have several functions related to host defence. Only one 
cathelicidin has been found in humans but several cathelicidin genes occur in the 
bovine genome. It has been proposed that these molecules may have a protective 
role against mastitis. The study characterized the cathelicidin gene-cluster in the 
bovine genome and identified sites of  expression in the bovine mammary gland.
Results showed that the seven known protein-coding cathelicidin genes are 
constitutively expressed in a broad range of tissue types, including the mammary 
gland. Cathelicidin proteins are a major component of the neutrophil secondary 
granule and increased levels of these proteins are observed in a range of 
inflammatory conditions. Extensive neutrophil recruitment from the circulation to 
the lumen of the mammary gland is a hallmark of the early immune response to 
mammary infection.
The study also suggested that other cells in addition to immune cells are capable of 
secreting these potent immunomodulatory molecules. Cathelicidins are 
constitutively expressed in the healthy mammary gland, while transcripts of several 
other protein-coding genes can be detected in leukocytes extracted from the milk 
of  animals with a high somatic cell count.
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3.2 Antibiotic resistance
During the last decades infections have lowered their sensibility to antibiotics.
Antimicrobial agents that are effective in vitro have failed or have been less 
powerful at the same concentration when used in vivo (Melchior, 2006-2). Actually, 
this difference of efficacy is related to planktonic bacteria versus sessile ones: in 
vitro studies regarding sessile communities of bacteria, attached to a surface and 
organized in their slurry matrix to form biofilm, have shown a loss of sensitivity to 
virtually all classes of  antibiotics (Melchior, 2006-1).
For this reason, the lack of efficacy of antibiotics in killing pathogens, commonly 
called antibiotic resistance, is considered caused by bacterial biofilm (Melchior, 
2006-1).
In addition, biofilm-associated bacteria shows an innate resistance not only to 
antibiotics and disinfectants but also to clearance by host defense mechanisms 
(Melchior, 2006-1).
An understanding of biofilm architecture and chemistry is needed to assess a valid 
eradication strategy.
3.2.1. Biofilm
The current definition of a bacterial biofilm is a well organized population of 
bacterial cells enclosed in a self-produced polymeric matrix and adherent to an inert 
or living surface (Costerton, 1999).
In most natural environments, microorganisms try to adhere to available surfaces. 
Hence, the free-swimming (or planktonic) phase can be viewed as a mechanism of 
dispersal from one surface to another (Melchior, 2006-1). 
Biofilm formation process can be described in three basic stages.
During phase 1, there is attachment of cells to a surface. The exopolysaccharides 
slime produced by cells in this initial phase is effective in facilitate clumping: the 
presence of adhesins, which are products of various genes by the living surface, 
actually promotes the adhesion of the first group of bacterial cells (Mack, 1999; 
Melchior, 2006-1). In addition, the presence of proteins such as fibronectin and 
fibrinogen speeds up the process (Melchior, 2006-1).
During phase 2, cell multiplication and formation of a mature structure consisting 
of many layers of cells, connected to each by extracellular hydrated 
polysaccharides, occur. This slime layers creates on the external surface a diffusion 
barrier that further protect the biofilm bacteria (Melchior, 2006-1).
In a final third phase, there is detachment and dispersal of planktonic bacteria from 
biofilm. These new bacteria are now free to find new surfaces to colonize and set 
up new populations.
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In particular this matrix seems able to protect bacteria both from components of 
the host immune system and from antibiotic aggression, enhancing the bacteria 
survival rate.
The mechanisms involved in bacterial survival to both host immune system and 
antimicrobial agents are commonly synthesized in three ways (Melchior, 2006-1; 
Lewis, 2001):
- delayed and/or restricted penetration of the antimicrobial agents and of 
components of  the host immune system through the biofilm matrix,
- reduced growth rate of  biofilm organisms,
- physiological changes into the biofilm and expression of possible biofilm-specific 
resistance genes.
2.1. Biofilm formation and maturation
In most natural environments, microorganisms try to
adhere to available surfaces. Hence, the free-swimming
(or planktonic) phase can be viewed as a mechanism
of dispersal from one surface to another. Following ini-
tial attachment of cells to a surface, surface motility and
binary division result in an aggregation of attached cells
(Stoodley et al., 2002). These primary cell aggregates
produce exopolysaccharides to facilitate clumping.
Thus, the initial phase of biofilm formation involves
two stages: the first stage comprises attachment of cells
to a surface, facilitated by cell wall associated adhesins,
which are products of various genes (Mack, 1999).
Attachment to native polymeric surfaces is increased
in the presence of matrix proteins including fibronectin,
and fibrinogen, whereas laminin showed no effect.
The second stage is characterized by cell multiplica-
tio and formation of a ature structure consisting of
many layers of cells, connected to each by extracellular
polysaccharides (Yarwood and Schlievert, 2003). Finally,
in the process of maturation, many staphylococci gener-
ate a glycocalyx, a slime layer that further protects the
biofilm bacteria. The chemical nature of these slime
layers is still not entirely elucidated, but evidence suggests
that it consists predominantly of hydrated
polysaccharides.
The growth potential of any bacterial biofilm is lim-
ited by the availability of nutrients to the cells within
the biofilm and distinct flow-through channels across
the biofilm aim to maintain perfusion (Stoodley et al.,
2002). Other factors that are known to control biofilm
maturation include internal pH, oxygen perfusion, car-
bon source and osmolarity (Dunne, 2002). When the
biofilm reaches a critical mass, a dynamic equilibrium
is reached at which the outermost cell layer begins to
generate planktonic organisms (Fig. 1). These bacteria
are free to escape the biofilm and to colonize other sur-
faces (Dunne, 2002).
2.2. Phenotypic and genotypic basis for biofilms produced
by staphylococci
Staphylococci colonies are know to show a typical
slime production, but until 1996 reports on the chemical
composition of this slime were conflicting. In that year,
Mack et al. (1996) reported that they had been able to
purify two distinct polysaccharide fractions from this
slime layer. Polysaccharide I (>80%) was shown to be
a linear homoglycan of at least 130 residues of b-1,6-
linked N-acetylglucosamine. Polysaccharide II (<20%)
had a lower content of non-N-acetylated D-glucosaminyl
residues and contained phosphate and ester-linked suc-
cinate. Polysaccharide I was found to be positively
charged, whereas polysaccharide II was anionic. The
structure of polysaccharide II appeared unique and
was denoted polysaccharide intercellular adhesin
(PIA), referring to its function in cell cluster formation.
These initial observations were made with biofilm-pro-
ducing S. epidermidis strains, but later PIA-related sub-
stances were described for many other staphylococci,
incl ding S. aureus (McKenney et al., 1999). It is nota-
ble that intact biofilms consist not only of PIA and var-
ious other components such as teichoic acid, the
staphylococcal sur ace protein (SSP-I), clumping factor
A (ClfA), accumulation associated protein (AAP) and
Fig. 1. Biofilm formation and maturation: attachment of planktonic bacteria, cellular aggregation, clumping and exopolysaccharide slime
production, mature biofilm with detachment of planktonic cells.
400 M.B. Melchior et al. / The Veterinary Journal 171 (2006) 398–407
Figure 3.2.1 Biofilm formation and maturation: attachment of planktonic bacteria, cellular 
aggregation, clumping and exopolysaccharide slime production, mature biofilm with detachment 
of  planktonic cells (Melchior, 2006-1).
Limited penetration
The biofilm matrix acts as a diffusion barrier that protects the external surface of 
the biofilm: it regulates the crossing of different substances through it and it is able 
to bind antimicrobials (Lewis, 2001). The barrier effect is competent to avoid the 
intrusion of large molecules, like antimicrobial proteins lysozyme and complement, 
as well as smaller antimicrobial peptides, like defensins and their analogs (Lewis, 
2001).
As for large positively charged antibiotics molecules, these are possibly neutralized 
or bound by the negatively charged exopolysaccharide protecting cells (Lewis, 2001) 
and are effectively ‘diluted’ to sublethal concentrations before they can reach all of 
the individual bacterial cells within the biofilm (Hall-Stoodley, 2004). The barrier 
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properties of the exopolysaccharide hydrogel might also protect against UV light 
and dehydration, and might localize enzymatic activity (Hall-Stoodley, 2004).
The penetration rate varies depending on the type of aggression. In most cases 
involving small antimicrobial molecules, the barrier of the polysaccharide matrix 
operates a delayed penetration, postponing the killing effect of antimicrobials on 
bacteria rather than provide full immunity (Lewis, 2001). 
In the meanwhile, within the biofilm, bacteria can operate an antimicrobial 
degradation, taking advantage of low concentration of antimicrobials that 
infiltrated the biofilm. Biofilm showed a synergistic effect between retarded 
diffusion and enzyme degradation. From this perspective an analogy between the 
single bacteria with its own outer membrane versus the biofilm community with 
the slime protection has been outlined (Lewis, 2001).
Decreased growth rate
Many antibiotics require at least some degree of cellular activity to produce their 
effect. In fact the mechanism of action of most antibiotics involves disruption of a 
microbial process (Hall-Stoodley, 2004).  
Within a biofilm, bacteria grow at different rates and some of them are present in a 
starving mode. This fact enhances the survival rate of the population, both 
modulating the nutrients intake and availability within the matrix (Costerton, 1999) 
and binding their existence to antimicrobials (Lewis, 2001). 
For instance, oxygen limitation is thought to contribute to the antibiotic resistance 
of biofilms since the efficacy of some antibiotics is reduced in its absence: in fact 
reduced oxygen levels may cause physiological and phenotypic changes that caused 
increased biofilm resistance to antibiotics (Clutterbuck, 2007).
Gene expression 
Biofilms are described as bacteria microcolonies attached on a surface, well 
developed in organized communities with functional heterogeneicity, specifically 
aimed to survive in a hostile environment (Costerton, 1999). 
Studies show how biofilms display significant convergent survival strategies, which 
mainly come from structural specialization. These attributes about specialization 
within the biofilm and biofilm development tactics seem to be conserved among an 
wide range of  prokaryotes (Hall-Stoodley, 2004).
Many authors report that biofilm formation is accompanied by notable genetic and 
physiological variations in the microorganisms (Melchior, 2006-1).
Within the biofilm, cells in different regions display a different gene expression 
(Costerton, 1999). Genetics can be considered as a survival biofilm active response, 
while adaptation to environmental condition is commonly appraised as passive 
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response (Hall-Stoodley, 2004). It has been proposed that the open water channels 
or voids that surround the structures within biofilms may act as pools of genes 
allowing for genetic acquisition and exchange by horizontal transfer (Wuertz, 2004; 
Clutterbuck, 2007).
The ultimate aim of biofilm active gene reaction seems to ensure survival to a 
subpopulations of  resistant phenotypes within the colony (Hall-Stoodley, 2004). 
This type of gene regulation has been termed quorum sensing and response and it 
is responsible to facilitate the cell-to-cell signaling required for biofilm 
development. These quorum sensing molecules differ between bacteria, with most 
Gram-negative organisms utilizing acylhomoserine lactones, and most Gram-
positive organisms using secreted peptides. The coordination of behavior that is 
facilitated by quorum sensing is thought to play an important role in the 
pathogenicity of certain organisms by regulating the expression of virulence 
determinants so that high cell densities of bacteria are reached before these 
determinants are expressed, thereby increasing the likelihood of a successful attack 
on the hosts defenses (Clutterbuck, 2007).
In addition, quorum sensing is also thought to be involved in determining biofilm 
thickness, being then an actual regulator of biofilm formation and maturation. In 
staphylococci, QS is established by the accessory gene regulator (Agr) system, 
which produces a secreted, post-translationally modified peptide that interacts with 
a two-component system in an auto feedback loop, ultimately resulting in a 
considerable shift in gene expression patterns during early stationary growth phase. 
In general, Agr up-regulates toxins and other acute virulence factors and down-
regulates surface proteins such as MSCRAMMs. Recent reports provided important 
insight into the QS-controlled factors that structure biofilms and cause detachment 
(Joo, 2012).
This small fraction of persister cells seems basically responsible for the very high 
level of resistance of the biofilm to killing (Lewis, 2001). The majority of bacteria 
within the biofilm is not necessarily resistant to antibiotics. However growth related 
antibiotics aggression forces part of biofilm bacteria to perform a slow growth 
rate. This way persisters survive and are indeed preserved by the presence of an 
antibiotic that inhibits their growth. Paradoxically, the antibiotic helps persisters 
persevere (Lewis, 2001).
Persisters could represent cells with disabled the programmed cells death process, a 
safety mechanism producing cells that will survive if an antibiotic reaches the entire 
population. Similarly, cells would need to discriminate between an unrepairable 
defect and starvation. Development of tolerance to antibiotics in starved cells 
might result from inhibition of the programmed cells death process, and might be 
aimed at preventing suicide when nutrients are limiting (Lewis, 2001).
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A New Era in Biofilm Research:
Molecular Genetic Dissection of
Biofilm Development
Research in this decade has begun to reveal
information about the molecular and genetic
basis of biofilm development. Biofilms in-
volving several different bacterial species
have been studied (6) but perhaps none more
intensively than biofilms of Pseudomonas
aeruginosa. Here, we use P. aeruginosa and
the chronic lung infections it causes in most
patients afflicted with the recessive genetic
disease cystic fibrosis (CF) as a model that
exemplifies modern research on biofilm in-
fections. Like other biofilms, P. aeruginosa-
biofilms are developed communities with in-
dividual bacterial cells embedded in an extra-
cellular polysaccharide matrix (22) and are
inherently resistant to antimicrobial treat-
ment. The pattern of development involves
initial attachment to a solid surface, the for-
mation of microcolonies on the surface, and
finally differentiation of microcolonies into
exopolysaccharide-encased, mature biofilms.
Initial attachment and microcolony forma-
tion. A recent report by O’Toole and Kolter
(23) describes a microtiter dish screen for the
isolation of P. aeruginosa mutants defective in
the initial steps of biofilm formation. Two gen-
eral classes of mutants, called sad (surface at-
tachment defective) mutants, were described.
One class constitutes flagella and motility mu-
tants and does not adhere well to the plastic
surface used. The other class consists of mu-
tants defective in the biogenesis of hair-like
appendages, Type IV pili. Whereas the wild-
type cells cluster into microcolonies (relatively
small groups of bacteria) on the plastic, the
pilus biogenesis mutants form a monolayer of
cells on the surface but are unable to form
microcolonies. Type IV pili in P. aeruginosa
are involved in a type of surface-associated
motility called twitching, and this twitching
might be required for the aggregation of cells
into microcolonies.
There is evidence that during this attach-
ment phase of biofilm development, perhaps
after microcolony formation, the transcription
of specific genes is activated. In particular,
studies with P. aeruginosa algC, algD, and
algU::lacZ reporter constructs show that the
transcription of these genes, which are required
for synthesis of the extracellular polysaccharide
(alginate in this case), is activated after attach-
ment to a solid surface (24). Thus, it appears
that attachment itself can initiate synthesis of
the extracellular matrix in which the sessile
bacteria are embedded. This notion—that bac-
teria have a sense of touch that enables detec-
tion of a surface and the expression of specific
genes—is in itself an exciting area that has been
more thoroughly studied in Vibrio parahaemo-
lyticus, which causes gastroenteritis in humans
(25).
Maturation of attached bacteria into a dif-
ferentiated biofilm. At an appropriate time, mi-
crocolonies differentiate into true biofilms: ex-
opolysaccharide-encased communities that are
resistant to biocides. What is the genetic pro-
gram leading to biofilm development? Is there a
signal that induces differentiation? The conver-
gence of biofilm research with another re-
search area, focused on the ability of bacteria
to function in special ways when in groups,
has provided some interesting clues about
biofilm maturation. Research on quorum
sensing in Gram-negative bacteria has shown
that acylhomoserine lactone signals are pro-
duced by individual bacterial cells. At a crit-
ical cell density, these signals can accumulate
and trigger the expression of specific sets of
genes [for reviews see (26)]. Could a quo-
rum-sensing signal be required for biofilm
development? Two P. aeruginosa quorum-
sensing systems have been characterized.
One, the LasR-LasI system, controls the ex-
pression of a battery of extracellular viru-
lence factors. It also controls the other sys-
tem, RhlR-RhlI, which in turn controls genes
including several required for the production
of a number of secondary metabolites. RhlI
catalyzes the synthesis of butyrylhomoserine
lactone, and LasI directs the synthesis of
3-oxododecanoylhomoserine lactone. The wild
type, a lasI mutant, and a rhlI mutant all can
colonize a glass surface and form microcolo-
nies. Microcolonies of the wild type and the
rhlI mutant differentiate into structured,
thick, biocide-resistant biofilms, whereas the
lasI mutant microcolonies remain thin, undif-
ferentiated, and sensitive to dispersion by a
weak detergent (0.2% sodium dodecyl sul-
fate). Addition of the missing signal, 3-oxo-
dodecanoylhomoserine lactone, to the lasI
mutant restores biofilm development (27).
This indicates that one specific quorum-sens-
ingsignal is required for biofilm differentia-
tion, at least under the conditions of the ex-
Fig. 1. Diagram of a medical biofilm. (A)
Planktonic bacteria can be cleared by an-
tibodies and phagocytes, and are suscepti-
ble to antibiotics. (B) Adherent bacterial
cells form biofilms preferentially on inert
surfaces, and these sessile communities
are resistant to antibodies, phagocytes,
and antibiotics. (C) Phagocytes are attract-
ed to the biofilms. Phagocytosis is frustrat-
ed but phagocytic enzymes are released.
(D) Phagocytic enzymes damage tissue
around the biofilm, and planktonic bacteria
are released from the biofilm. Release may
cause dissemination and acute infection in
neighboring tissue.
21 MAY 1999 VOL 284 SCIENCE www.sciencemag.org1320
M I C R O B E S , I M M U N I T Y , A N D D I S E A S E
Figure 3.2.2. Diagram of a medical biofilm. (A) Planktonic bacteria can be cleared by antibodies 
and phagocytes, and are susceptible to antibiotics. (B) Adherent bacterial cells form biofilms 
preferentially on inert surfaces, and these sessile communities are resistant to antibodies, 
phagocytes, and antibiotics. (C) Phagocytes are attract- ed to the biofilms. Phagocytosis is 
frustrated but phagocytic enzymes are released. (D) Phagocytic enzymes damage tissue around 
the biofilm, and planktonic bacteria are released from the biofilm. Release may cause 
dissemination and acute infection in neighboring tissue (Costerton, 1999).
In conclusion, biofilms are hard to eradicate and are the cause of many persistent 
infections (Lewis, 2001), since they show resistance to bacterial agents 10-1000 
times more than planktonic bacteria of the same strain (Melchior, 2006-1). Some 
authors hypothesize that biofilm formation is likely to be an ancient adaptation of 
prokaryotic life (Hall-Stoodley, 2004).
Increasing evidence suggests that antibiotics are at the present time not only less 
effective against bacterial biofilms, but also may stimulate the biofilm formation. 
(Melchior, 2006-1).
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3.2.2. Biofilm and possible deactivation of  host immune system
It has been also proposed that biofilm infections are in a sense very similar to 
planktonic infections in the absence of an immune response. The biofilm 
exopolymer physically protects the cells from the components of the immune 
system. In fact, usual therapies are based on the assumption that killing a majority 
of pathogens in many cases is just as good as killing them all. This is often the case, 
because the immune system collaborates with the antibiotics and probably “mops 
up” the remaining persisters. Persisters do become a problem when the immune 
system is not operating.
The presence of persisters that can rebound when the antibiotic concentration 
drops would explain the necessity of therapy with a combination of unrelated 
drugs that together probably eradicate persisters.
If the concentration of the antibiotic temporarily drops or if symptoms disappear 
due to the eradication of planktonic cells and therapy is discontinued, the persisters 
will reform the biofilm, which will begin to shed off new planktonic cells. This 
dynamic explains the relapsing nature of biofilm infections and the need for a 
lengthy antibiotic therapy or a definitive effective therapy. This view of a biofilm 
infection suggests, somewhat counterintuitively, that the recalcitrance of biofilms 
does not necessarily rely on their higher levels of intrinsic resistance to killing by 
antibiotics than the level of intrinsic resistance of planktonic cells. Indeed, if a 
biofilm of a particular species under given conditions in vivo happens to be just as 
sensitive or even more sensitive to killing by antibiotics than a planktonic 
population (say, that this biofilm produces fewer persisters than a planktonic 
population), it will still survive better than planktonic cells, since it is invulnerable 
to immune attack (Lewis, 2001).
3.2.3. Biofilm and mastitis
The relationship between the ability to produce chronic bovine mastitis and biofilm 
formation has been demonstrated (Cucarella, 2004).
Studies of Staphilococcus aureus in mammary tissue in acute and chronic 
infections revealed that the bacteria are typically located in clusters within the 
alveoli and lactiferous ducts in association with the epithelial cells and invaded in 
the interstitial tissue (Hensen, 2000; Melchior, 2006-1). These bacterial clusters 
appear approximately 24 h after exposure to the pathogen along with the 
establishment of  the intramammary infection (Melchior, 2006-1).
According to a recent study, the increase in the somatic cell count in S. aureus 
infections is markedly higher than in coagulase-negative staphylococci mastitis, 
since the species capable of coagulating blood plasma are considered potentially 
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more pathogenic due to the production of an enzyme that enables the 
microorganism to persist in the presence of  a host immune response. 
Moreover, some milk samples analyzed were negative on Californian Mastitis Test 
but positive for Staphylococcus spp. This result reinforces the fact that even when 
triage tests are used on the dairy farms, there are animals that may harbor mastitis-
causing agents. (da Costa Krewer, 2014).
It is in fact reported (Cucarella, 2004) that this situation has important 
consequences in milk production at the farm level, as mastitis control inadvertently 
allowed the misclassification of cows as uninfected when they were in fact infected 
with ica- and bap-positive bacteria. These microorganisms remained undetected in 
the udder and the infected cows were not submitted to antibiotic treatment, so that 
a further spread and persistence of mastitis in the farm with consequent 
production losses could take place. The low SCC associated with a high mammary 
gland colonization by some bap-positive ica-positive isolates also suggests a 
reduced toxin production during these infections.
On one hand, bacteria may form biofilms with little or no obvious harmful effect 
on the host which are therefore frequently undetected. Alternatively, non-biofilm-
forming bacteria may produce toxins, become more pathogenic in the short term, 
and cause damage to the host tissues. This may result in an exposure of host 
adhesins which enable the bacteria to adhere by interacting with host receptor 
proteins and to spread to other body sites.
Antibiotics to control chronic bovine mastitis are usually chosen on the basis of 
conventional in vitro diffusion and dilution evaluation methods and without taking 
into account the role of biofilm formation on resistance. As high concentrations of 
many known antibiotics are required to kill biofilm bacteria and lead only to a 
partial killing effect, there is a need to find antimicrobials that are efficient against 
biofilm bacteria.
It is likely that the presence of Bap reduced infectivity in the short term by 
blocking early adherence dependent on host- MSCRAMM interaction but had the 
opposite effect in late adherence, allowing longer bacterial persistence in the 
mammary gland (Cucarella, 2004).
In addition other studies outline that skim milk and slime production are two 
factors that have a positive effect on biofilm production by bovine isolates of S. 
aureus. In fact, biofilm production is increased in a skim-milk medium (Fabres-
Klein, 2015). Lactose and milk whey contribute to capsule polysaccharide and 
biofilm formation in S. aureus, because the presence of slime and milk seems able 
to promote a change in the bacterial lifestyle that increases the chances of survival 
in the extracellular medium. For this reason, mastitic altered milk boosts biofilm 
production and hence promotes bacterial survival, setting up a vicious cycle. 
Biofilm formation has thus an important role in the virulence of S. aureus isolated 
from bovine intramammary infections (Clutterbuck, 2007).
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3.3 Antimicrobial peptides
3.3.1. Multifunctional role of  AMPs
Antimicrobial peptides (AMPs) have an essential role in the mammals immune 
defense system complexity, where they exert a multifunctional activity. 
The extreme diversity of molecules referred to as AMPs embraces a list of 1200 
AMPs and a variety of classification has been proposed, based on their being small, 
having positive charge, amphiphatic structure, α-helix structures, β-sheet structures 
stabilized by disulfide bridges or peptides with extended or loop structures.
The expression of AMPs differs depending on the cell and tissue type, but in most 
cases AMPs are co-expressed as groups that act together.
Relatively little information is available on the immunological function for most of 
these peptides, and it is unlikely that the immunomodulatory actions of the 
mammalian AMPs are also a component of the biology of the hundreds of AMPs 
produced by most prokaryotes and invertebrates. Thus, the first important concept 
to confer in a discussion of the AMPs is that they are similar only by their capacity 
to directly kill or inhibit the growth of  microbes. 
Some similarities in their structure are possibly responsible for their ability to 
influence lipid membrane structures. Cathelicidins and defensins are the most 
studied AMPs in mammals.
Cathelicidins.
Cathelicidin peptides are a highly heterogeneous group of molecules both within 
and between species: they are named together because, despite their structural 
diversity, they encode a protein that acts as a cysteine protease inhibitor and also 
possesses some antimicrobial activity.
In human neutrophils and other cell types hCAP18 is processed to release from the 
carboxy (C-) terminus of the precursor protein an antimicrobial peptide of 37 
amino acids. As a mature peptide, LL37 is well known for its rapid, potent and 
broad-spectrum antimicrobial activity when released from the C-terminus of 
hCAP18. Its processing is essential for activation of its antimicrobial activity in 
vivo.
Defensins.
In mammalian species, around 50 α-defensins and 90 β-defensins and also θ-
defensins have been identified.
All defensins are cationic, microbicidal, lack glycosyl- or acyl- side-chain 
modifications and contain six highly conserved cysteine residues which form three 
pairs of intramolecular disulfide bonds. Although mammalian defensin peptides 
exhibit a large variability in their sequences, the six cysteines are retained.
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Similar to cathelicidins, defensins are activated by proteolytic processing from an 
inactive precursor.
3.3.1.1. Expression and regulation of  AMPs
Because AMPs are expressed as pro-peptides followed by proteolytic processing to 
release the biologically active peptides, regulation of function is as dependent on 
the expression of appropriate proteases for processing as it is on the expression of 
the AMP gene product itself. These are accomplished differentially depending on 
the specific peptide and the tissue or cell type.
Recent observations have shown that the constitutive expression of AMPs is under 
strict developmental control and influenced by age and sexual maturation.
The down-regulation of AMPs occurs when expression is turned off and is often 
associated with increased susceptibility to infection by pathogens otherwise 
sensitive to the AMPs. For example, psychological stress has been shown to have 
adverse effects on cathelicidin expression through the induction of endogenous 
glucocorticoids (GCs). Indeed, psychological stress and systemic or topical GC 
administration has been observed to down-regulate epidermal expression of 
murine cathelicidin and α-defensin 3, leading to increased severity of group A 
Streptococcus pyogenes skin infection. In addition, the capacity to decrease AMP 
expression is also a microbial virulence factor.
3.3.1.2. AMPs selective antimicrobial activity
Usually, the expression of these AMPs is increased at the onset of infection in 
response to stimuli. In vitro, most AMPs act against many different types of 
microbes including gram-negative and gram-positive bacteria, protozoa, fungi and 
some viruses, due to their capacity to directly disrupt the microbial cell membrane 
and thereby result in killing. Disruption of lipid bilayers by AMPs occurs through a 
variety of  mechanisms.
In general, cationic AMPs are attracted by electrostatic forces to the negative 
phospholipid headgroups on the membrane surface provided by capsular 
polysaccharides, which include lipopolysaccarides (LPS) in Gram-negative bacteria 
and teichoic acids (TA), lipoteichoic acids (LTA) and lysylphosphatidylglycerol in 
Gram-positive bacteria. Once AMPs gain access to the cytoplasmic membrane they 
interact with the lipid bilayer, followed by displacement of lipids, alteration of 
membrane structure and the creation of a physical hole causing cellular contents to 
leak out. Collectively, all these are well established models representative of the 
mechanisms for AMPs, and each model provides a different view of peptide 
activity, but none of these models is capable of adequately explaining their 
effectiveness in vivo.
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The selective toxicity of AMPs against microbes and not against host cells is 
possibly due to the cholesterol content of eukaryotic membranes. Unlike 
eukaryotic cell membranes, bacterial cell membranes are free of cholesterol. For 
example, the AMP sarcotoxin IA Was shown to be less disruptive to liposomes 
containing cholesterol than cholesterol-free liposomes. Because cholesterol is 
known to cause condensation of phospholipid bilayers, it might prevent AMPs 
from penetrating into the cytoplasmic membrane of  eukaryotic cells.
In addition, the asymmetric distribution of phospholipids in the cytoplasmic 
membrane of eukaryotic cells might also contribute to the insensitivity of 
eukaryotic cells to AMPs. 
Moreover, the cytotoxic effects of AMPs to eukaryotic host cells in vivo are also 
substantially attenuated by serum components such as apolipoprotein A-I and B, or 
other lipoproteins, which have been shown to bind to LL37.
Despite the selective activity of many AMPs for microbial membranes, several 
studies have also shown that these AMPs at high concentrations will also destroy 
eukaryotic cells in vitro, such as T lymphocytes, leading to the hypothesis that they 
might also have a role in tumor surveillance. In spite of this, the cytotoxic 
concentrations of AMPs are, in general, higher than the concentrations required 
for elimination of  microbes, revealing a cell-selective killing mechanism.
3.3.1.3. AMPs modulation of  host inflammatory responses
The minimal inhibitory concentrations (MIC) of AMPs against microbes in vitro 
are typically much higher than the physiological concentrations of peptides found 
in vivo under resting conditions. 
It has been suggested that they can either:
- act synergistically with other classes of  AMPs to exert their desired effect,
-accumulate, in situations of inflammation, at a high local concentration 
sufficiently above the MIC, thus acting alone as a classic AMP,
- function as potent immune regulators, altering host gene expression, acting as 
chemokines and/or inducing chemokine production, inhibiting LPS- or 
hyaluronan-induced pro-inflammatory cytokine production, promoting wound 
healing and modulating the responses of dendritic cells or T cells of the adaptive 
immune response.
In this way they act as a bridge between innate and adaptive immunity.
AMPs influence the outcome of  infection in at least three ways:
- they act as direct antimicrobials,
- they are chemotactic and they induce the release of multiple cytokines and 
chemokines that further refine and amplify the innate immune response. Upon 
stimulation by microbial pathogens, local cells release AMPs at the site of the 
infection or injury. In addition to inhibiting microbial growth, an additional 
function of some of these AMPs is that they act to directly recruit leukocytes or 
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induce the expression of chemokines or cytokines, indirectly promoting 
recruitment of effector cells such as neutrophils, monocytes, macrophages, 
immature dendritic cells and T cells. Both defensins and cathelicidins have been 
shown to be chemotactic.
- they modify inflammation: mammalian AMPs have a crucial role in regulation of 
TLR-dependent inflammatory response. In this scenario, the AMP acts as a 
scavenger for the activating ligand, removing it before it can trigger inflammation. 
Moreover, it is suggested that AMPs might have a role in preventing sepsis.
-promote wound healing, by many mechanisms, such as stimulation of migration, 
proliferation and tube formation of endothelial cells in wounds, leading to 
accelerated wound closure.
AMPs have been shown to participate in alerting, mobilizing and amplifying innate 
and adaptive immune responses of the host, and will confer protection against 
microbial infections. 
Decreased expression of  AMPs can increase susceptibility to infectious diseases.
3.3.1.4. Microbial resistance to AMPs
A particular attention must be focused on  microbes evolution and their attempt to 
conquer AMPs resistance. AMPs exert a multidimensional strategy to respond to 
microbial invasion. On the contrary, by acting through a single approach, antibiotic 
function can be completely evaded by a single resistance system. It is apparent 
today that many pathogenic microbes have evolved mechanisms to avoid the 
antimicrobial action of  different AMPs, yet the expression of AMPs still protects 
the host.
Several mechanisms have been described for microbial resistance to AMPs. Some 
microbes use advanced strategies to down-regulate the expression of AMPs or 
produce proteases to degrade AMPs. Microbes seem able to: 
- release plasmid DNA to turn off the expression of antimicrobial peptides in 
epithelial cells or monocytes, and this helps the bacteria evade AMP function,
- for the microbe to enzymatically inactivate the AMP before it can act,
- to change the composition of their cell membrane, resulting in the reduction of 
the net negative charge of  the bacterial membrane so as to repel cationic AMPs.
Notwithstanding the AMPs antimicrobial activity against planktonic bacteria, also 
some experiments about AMPs efficacy against biofilm have been reported. In 
particular, RNA III inhibiting peptide (RIP) is known to inhibit S. aureus 
pathogenesis by disrupting the quorum-sensing mechanisms that characterizes 
bacteria sessile growth. 
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However, RIP was not able to totally eradicate biofilm formation when it was used 
alone. It is reported that the activity of RIP was synergistic with those of 
antibiotics for the complete prevention of drug-resistant S. aureus infections 
(Giacometti, 2003).
In conclusion, along with the capacity of AMPs to directly kill microbes, AMPs 
also boost specific innate immune responses and exert selective 
immunomodulatory effects on the host. Upon exposure to danger, AMPs create an 
overall balance by inhibiting microbial growth, attenuating exacerbated 
inflammatory responses and stimulating certain beneficial aspects of inflammation. 
This combined functional profile highlights the unique temporal niche that AMPs 
occupy in microbial defense (i.e. they are ideally suited for rapid but transient 
responses). This overall presentation of  AMPs is owed to Lai, Gallo, 2009, where not differently reported.
In-depth analisys: Membrane action of  AMPs (Lai, Gallo, 2009)
There are several mechanisms by which different classes of AMPs could act on the microbial target membrane. 
In the ‘carpet model’. peptides accumulate on and orient parallel to the membrane surface. At a certain high 
concentration of peptides, AMPs disrupt the bilayer membrane in a detergent-like manner, resulting in the 
formation of micelles and leakage of cellular contents. In the ‘toroidal-hole model’, the polar heads of the 
peptides face the polar head groups of the lipids, inducing the lipids to form a continuous bend from the top to 
the bottom in the fashion of a toroid which is lined by both the peptides and the lipid head groups. Some 
cationic AMPs adopt an α-helical configuration, attach to, aggregate and insert into oriented bilayers that are 
hydrated with water vapor, leading to the formation of ‘barrel-stave’ holes in the membrane. For this model, the 
hydrophobic peptide regions align with the lipid core region of the bilayer and the hydrophilic peptide regions 
form the interior region of the pore. Notably, the differences between the toroidal model from the barrel- stave 
model is that peptides in the former are always associated with the lipid head groups even when they are 
perpendicularly inserted in the lipid bilayer. Finally, although most AMPs have been shown to disrupt cell 
membranes and induce microbial killing, a few  AMPs kill bacteria without any detectable lysis. These AMPs can 
penetrate the cell membrane and bind to different targets, such as DNA, to inhibit bacterial growth.
In-depth analisys: AMPs conquer microbial resistance (Lai, Gallo, 2009)
Microbes have evolved several mechanisms to degrade AMPs, yet the expression of AMPs continues to provide 
protection against infection. Why? Several theories can be advanced to explain their effectiveness in mammalian 
immunity. First, even though most pathogens have developed some countermeasures against AMPs, strict 
regulation of the expression of AMPs at the infection site leads to extremely high concentrations of AMPs in 
vivo that cannot be completely overcome by the microbe. This combined with simultaneous production of a 
variety of different AMPs, impedes microbial colonization and growth. In addition, the high costs for microbes 
to develop and express resistance genes preclude modifications that allow  total resistance. In particular, it is 
difficult to evade the membrane-disturbing activity of AMPs while preserving the functional and structural 
integrity of the microbial cell wall and membrane. Furthermore, a strategy of destruction of the AMPs also 
poses several problems for the microbe. Most peptides are created from sequences of amino acids lacking 
unique epitopes that could serve as the recognition site of a specifically evolved protease that would be required 
for selective destruction of the AMP. Thus, it is difficult to design a degradation mechanism that would not also 
degrade necessary host proteins for attachment or microbial proteins necessary for survival. Finally, we have 
seen that all multicellular organisms attack microbes with multiple peptides of different structural classes, hence 
destruction of  one peptide might not suffice to avoid the lethal assault of  a diverse group of  AMPs.
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3.3.2. AMPs modulating activity during inflammation and tumorigenesis
The strict relation between inflammation and cancer imply the need of a deeper 
understanding of  the complex role of  AMPs during tumorigenesis.
A number of studies have addressed the role of AMP during carcinogenesis and 
cancer progression, arriving at contradictory conclusions with regard to anti-tumor 
or tumor promoting activities. It has been recently reported that AMPs seem to 
exert a cytotoxic effect against tumor cells (Al-Rayahi, 2015).
During inflammation, some complement components are generated leading to 
chemoattraction of immune cells such as T lymphocytes, monocytes, and 
eosinophils. Subsequently, the interaction of these components with their receptors 
leads to release of cytokines and reactive oxygen species resulting in tissue damage. 
Persistent inflammation leads to the establishment of a microenvironment 
supportive for tumor growth. Tumor-mediated complement activation provides a 
continuous source of complement activation bioactive products creating an 
inflammatory environment supporting tumor growth. It was found that activation 
of C3aR and C5aR lead to an increase in expression of IL-6 mRNA, which is a 
potent cytokine capable of stimulating angiogenesis and inhibiting apoptosis in 
tumor cells (Al-Rayahi, 2015).
In addition to complement components, there is good evidence that certain AMP 
such as defensins and Cathelicidins influence the mobilization from bone marrow 
and recruitment of  cells in the tumor microenvironment (Al-Rayahi, 2015).
Taken together, both complement components and some antimicrobial peptides of 
the innate immune defense arm have a role in regulating and trafficking of immune 
cells during tumorigenesis as well as in modulating the adaptive anti-tumor immune 
response (Al-Rayahi, 2015).
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3.3.3. Endogenous AMPs activity during bovine mastitis infection
The role of defensins and cathelicidins in protecting from bovine mastitis infection 
has been demonstrated (Roosen, 2004; Tomasinsig, 2010). In addition, it is 
reported that milk cathelicidin levels increase following intramammary infection 
(Smolenski, 2011). Increased expression of genes encoding β-defensins in the 
infected udder confirms their crucial role in the defense of the cow mammary 
gland against mastitis. On the other hand, the elevated cathelicidin transcripts in 
non-infected tissues indicate their role in the maintenance of healthy mammary 
tissues. The expression levels of investigated genes are likely to depend on the 
duration of  the infection and type of  bacteria (Kosciuczuk, 2014).
It is likely that the simultaneous presence of a wide range of these peptides at an 
inflammatory site results in mutual potentiation of the antimicrobial activity. This 
may be achieved, for instance, through faster cellular delivery of AMPs acting on 
intracellular targets as a result of perturbation of bacterial membranes by 
membrane-active AMPs. The occurrence of multiple targets would also decrease 
the likelihood of microorganisms acquiring resistance to the AMPs (Tomasinsig, 
2010).
By extension, the overall antimicrobial activity is expected to increase dramatically 
when the entire arsenal of antimicrobial peptides, including cathelicidins, defensins, 
and other AMPs, is released from neutrophils, a circumstance that likely takes place 
in vivo in mastitic milk following neutrophil recruitment and activation at sites of 
udder infection (Tomasinsig, 2010).
In addition, it has been demontrated that some AMPs are largely inhibited in milk 
and fully active in whey (Tomasinsig, 2010). The strong influence of the milk 
composition on the antimicrobial activities of cathelicidins becomes particularly 
relevant when the physical and chemical properties of healthy and mastitic milk are 
compared. Mastitis causes alterations that turn milk into a whey-like fluid with a 
reduced content of different milk components, including caseins and fat, and this 
provides a more suitable environment for efficient activity of AMPs, as confirmed 
by the finding that cathelicidins in general maintained efficient activity in mastitic 
milk.
Moreover, AMPs triggered the expression of proinflammatory mediator tumor 
necrosis factor alpha (TNF-α) in mammary epithelial cells at low micromolar 
concentrations, thus providing an important mechanism for the stimulation of 
other immune responses. The relevance of TNF-α to mastitis is suggested by its 
increased expression in milk somatic cells after E. coli intramammary infection and 
by the finding that it improves phagocytosis and killing of S. aureus by neutrophils 
(Tomasinsig, 2010).
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Besides, the cytokine promotes the recruitment of neutrophils to infected 
mammary glands by inducing expression of adhesion molecules in endothelial cells 
and stimulates AMP production, setting up a positive loop (Tomasinsig, 2010).
3.3.4. Experimental data about exogenous AMPs efficacy during bovine mastitis 
infection
Experimental studies investigated AMPs activity in different animal pathologies, 
such as promoting wound healing in mice, dogs (Kim, 2009) and horses (Carmona, 
2006), resolution of equine joint (Broeckx, 2014) and tendon (Carter, 2003) 
diseases,  and bovine udder regeneration (Lange Consiglio, 2014).
Among these studies, the intramammary administration of platelet concentrate 
(PC) as an unconventional therapy in bovine mastitis (Lange Consiglio, 2014) 
shows a higher efficacy of the associated treatment PC-antibiotic versus the PC-
alone and antibiotic-alone treatments.
The experimental approach is based on the regenerative properties of the platelet 
concentrate, obtained as stated in literature (Anitua, 2004; Zimmermann, 2003).
Comparing the antibiotic-alone versus the PC-alone treatments, the rate of 
improvement and relapse were not statistically different regarding acute mastitis, 
but it is noteworthy that the treatment with PC alone was better than antibiotic 
alone for chronic mastitis. Particularly in the case of chronic mastitis, these findings 
suggested a possible role of growth factors in tissue protection or repair processes, 
or both. Platelet concentrate, in fact, contains chemokines, some of which act in 
synergy with white blood cells, whereas others are chemotactic and able to recall 
monocytes and macrophages at the site of infection. The chemotactic action of PC 
is not limited to mobilize macrophages to the site but also to activate them. The 
macrophages, attracted by the chemotactic action of growth factors, would be able 
to resolve the inflammation phase, promoting tissue remodeling due to the 
secretion of factors that stimulate the production of fibroblasts (such as PDGF), 
factors that regulate the synthesis of tissue connective components (such as TGF-
β), and angiogenic factors (such as vascular endothelial growth factor). In summary, 
the therapy is believed to be based on the action of both growth factors and 
chemokines released by platelets that act synergistically to increase the infiltration 
of neutrophils and macrophages, promote angiogenesis, fibroplasia, matrix 
deposition, and re-epithelialization (Lange Consiglio, 2014).
The study leads to the belief that, even missing a complete list of AMPs present in 
bovine PC, it is possible to speculate that PC comprises an uncertain amount of 
AMPs and is also able to exert an antibacterial effect.
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The promising results of AMPs and GFs in different clinical pathologies is leading 
to a standardization and optimization of platelet-rich plasma preparation, aimed to 
a better quantification of  cytokines and growth factors platelet derived.
As far as known, PC contains different AMPs and GFs and for human blood 
growth factors, cytokines and chemokines secreted by the concentrated platelets 
has been quantified: high concentrations of platelet-derived growth factor, 
endothelial growth factor and transforming growth factor (TGF) were secreted, 
together with the anti-inflammatory and a various range of proinflammatory 
cytokines interleukin, tumor necrosis factor and interferon (Amable, 2013).
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3.4 Ozone
Ozone is a three oxygen molecule, and has interesting physical properties. It is an 
unstable gas that has an half-life of about 40 minutes at 20°C (Bocci, 2011) and it 
decomposes generating a diatomic oxygen molecule and very active atomic oxygen 
(Bialoszewski, 2011).
Ozone is well known for being very useful in the stratosphere because it absorbs 
dangerous UV radiations. However, its characteristic of being toxic in the 
troposphere for the pulmonary tract makes its use controversial (Bocci, 2006).
Ozone is 1.6-fold denser and 10-fold more soluble in water (49.0 mL in 100 mL 
water at 0°C) than oxygen. It is the third most potent oxidant after fluorine and 
persulfate and because of this oxidative feature it exhibits antimicrobial activity 
(Bocci, 2006). 
As any residual ozone naturally decomposes into non-toxic oxygen, ozone presents 
interesting aspects for its use in the food industry or in medicine (Bialoszewski, 
2011).
It is an excellent disinfectant, able to eliminate most of pathogens contaminating 
surfaces and aqueous solutions: its effectiveness in destroying bacteria, fungi and 
viruses has been largely demonstrated, but when in contact with corporal fluids it 
displays complex mechanisms of action and it looses its direct killing power, as 
further described (Bocci, 2012).
Ozone is used for medical purpose in a gaseous oxygen/ozone mixture, where 
oxygen rate is minimum 95%. Depending on therapeutical purposes, ways of 
administration and ozone concentrations, it is possible to obtain very different 
effects. For internal use its versatility is impressive because if properly used it can 
be proficient in vascular diseases (chronic limb ischemia, diabetic foot, heart 
infarction and stroke), besides in orthopedics and odontoiatry (Bocci, 2011). A 
deeper understanding of its mechanism of action, where known, is necessary to 
properly link specific concentrations range and applications to beneficial effects. 
Ozone has therapeutical effects on metabolism in inflamed tissues, activates the 
body’s immune response and shows antimicrobial and regenerating activity for 
topical use. The chemical properties of ozone are utilized in ozone therapy to treat 
infected wounds, decubitus ulcers, burns, ulcerations, inflammation of skin and 
bone tissue. Ozone therapy is also used to treat inflammation and infections of 
certain internal organs, especially when antibiotic therapy has failed to control 
multidrug-resistant bacteria (Bialoszewski, 2011). 
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3.4.1. Ex vivo administration - AHT
One of the most studied ozone way of administration is auto-hemo-transfusion
(AHT). Its understanding is useful to clarify the ozone multiple mechanisms of 
action and thereby it is here reported.
AHT consists in a blood collection of about 200 mL, thus ozonized through 
blending with a gaseous oxygen/ozone mixture and then re-infused into the same 
donor patient.
When in contact with blood, ozone reacts in a few seconds, producing a cascade of 
effects. Owing to the potent antioxidant capacity of blood due to its hydrophilic, 
lipophilic antioxidants and cellular enzymes, some of the ozone dose dissolved in 
the water of plasma is instantly quenched by free antioxidants (mainly uric acid, 
ascorbic acid, reduced glutathione - GSH, cysteine and albumin), while the 
remaining ozone reacts with polyunsaturated fatty acid (PUFA) mostly present in 
the three hydrophobic tasks of  albumin.
-R-CH=CH-R + H2O + O3  → 2RCHO + H2O2  (Bocci, 2011).
Thus, the potential energy of ozone is finally transferred into two fundamental 
messengers such as H2O2 as a reactive oxygen species (ROS) and aldehydic 
molecules of which 4-hydroxynonenal (4-HNE) and trans-4- hydroxyhexenal (4-
HHE) are the relevant lipid oxidation products (LOP):
Plasmatic water + O3 → H2O2 + 4-HNE + 4-HHE (Bocci, 2011).
Both ROS and LOPs ozone metabolites acts as messenger and cause a mild 
oxidative stress that boost the host immune system, activating a cascade of 
beneficial effects, such as:
(1) Improvement in blood circulation and oxygen delivery to ischemic tissues as a 
result of the concerted effect of NO and CO and an increase in intraeryth- rocytic 
2,3-diphosphoglycerate (2,3-DPG) level.
(2) Enhancement of  the general metabolism through improved oxygen delivery.
(3) Up-regulation of a number of antioxidant enzymes as well of heme-
oxygenase-1 and heat stress protein-70.
(4) Induction of a mild activation of the immune system and enhanced release of 
growth factors.
(5) Absence of  acute or late adverse effects. 
(6)A feeling of wellness, most likely due to the stimulation of the neuroendocrine 
system (Bocci, 2012).
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Due to the high ozone reactivity, these biochemical reactions occur in a few 
seconds and in fact, within the canonical five minutes of mixing an average 200 mL 
of human blood ex vivo in a sterile glass bottle with the 200 mL corresponding 
volume of the gas mixture oxygen/ozone, ozone is totally exhausted while about 
95% oxygen, dissolved in the plasma water, fully saturates hemoglobin (Bocci, 
2011).
During the initial fast and multiple reactions of ozone with the plasmatic 
components, a variable amount of the ozone dose is neutralized by the wealth of 
the hydrophilic antioxidants. It is noteworthy that, with the exception of uric acid 
oxidized to allantoin, dehydroascorbate and GSH disulfide are reduced back to 
their normal value in less than twenty minutes due to the exceptional efficiency of 
the recycling system based on a multitude of reducing molecules such as alpha-
lipoate, Vitamin E, thioredoxin, and last but not least NADPH  acting in a well-
coordinated sequence of  electron donations (Bocci, 2011).
Most importantly it is reported (Bocci, 2011) that, H2O2, being unionized, rapidly 
enters into all blood cells and the chemical gradient between plasma-cells has been 
measured to be about 10% of the extracellular concentration. In other words, when 
the highest ozone concentration is mixed with blood, depending upon the inter-
individual variability of antioxidant potency (1.28-1.83 mmol/L plasma), the 
highest H2O2 concentration measured in plasma is about 40 μM and therefore 
inside the cells is at most 4 μM. This sudden inflow of this small amount of H2O2 
inside blood cells is the indispensable stimulus to activate a series of biochemical 
reactions as follows:
- in the erythrocytes: activation of glycolysis with increase of ATP and 2,3-
diphosphoglycerate. Functionally, the oxyhemoglobin sigmoid curve shifts to the 
right and increases the release of oxygen at the tissue level. The erythrocytes mop 
up most of the H2O2 and promptly reduce it to water by GSH. The sudden 
formation of GSSG (oxidized glutathione) alters the GSH/ GSSG ratio but the 
cell quickly correct it by either extruding some glutathione-disulphide or by 
reducing it via GSH reductase at the expense of either ascorbic acid or thioredoxin, 
which has two-SH groups. Moreover, the activation of glucose-6-phosphate 
dehydrogenase (G6PDH) provides reducing power and activate glycolysis;
- in the leukocytes: neutrophil phagocytic activity is enhanced. Inside monocytes 
and lymphocytes, H2O2 activates a tyrosin-kinase with consequent phosphorylation 
of IkB, one of the trimeric components at rest of the NF-kB. The phosphorylated 
IkB detaches from the trimer and it is broken down in the proteasome. The 
remaining eterodimer p50-p65 is transferred into the nucleus where it can activate 
about 100 genes. Of great significance it is the final release of some cytokines 
(IFNg and IL-8) and of  some acute-phase proteins;
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- in the platelets. In relation to the ozone concentration, we have measured release 
of PDGF-AB, TGFb-1 and IL-8. Growth factors have a specific relevance in 
enhancing ulcer’s healing in peripheral arterial disease (PAD).
It must be said that the H2O2 concentration in the cells (4 μM) is essential for 
switching on cellular responses and it probably lasts few seconds as GSH-Pxs, 
peroxiredoxin and catalase promptly reduce it to H2O. In plasma, the H2O2 half-life 
is less than 1 minute and it is absent during blood re-infusion (Bocci, 2011).
3.4.2. Use of  ozone as antimicrobial agent
In the last decades, various in vitro and in vivo experimental and clinical studies 
have demonstrated the bactericidal effect of the topical application of ozone in 
different situations, including the management of infected wounds. Ozone is a 
potent oxidant and an important disinfectant, acting on microorganisms by means 
of oxidation of their membrane. Ozone reacts with lipid double bonds, thus 
leading to bacterial wall lysis and bacterial cell content extravasation. By entering 
the cell, ozone promotes oxidation of nucleic and amino acids. Cell lysis depends 
on the extent of  these reactions disinfectant effect of  ozone. 
It has been reported that ozone can be employed as a bactericidal agent under 
various forms, such as ozonized saline solution, ozonized water, ozonized oil, 
ozone associated with other substances and it is valuable in all cutaneous and 
mucosal infections and ulcers.  The topical use of ozone has also been reported for 
environment decontamination in diverse situations, since low doses of gaseous 
oxygen/ozone mixture completely prevented the in vitro growth of all bacterial 
strains (Fontes, 2012). 
With the spreading microbial lack of sensitivity to killing agents, studies have been 
performed to evaluate the efficacy of ozone on specific microbial strains. Results 
showed that a gaseous oxygen/ozone mixture effectively inhibited the growth of 
all potentially pathogenic bacterial strains with known antimicrobial resistance, by a 
single topical application by nebulization of  a low ozone dose. (Fontes, 2012).
3.4.3. Ozone as active agent against microbial biofilm
Recently, in vitro experiments with ozonated saline showed it efficacy against both 
planktonic and biofilm growing Staphylococcus aureus (Al-Saadi, 2015) and other 
bacterial biofilm (Bialoszewski, 2011).
The study (Al-Saadi, 2015) showed rapid clearance of planktonic bacteria, and a 
delayed, but complete, eradication of  biofilm bacteria. 
Ozonated saline was found to be effective in rapidly killing planktonic S. aureus at a 
very high initial density.
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Although planktonic bacteria are found in clinical infections, bacterial biofilms 
represent a more challenging treatment target in comparison with planktonic 
bacteria. The ability of ozone to eradicate S. aureus biofilms is, therefore, crucial to 
the suitability of this technique for the eventual clinical application. In comparison 
with the effect on planktonic bacteria, biofilm growth rendered the S. aureus 
significantly more resistant to ozone, despite the fact that the total number of 
bacterial cells in the planktonic experiment exceeded the number of bacteria in the 
biofilm experiment by a factor of approximately 100. After 60 minutes, all the 
planktonic bacteria were entirely eradicated; however, after the same period, the 
adherent biofilm was relatively unaffected by ozone with only minor loss of 
viability or structural damage. Complete eradication of the biofilm from the surface 
of  the TAN discs was achieved after 360 minutes of  ozone exposure.
Also a cytotoxicity test was performed. Cell cytotoxicity measurements showed no 
persistent effect on primary ovine osteoblasts and no effect after short exposure 
time.
Ozone antimicrobial broad spectrum effectiveness, its lack of cytotoxicity and its 
rapid degradation into its well known metabolites are a significant advantage over 
other antiseptics, which would not be so rapidly degraded in human tissue and 
represent a greater toxicity risk (Al-Saadi, 2015).
3.4.4. Ozone treatment against bovine mastitis
As for bovine mastitis, the therapeutical use of ozone reviewed the infusion of 
gaseous ozone into the inflamed quarter and the mammary irrigation with 
ozonated water have been investigated.
In the first study, ozone gas insufflation into the udder showed an interesting 
efficacy: 60% of mastitic cows did not require any antibiotics for recovery (Ogata, 
2000).
However, due to technical difficulties, this practice didn’t receive attention from the 
farmers.
The second study clearly demonstrated that cows receiving mammary irrigation 
had higher cure rates than those receiving an antibiotic treatment alone.
Although it is well recognized that ozone has sterilization capabilities, it was 
reported that physical elimination of both microorganisms and endotoxins from 
the mammary glands by flushing might be essentially important, rather than the 
sterilization effect of  irrigation fluids.
In addition, it has been reported that treatment with ozone released fewer 
endotoxins in the milk than treatment with antibiotics. Moreover ozone may result 
in the down-regulation of  the cytotoxic activity of  immunocytes.
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At the time, the study did not confirm the efficacy of ozone water in the in vivo 
evaluation, since mammary irrigation with normal saline was as effective as ozone 
water for acute coliform mastitis in dairy cattle (Shinozuka, 2009).
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3.5 Ozonated oil
Ozonated oil is a vegetable oil bubbled for a precise amount of time with a 
oxygen/ozone mixture, where oxygen rate is at least 95%. 
During the last decades, the usage of vegetable matrices in the form of ozonated 
oils has been proposed and several researchers have shown a positive effect in the 
wound, based on their bactericidal, antiviral, and antifungal properties.
Thus, several experiments have been performed to evaluate the MIC antimicrobial 
activity of ozonated oil and to optimize its efficacy in relation to properties of 
different vegetable oils. 
The direct ozonation of vegetable oils with unsaturated fatty acids leads to the 
formation of the 1,2,4-trioxolane moiety, which represents the active form of 
ozone in these substrates. The trioxolane ring within the vegetable ozonated 
matrices quickly generates some compounds responsible for the healing process 
when applied in either a humid wound or an ulcer. Moreover, it is accountable for 
antimicrobial and antimycotic treatments. All these effects occur in the absence of 
cutaneous adverse reactions (Zanardi, 2013).
During the ozonation process, ozone reacts with olefins by adding on the carbon–
carbon double bonds therefore the longer the reaction, the more unsaturations are 
consumed inducing a decrease in II. As regard for instance to sunflower oil, 
because it contains more unsaturations than other vegetable oils, it takes more time 
to consume them all (Moureu, 2015).
[(Fig._4)TD$FIG]
Fig. 4. Criegee mechanism.
[(Fig._5)TD$FIG]
Fig. 5. Correlations between MIC values and IP or AV for the different bacterial strains studied. Shaded markers were excluded to trace the trend lines.
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Figure 3.5.1. Criegee mechanism during oil ozonation (Moureu, 2015).
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3.5.1. Antimicrobial activity of  sunflower ozonated oil
Among different oils, sunflower oil is so far the best known, and at least it was the 
best investigated at the beginning of  the experiment further described. 
The remarkable sunfower ozonized oil (SOO) bactericidal properties and its direct 
action on the pathogenic microorganism without damaging the human epithelium 
have been reported (Sechi, 2001).
The stability of SOO at different temperatures was also determined  stable for up 
to 1 year in the temperature range -10 to +8°C. Moreover, it is stable for up to 6 
months at room temperature (27±30°C); after this period, the antimicrobial 
properties diminish. The pH is also stable for up to 1 year in the temperature range 
-10 to +8°C. At 30°C, the pH is stable for up to 6 months. The MIC values after 
this period increase from 2,37 to 19 mg/ml (Sechi, 2001).
For a deeper understanding of its properties, SOO that shown antibacterial and 
antifungal activity was characterized by: 
Peroxide Index (IP), which indicates the quantity of peroxide within the SOO. It is 
defined as the quantity of active oxygen per kilogram of SOO (mmol/kg). A range 
of IP between 500 and 800 (mmol/kg) was considered. The best antimicrobial 
activity was seen with an IP of  650 (mmol/kg).
Acidity Index, which indicates the free fatty acid in the SOO. It is defined as the 
number of milligrams of potassium hydroxide that are necessary to neutralize the 
free fatty acid in 1 milligram of SOO. In SO, the value must range between 6 and 8 
units whereas in SOO, it is not above to 25 units. 
Aldehyde concentration. The aldehyde concentration is measured by adding free 
hydroxylamine to the aldehyde carboxylic group. The results are expressed in 
mmol/g of  SOO; the interval must range between 0,4 and 0,9 mmol/g.
Iodine Index, which is a measure of the unsaturation rate of sunflower oil 
expressed as the number of grams of iodine that react with 100 grams of SO. In 
SO, the rate varies between 125 and 135 units whereas in SOO, the value is 
between 50 and 90 units. 
Viscosity, which is a measure of the polymerization by condensation of the 
peroxides forming in the SO ozonization process. The values are expressed in 
mPa.s (centipoise or cP value; Institute of Standards and Technology). In order to 
obtain SOO with an IP between 500 and 800, the viscosity must be between 100 
and 450 mPa.s.
The activity of SOO against all tested bacteria, including b-lactam-, vancomicin- 
and gentamicin-resistant strains, is expressed in mg/ml. These concentrations may 
seem high if compared with the amount of antibiotics, expressed in μg/ml, 
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necessary to inhibit bacterial growth. This is due to the dilution of the active 
compounds in the SO that has not been altered in the ozonization process.
It seems from these preliminary results that Mycobacteria are even more 
susceptible to SOO than the other bacteria tested. This may be explained in part by 
the composition of their cell wall and the high lipid content, which may facilitate 
the passage of  SOO-active compounds into the bacteria (Sechi, 2001).
Susceptibility to SOO of  different pathogens is shown in the following tables.
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Table 1.5.1
Susceptibility to Oleozon 
(SOO) of d i f f e ren t 
species of  Mycobacteria
(Sechi, 2000)
Table 1.5.2
Susceptibility to Oleozon 
( S O O ) o f d i f f e r e n t 
enterococci, staphylococci, 





Susceptibility of different 
c l i n i c a l i s o l a t e s o f 
Enterococcus faecium, 
E n t . f a e c a l i s , 
Streptococcus pyogenes, 
Staphylococcus aureus, 
S t a p h . e p i d e r m i d i s , 




There is thus a general conviction that ozone is one of the best compounds for 
killing bacteria, viruses, and parasites present as well as against biofilms: 
antibacterial effectiveness of ozonated oils in mucosal and cutaneous infected 
wounds and ulcers has been successfully proven (Zanardi, 2013). SOO is effective 
against herpes, mycobacteria, staphylococci and streptococci and it is considered a 
competitive antimicrobial agent (Sechi, 2001).
As it is possible to observe in figure 1.5.2, experiments showed how both bacterial 
and C. albicans cells maintained intact shapes and size, just after ozonated oil 
exposition. Also the surface morphology of the cells was unaltered with respect to 
untreated ones, as well as the number of damaged cells. The only exception 
occurred at cellular surface of P. aeruginosa where the cells showed a rough outside 
with the appearance of tiny bumps similar to small vesicles, after contact with 
ozonated oil  (Zanardi, 2013).
The believe is that ulcers with scarce tendency to heal are due to a local hypoxic 
situation, presence of bacteria, minimal cell proliferation, and a reduced production 
of extracellular matrix. In reported experiments, by using the ozonated oil in vivo, 
the “restitutio ad integrum” including the final healing and scar tissue remodeling 
takes much less time in elderly and/or diabetic patients without any generalized or 
local side effects (Zanardi, 2013).
How ozonated oil precisely acts remains a debatable question. According to the 
SEM results, the anti-infective activity is not dependent on structural alterations at 
the level of microorganisms. However, it seems likely that 1,2,4-trioxolane present 
in the ozonated oil, when added to the warm exudates film of the ulcer, slowly 
decomposes generating local oxygen, H2O2 as reactive oxygen species (ROS), and a 
trace of lipid oxidation products (4-HNE). Such a cascade can explain the 
prolonged disinfectant action and stimulation of proliferative activity of fibroblasts 
and keratinoblasts (Zanardi, 2013).
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Table 2: Viability (%) of the di'erent strains as obtainedwith respect to control (microbial count in the presence of the corresponding amount
of SO; see text for further details).
Type Treatment time 25mgOSO/5mL of microorganism suspension 50mgOSO/5mL of microorganism suspension
l-OSO m-OSO h-OSO l-OSO m-OSO h-OSO
S. aureus
1 h 65 58 58 57 47 47
3 h 20 21 0.2 1 3.6 0.2
6 h 0 0 0 0 0 0
P. aeruginosa
1 h 100 100 100 100 100 25
3 h 100 100 5.7 13.7 15.1 2
6 h 5 5 0 1.8 3.8 0
E. faecalis
1 h 100 100 100 100 100 100
3 h 100 100 100 100 27 23
6 h 20 15 0.1 7 0.1 0
E. coli
1 h 100 100 100 100 100 100
3 h 0.8 0.8 0.5 0.4 0.4 0.4
6 h 0.4 0.4 0 0.3 0.2 0
C. albicans
1 h 100 100 100 100 100 100
3 h 39 38 18 13 13 0.2
6 h 1.6 0 0 0 0 0
2.4. SEM Characterization. 0e morphology of microorgan-
isms before and a1er oil treatment (2rst line experiment, a1er
six hours) was investigated by Scanning ElectronMicroscopy
(SEM) studies. A drop of liquid cell suspension was placed on
poly-l-lysine treated glass coverslip for 2veminutes.0en, the
coverslip was 2xed for immersion in a 2.5% glutaraldehyde
solution in phosphate bu'er 0.1M pH 7.2 (PB) for 2 hours at
4∘C, washed in PB, post2xed in 1% OsO4 in PB for 30min.
at 4∘C, dehydrated in ascending alcohol series, incubated
for three times in tert-butanol, and 2nally freeze dried.
A1erwards, the coverslip was mounted on aluminum stub,
coatedwith 20 nmgold in BalzersMED 010 sputtering device,
and observed in Philips XL20 scanning electron microscope
at 20 kV.
2.5. Statistical Analysis. Results were obtained from at least
2ve independent measurements and expressed as the mean ±
SD, unless otherwise stated. Statistical evaluations were per-
formed by a one-way analysis of variance (ANOVA) using
a statistics so1ware (InStat so1ware, version 3.0, GraphPAD
So1ware Inc., San Diego, CA). Bonferroni test was employed
a1er ANOVA to evaluate statistical di'erence between indi-
vidual means. Signi2cance was de2ned as a 푃 value of less
than 0.05.
3. Results
Table 2 shows the bactericidal e'ect with respect to time
(1, 3, and 6 h) of di'erent amounts (25mg and 50mg)
of l-OSO, m-OSO, and h-OSO dispersed in the bacterial
suspensions at about 107 CFUmL−1. As it was expected, it
has been possible to observe a concentration-dependent
disinfectant trend. However, di'erences in behavior between
the various strains tested at the di'erent experimental
conditions have been detected. In detail, no viable bacteria
were obtained only a1er six hours and at the maximum
peroxide content of the ozonated oils, except in the case
of the less amount of OSO for E. faecalis that appeared to
be the most resistant strain. Considering all the data, also
P. aeruginosa and, to a lesser extent, C. albicans were quite
resistant. On the contrary, S. aureus appeared to be the most
sensitive one, with a sensible growth diminution since a1er
the 2rst hour with the minimum content of both ozonated
oil and peroxide content. As regards E. coli, a1er three
hours, a marked sensitivity to treatment has been observed,
regardless of the amount of the ozonated oil.
In order to have more information on the mechanism of
degradation, S.E.M. investigation has been performed [20],
and the results are shown in Figure 1. As it is possible to
observe, both bacterial andC. albicans cellsmaintained intact
shapes and size, just a1er ozonated oil exposition. Also the
surface morphology of the cells was unaltered with respect to
untreated ones, as well as the number of damaged cells. 0e
only exception occurred at cellular surface of P. aeruginosa
where the cells showed a rough outside with the appearance
of tiny bumps similar to small vesicles, a1er contact with
ozonated oil (Figure 1, arrowheads).
Moreover, to simulate the in vivo conditions of applica-
tion of the ozonated oils and to evaluate both if and howmuch
the presence of cutaneous infection exudates can compromise
the ozonated oil e3cacy, the bactericidal e'ect with respect
to time (1, 3, and 6 h) of 100mg of h-OSO dispersed in the
bacterial suspensions at about 104 CFUmL−1 either in the
absence or in the presence of serum at di'erent concentra-
tions (2.5%, 5%, and 10%)has been studied. For completeness’
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S. aureus E. faecalis P. aeruginosa E. coli C. albicans
(b)
Figure 1: Scanning electron micrographs of the surface morphology of the cells a(er contact with either ozonated sesame oil (a) or sesame
oil as control (b). Scale bars corresp n to 2휇m, except for Candida albicans (5휇m). Arrowheads show small v sicles on cellular surface of
Pseudomonas aeruginosa (see text for further details).
sake, blood and plasma are unsuitable to be tested because in
the presence of bacterial suspensions they tend to coagulate.
On the contrary, human serum while having a comparable
amount of antioxidants does not present these drawbacks.
As previously stated, the in vitro use of SO and its deriva-
tives needs the emulsi+cation with a surfactant, like the
nonionic one Tween 80. Such experimental conditions have
been calibrated a(er preliminary tests in order to obtain the
best antibacterial e.ect against E. faecalis in the presence of
about 104 cfu/mL, assuming that such a quantity corresponds
to 107 cfu/g of infected cutaneous lesions [21].
Figure 2 shows that the presence of human serum as low
as 2.5% increased microorganism survival even at higher
concentration of the oil at the higher peroxide content,
indicating the role of protective biomolecules as antioxidants
present in serum. Moreover, the bacterial viability totally
remained when samples have been added with 10% of fresh
serum (data not shown). However, in patients a(er the
appropriate elimination of exudates, the ozonated SO is
charged every 12 hours, and its therapeutic activity is likely
to be more e.ective. We are planning to evaluate the e.ect of
such ozone derivatives in vivo in a clinical trial.
4. Discussion
It is known that ulcers with scarce tendency to heal are due
to a local hypoxic situation, presence of bacteria, minimal
cell proliferation, and a reduced production of extracellular
matrix. In our experience, by using the ozonated oil in vivo,
the “restitutio ad integrum” including the +nal healing and
scar tissue remodeling takes much less time in elderly and/or
diabetic patients without any generalized or local side e.ects
[13].
We have tested typical microorganisms as representative
of either Gram-positive or Gram-negative aerobic bacteria
o(en detected in human wounds and ulcers with slow ten-
dency to heal. 0e experimental method that has been used
was selected because other procedures (such as depositing
the ozonated oil in small wells) did not reliably work due to
the poor di.usion of ozonated oil throughout the medium.
Reproducibility of results was excellent, and the experimental
method closely reproduced the in vivo situation when the
ozonated oil is applied (usually twice daily) on the ulcers.
One point that needs to be emphasized is that, before the
oil application, the damaged skin surface must be cleaned
by removing necrotic tissue, pus, loose +brin deposition,
and excess of 1uid exudates. Such a cleaning operation can
be done by curettage and washing the surface, preferably
with ozonated water or diluted H2O2 solution, useful to
eliminate most of the plasma proteins, hence antioxidants,
which will limit the disinfection and the healing stimulation.
How ozonated oil precisely acts remains a debatable question.
According to the SEM results, the anti-infective activity is not
dependent on structural alterations at the level of microor-
ganisms.However, it seems likely that 1,2,4-trioxolane present
in the ozonated oil, when added to the warm exudates +lm
of the ulcer, slowly decomposes generating local oxygen,
H2O2 as reactive oxygen species (ROS), and a trace of lipid
oxidation products (4-HNE). Such a cascade can explain the
prolonged disinfectant action and stimulation of proliferative
activity of +broblasts and keratinoblasts [12]. Other relevant
questions are: (i) how much oil should be used? As the
application is repeated every 12 hours, an oil layer of about
2mm is enough; (ii) at what ozonation degree? 0e purpose
of preparing a “weak”, “medium”, and “strong” oil re1ects the
need of treating either small, ample, or very infected ulcers.
0us, it is supposed that as an ulcer progressively improves,
ozonated oil with lower grade of peroxide will be used.
It is unfortunate that the topical use of cleaning the ulcer
and the application of ozonated oil remain mostly con+ned
to a few countries which have become knowledgeable of
Table 3.5.4 Viability (%) of the different strains as obtained with respect to control (microbial 
count in the presence of  the corresponding amount of  SO (Zanardi, 2013).
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Table 2: Viability (%) of the di'erent strains as obtainedwith respect to control (microbial count in the presence of the corresponding amount
of SO; see text for further details).
Type Treatment time 25mgOSO/5mL of microorganism suspension 50mgOSO/5mL of microorganism suspension
l-OSO m-OSO h-OSO l-OSO m-OSO h-OSO
S. aureus
1 65 58 58 57 47 47
3 h 20 21 0.2 1 3.6 0.2
6 h 0 0 0 0 0 0
P. aeruginosa
1 100 100 100 100 100 25
3 h 100 100 5.7 13.7 15.1 2
6 h 5 5 0 1.8 3.8 0
E. faecalis
1 100 100 100 100 100 100
3 h 100 100 100 100 27 23
6 h 20 15 0.1 7 0.1 0
E. coli
1 100 100 100 100 100 100
3 h 0.8 0.8 0.5 0.4 0.4 0.4
6 h 0.4 0.4 0 0.3 0.2 0
C. albicans
1 h 100 100 100 100 100 100
3 h 39 38 18 13 13 0.2
6 h 1.6 0 0 0 0 0
2.4. SEM Characterization. 0e morphology of microorgan-
isms before and a1er oil treatment (2rst line experiment, a1er
six hours) was investigated by Scanning ElectronMicroscopy
(SEM) studies. A drop of liquid cell suspension was placed on
poly-l-lysine treated glass coverslip for 2veminutes.0en, the
coverslip was 2xed for immersion in a 2.5% glutaraldehyde
solution in phosphate bu'er 0.1M pH 7.2 (PB) for 2 hours at
4∘C, washed in PB, post2xed in 1% OsO4 in PB for 30min.
at 4∘C, dehydrated in ascending alcohol series, incubated
for three times in tert-butanol, and 2nally freeze dried.
A1erwards, the coverslip was mounted on aluminum stub,
coatedwi h 20 nmgold in BalzersMED 010 sputtering device,
and observe in Philips XL20 canning electron microscope
at 20 kV.
2.5. Statistical Analysis. Results were obtained from at least
2ve independent measurements and expressed as the mean ±
SD, unless otherwise stated. Statistical evaluations were per-
formed by a one-way analysis of variance (ANOVA) using
a statistics so1ware (InStat so1ware, version 3.0, GraphPAD
So1ware Inc., San Diego, CA). Bonferroni test was employed
a1er ANOVA to evaluate statistical di'erence between indi-
vidual means. Signi2cance was de2ned as a 푃 value of less
than 0.05.
3. Results
Table 2 shows the bactericidal e'ect with respect to time
(1, 3, and 6 h) of di'erent amounts (25mg and 50mg)
of l-OSO, m-OSO, and h-OSO dispersed in the bacterial
suspensions at about 107 CFUmL−1. As it was expected, it
has been possible to observe a concentration-dependent
disinfectant trend. However, di'erences in behavior between
the various strains tested at the di'erent experimental
conditions have been detected. In detail, no viable bacteria
were obtained only a1er six hours and at the maximum
peroxide content of the ozonated oils, except in the case
of the less amount of OSO for E. faecalis that appeared to
be the most resistant strain. Considering all the data, also
P. aeruginosa and, to a lesser extent, C. albicans were quite
resistant. On the contrary, S. aureus appeared to be the most
sensitive one, with a sensible growth diminution since a1er
the 2rst hour with the minimum content of both ozonated
oil and peroxide content. As regards E. coli, a1er three
hours, a marked sensitivity to treatment has been observed,
regardless of the amount of the ozonated oil.
In order to have more information on the mechanism of
degradation, S.E.M. investigation has been performed [20],
and the results are shown in Figure 1. As it is possible to
observe, both bacterial andC. albicans cellsmaintained intact
shapes and size, just a1er ozonated oil exposition. Also the
surface morphology of the cells was unaltered with respect to
untreated ones, as well as the number of damaged cells. 0e
only exception occurred at cellular surface of P. aeruginosa
where the cells showed a rough outside with the appearance
of tiny bumps simil r o small vesicles, a1er contact with
ozonated oil (Figure 1, arrowheads).
Moreover, to simulate the in vivo conditions of applica-
tion of the ozonated oils and to evaluate both if and howmuch
the presence of cutaneous infection exudates can compromise
the ozonated oil e3cacy, the bactericidal e'ect with respect
to time (1, 3, and 6 h) of 100mg of h-OSO dispersed in the
bacterial suspensions at about 104 CFUmL−1 either in the
absence or in the presence of serum at di'erent concentra-
tions (2.5%, 5%, and 10%)has been studied. For completeness’
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S. aureus E. faecalis P. aeruginosa E. coli C. lbicans
(b)
Figure 1: Scanning electron micrographs of the surface m rphology of the cells a(er contact with ei her oz nated s same oil (a) or sesame
oil as control (b). Scale bars corresp n to 2휇m, except for Candida albicans (5휇m). Arrowheads show small v sicles on cellular surface of
Pseudomonas aeruginosa (see text for further details).
sake, blood and plasma are unsuitable to be tested because in
the presence of bacterial suspensions they tend to coagulate.
On the contrary, human serum while having comparabl
amou t of antioxidants does not present hese drawbacks.
As previously stated, the in vitro use of SO and its deriva-
tives needs the emulsi+cation with a surfactant, like the
nonionic one Tween 80. Suc experimental conditions have
been calibrated a(er preliminary tests in order to obtain the
best antibacterial e.ect against E. faecalis in the presence of
bout 104 cfu/mL, assuming that such a qu ntity corresponds
t 107 cfu/g of infect d cutaneous lesions [21].
Figure 2 shows that the presence of human serum as low
as 2.5% increased microorganism survival even at higher
concentration of the oil at the higher peroxide content,
indicating the role of protective biomolecules as antioxidants
present in serum. Moreover, the bacterial viability totally
remained when samples have been added with 10% of fresh
serum (data not shown). However, in patients a(er the
appropriate elimination of exudates, the ozonated SO is
charged every 12 hours, and its therapeutic activity is likely
to be more e.ective. We are planning to evaluate the e.ect of
such ozone derivatives in vivo in a clinical trial.
4. Discussion
It is known that ulcers with scarce tendency to heal are due
to a local hypoxic situation, presence of bacteria, minimal
cell proliferation, and a reduced production of extracellular
matrix. In our experience, by using the ozonated oil in vivo,
the “restitutio ad integrum” including the +nal healing and
scar tissue remodeling takes much less ti e in elderly and/or
diabetic patients without any generalized or local side e. cts
[13].
We have tested typical microorganisms as representative
of either Gram-positive or Gram-negative aerobic bacteria
o(en detected in hu an wounds and ulcers with slow ten-
dency to heal. 0e experimental method that has been used
was selected because other procedures (such as depositing
the ozonated oil in small wells) did not reliably work due to
the poor di.usion of ozonated oil throughout the medium.
Reproducibility of results was excellent, and the experimental
method closely reproduced the in vivo situation when the
ozonated oil is applied (usually twice daily) on the ulcers.
One point that needs to be emphasized is that, before the
oil application, the damaged skin surface must be cleaned
by removing necrotic tissue, pus, loose +brin deposition,
and excess of 1uid exudates. Such a cleaning operation can
be done by curettage and washing the surface, preferably
with ozonated water or diluted H2O2 solution, useful to
eliminate most of the plasma proteins, hence antioxidants,
which will limit the disinfection and the healing sti ulation.
How ozonated oil precisely acts remains a debatable question.
According to the SEM results, the anti-infective activity is not
dependent on structural alterations at the level of microor-
ganisms.However, it seems likely that 1,2,4-trioxolane present
in the ozonated oil, when added to the warm exudates +lm
of the ulcer, slowly decomposes generating local oxygen,
H2O2 as reactive oxygen species (ROS), and a trace of lipid
oxidation products (4-HNE). Such a cascade can explain the
prolonged disinfectant action and stimulation of proliferative
activity of +broblasts and keratinoblasts [12]. Other relevant
questions are: (i) how much oil should be used? As the
application is repeated every 12 hours, an oil layer of about
2mm is enough; (ii) at what ozonation degree? 0e purpose
of preparing a “weak”, “medium”, and “strong” oil re1ects the
need of treating either small, ample, or very i fected ulcers.
0us, it is supposed that as an ulcer progressively improv s,
zonated oil with lo er grade of p roxide will be us d.
It is unfortunate that the topical use of cleaning the ulcer
and the application of ozonated oil remain mostly con+ned
to a few countries which have become knowledgeable of
Figure 3.5.2 Scanning electron micrographs of the surface morphology of the cells after contact 
with either ozonated sesame oil (a) or sesame oil as control (b). Scale bars correspond to 2 m, 
except for Candida albicans (5 m). Arrowheads show small vesicles on cellular surface of 
Psudomonas aeruginosa (Zanardi, 2013).
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3.5.2. Wound healing mechanisms of  ozonated oils
The effect of different ozonated oils (olive, sesame and linseed) with the same level 
of ozonation have on wound healing rate has been studied and showed that the 
factors that seems to be involved in the wound healing process are the peroxidation 
levels of the ozonated oil and their different composition in PUFA (Valacchi, 
2013).
It has been demonstrated that ozone easily reacts with PUFA of the vegetable oils 
firstly forming the trioxolane moiety that when an ozonated oil is applied on the 
wound containing exudates it decomposes releasing its derivative products such as 
aldehydes and H2O2, that act as previously described enhancing tissue oxygenation 
and regeneration.
Several histological parameters and the level of key proteins such as VEGF and 
PCNA have been analyzed. Only treatment with ozonated sesame oil showed a 
faster wound closure in the first 7 days. This effect paralleled with the increased 
VEGF and PCNA levels, NFkB nuclear translocation and 4-HNE formation. The 
study showed that not only the ozonation grade is of importance for the 
improvement of  wound healing process but also the typical composition of  the oil.
NFkB activation has been also associated with VEGF and PCNA induction and 
this explains the increased levels of both proteins in the tissue treated with 
ozonated sesame oil. In general, the events that characterize the wound healing 
process can be summarized as the inflammation stage (Phase I); proliferation with 
synthesis of extracellular matrix  (Phase II) and the remodeling stage (Phase III) in 
which the scar is transformed to the healed wound. During this well coordinated 
process there is the appearance of several cell types that follow a specific order 
(platelets, neutrophils, macrophages, lymphocytes, fibroblasts and angiogenesis) and 
it has been shown that VEGF plays a critical role the regulation of  all these events. 
In addition, it has been shown a direct correlation between NFkB activation and 
PCNA regulation: in fact an increased NFkB nuclear translocation in the tissue 
treated with ozonated sesame oil were detected. NFkB is a redox transcription 
factor, modulated by oxidative stress and peroxidation products and the role of 4-
HNE in the activation of NFkB has been studied in several cells type. Studies show 
that ozonated sesame oil induced a clear activation of NFkB in cutaneous tissues 
(Valacchi, 2013).
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3.5.3. Use of  ozonated oil for bovine mastitis therapy
The use of ozonated oil has been recently suggested for dairy mastitis treatment 
(Moureu, 2015). Ozonized vegetable oils could be a new way to prevent and/or to 
treat mastitis. It has been shown that ozonized sunflower oil has an antibacterial 
activity against S. aureus and E. coli but the effect of this product on S. uberis has 
never been studied (Moureu, 2015).
Previous reported cases (Marusi, 2003) showed a beneficial use of ozonated oil as 
bovine mastitis treatment, describing an interesting cure rate without antibiotics 
(60-70%), and overall a significative reduction in swelling and redness.
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A preliminary study was performed between December 2011 and May 2012. A 
MIX made up of PC and OO was compared to ATB to test acute mastitis 
resolution efficacy. MIX showed promising results and, in the single concentration 
tested,  was able to kill S.aureus in 2 cases on 4.
4.2 Introduction 
Herds characterized by the presence of contagious and non contagious pathogens 
were enrolled in this preliminary study. MIX was administrated in 5 mL filled-up 
syringes (a half PC dose and a half OO dose), within three days from infection 
detecting, for a total of six doses (2 after morning milking and 2 after evening 
milking). MIX results are at least comparable to ATB ones, and MIX could also 
have a potential in killing contagious pathogens.
4.3 Materials and methods
4.3.1. Experimental design
A preliminary study was performed between December 2011 and May 2012.
Farms. The preliminary experiment was carried out in 2 farms managed in a cubicle 
yard and divided into two different lactation groups. Herd size varied from 80 to 
100 cows in lactation, following a twice-daily milking regimen. Cows suffering from 
mastitis were identified at milking time by the farmer. Mastitis diagnosis was 
subsequently confirmed by the veterinarian enrolled in the study for examining the 
cows for inclusion in the trial and for data gathering.
Mastitis Diagnosis. The careful diagnosis of mastitis took into account the changes in 
the milk (chunks, flakes, clots or blood), the changes in the condition of the 
affected quarter (swelling, redness, hardening, heat or pain), and the general 
condition of the animals. Due to well known difficulties of chronic mastitis 
diagnosis, this study took into consideration acute mastitis only for its purpose.
Acute mastitis is characterized by visible signs, such as abnormal milk (flakes, clots, 
decrease in milk production, and sometimes milk discoloration) and hot, swollen, 
and painful quarters. Milk production decreases and the milk composition is 
considerably altered (Harmon, 1994). 
Animals. A total of 40 animals were enrolled in this preliminary study. On each 
farm, cows that fulfilled the inclusion criteria were randomly allocated into 2 
groups: (1) antibiotic (control) group (20 animals), which was treated with 
intramammary antibiotic; (2) MIX group (20 animals), which was treated with a 
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blending of platelet concentrate with ozonated oil, as further described. Each 
animal was enrolled only once.
4.3.2. Preparation of  therapies
4.3.2.1. Preparation of  platelet concentrate (PC)
Collection of Blood. Because it takes time for PC preparation and to have the 
prescribed amount of PC immediately available for treatment as soon as a mastitis 
case was diagnosed, a stock of PC was prepared and kept separated for each one of 
the farms involved in the experiment. In this way, the PC obtained from blood 
donor cows, in good health, free from infections and without any medication 
during the previous 2 mo, was used in a heterologous way for treating only the 
mastitic cows belonging to the same farm of  the blood donor cows.
In addition, all herds followed a national control program against Tbc, Laeukosis 
and Brucellosis, along with a voluntary control plan on other contagious 
pathologies, such as Bvd and Ibr. Blood donor cows were controlled and 
enrollment admitted immune certified cows only.
After surgical scrub preparation of a few centimeters of skin around the 
subcutaneous jugular vein, 450 mL of blood was collected in ad hoc Terumo blood 
bags (Terumo Srl, Rome, Italy) containing citrate-phosphate-dextrose-adenine 
(CPDA-1) using the 16-gauge needle provided with the bags. The bags were 
transported at+4°C to the laboratory within 2 h of collection and immediately 
processed.
Double Centrifugation Method. All separation steps were performed under a 
horizontal laminar flow hood in aseptic conditions. To prepare the PC, the blood 
was drawn into sterile Falcon tubes of 50 mL each (EuroClone SpA, Milan, Italy). 
The tubes were centrifuged at 100 × g for 30 min at 4°C. This caused separation of 
the blood into 3 components: red blood cells at the lowest level, “buffy coat” in the 
middle layer, and platelet-rich plasma (PRP) in the upper layer. Afterward, the PRP 
was carefully aspirated and distributed in new 50-mL tubes and centrifuged again at 
1,500 × g for 10 min at 4°C to obtain the platelet pellet and the poor platelet 
plasma (PPP) at the upper layer. Afterward, two-thirds of the volume of PPP was 
aspirated for later use and the pellet mixed in the residual PPP volume to allow for 
platelet count before the final dilution with PPP to obtain PC at a standard 
concentration of 1 × 109 platelet/mL. All platelet counts on peripheral blood, PRP, 
and PC were performed using a HeCo Vet automatic hematology analyzer (SEAC, 
Florence, Italy).
The total amount of PC obtained for each donor was aliquoted in 10 mL ready-to-
use doses that were stored in syringes. Each syringe has been filled up with 2,5 mL 
of PC and kept under the horizontal laminar flow hood in aseptic conditions for 
MIX preparation, as further described. 
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4.3.2.2. Preparation of  ozonated oil
Edible raw squeezed sunflower oil was poured into a sterile glass beaker and 
bubbled with O2/O3 mixture for different times in order to obtain a O2/O3 
mixture  saturation in the oil at the desired proportion. 
The O2/O3 mixture was prepared by Dr.Hansler GmbH-Ozonosan ozone 
generator and settled to have a O3 concentration in the mixture of 30 mg/L. A 
bubble time of 15 minutes every 100ml of oil led the oil to saturation, as 
controlled samples declared. 
4.3.2.3. Preparation of  mix
The blending of PC platelet concentrate with OO ozonated oil was prepared using 
the PC syringes and the OO, both previously prepared and kept under the 
horizontal laminar flow hood in aseptic conditions. 
Each syringe of 2,5 mL of PC has been added with 2,5 mL of OO. The MIX 
syringes were then frozen at −196°C in liquid nitrogen and thawed at 25°C to allow 
the release of platelet-derived factors, through thermal shock. Platelet count on a 
sample of each preparation has been performed to guarantee the total platelet 
breakdown and release of platelet-derived factors. In addition, the MIX was 
subjected to bacteriological examination to verify its sterility.
Syringes containing the MIX dose were kept frozen at −20°C until use.
4.3.3. Indicators of  udder inflammation
SCC. Somatic cell count was performed starting at d 0, and then at d 7, and 14 of 
treatment. Somatic cell counts were assessed by Istituto Zooprofilattico 
Sperimentale della Lombardia e dell’Emilia Romagna. 
Bacteriological Analysis. Quarter milk samples for bacteriological assays were 
collected before milking using an aseptic procedure at the start of the treatment (d 
0) from each affected quarter. Bacteriological analyses were performed by Istituto 
Zooprofilattico Sperimentale della Lombardia e dell’Emilia Romagna.
4.3.4. Intramammary administration of  therapies
All herd milking procedures included pre-milking cleaning of the teats with 
detergent and single-use paper towels and teat dipping at the end of milking with 
an approved teat disinfectant. All cows were treated after milking as hereafter 
described. After thawing, the syringe in which MIX was stored was connected to a 
sterile disposable teat cannula to help the intramammary inoculation of MIX 
through the teat canal. The antibiotic for local use, chosen on the basis of an 
antibiogram test, was inoculated using the same procedure, according to 
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manufacturer indications. Following inoculation, the udder was gently rubbed with 
upward movement of  the hands to distribute the product. 
As for the preliminary study, five milliliters of MIX or antibiotic alone was 
administrated for 3 consecutive days, depending on the treatment group.
After these treatments, teat dipping was performed.
4.3.5. Classification of  outcomes
Treatment outcomes were assessed by clinical and laboratory evaluations. Clinical 
improvement was defined as the return of quarter and milk secretion to normal. It 
was assessed by visual observation of milk composition and palpation of the 
udder. Good improvement of an udder quarter was defined as having clinically 
progressed and showing, at the time of last examination, an SCC value decreasing 
at least under a value of  300.000 cells/mL.
Bacteriological assays were performed at day 0 and at day 14. Resolution of the 
infection was besides defined as showing no bacterial growth at day 14.
4.3.6. Statistical analysis
The collection efficiency of platelets for each PC obtained by double centrifugation 
tube methods was analyzed using the following formula (Weibrich, 2005):
efficiency for platelet collection = [platelet count μL in PC×volume of PC]/
[platelet count in whole blood μL×volume of  whole blood].
Data were collected in a database and analyzed by the general linear model for 
repeated measures on GraphPad InStat 3.00 for Windows software (Graph- Pad 
Software Inc., La Jolla, CA). The between-subjects factor was represented by 
treatments (3 levels) and the within-subjects factor was represented by sampling 
time (4 levels) and the model applied was a full factorial, with polynomial contrasts 
for within-subjects factor. The statistical analysis of bacteriological data was 
conducted using the Fisher exact test. For all tests, differences were considered 
statistically significant at P ≤ 0.05.
4.4 Results
4.4.1. Platelet collection efficiency
The platelet collection efficiency for the PC obtained by the double centrifugation 
protocol was (mean ± SD) 109 ± 2.3%, indicating that 109 ± 2.3 mL of PC at the 
concentration of  1 × 109 platelet/mL was obtained from 10 mL of  blood.
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4.4.2. SCC and bacteriological assay
At time 0, the average value of SCC was 7,4 × 106 cells/ mL with a standard 
deviation of  6,2 × 106 cells/mL.
The allocation of the enrolled quarters into the 2 different experimental groups 
was performed randomly at the treatment start before the results of the 
bacteriological assays. The distribution of the enrolled quarters positive for 
bacterial growth was random and not significantly different among the treatment 
groups, except for 4 cases of  Staphilococcus Aureus in the mix group. 
Bacteriological detection at day 0 is reported in the following Table 4.1. 










7 57,14% 4 42,86% 3
4 75,00% 3 25,00% 1
4 50,00% 2 50,00% 2
2 50,00% 1 50,00% 1
2 50,00% 1 50,00% 1
6 50,00% 3 50,00% 3
5 60,00% 3 40,00% 2
6 50,00% 3 50,00% 3
4 0,00% 0 100,00% 4
40 20 20
Table 4.2 - Allocation of enrolled quarters with acute mastitis positive to bacterial growth into 2 
experimental groups.
4.4.3. Treatments
Results of the treatments with ATB and MIX are reported in Table 4.2. Statistical 
analysis showed that the MIX treatment had significantly superior performance 
compared with antibiotic relative to the improvement of mammary mastitic 
quarters. 
The MIX treatment decreased the mean value of SCC more significantly than the 
antibiotic treatment. 
SCC MED S0 SCC SD± S0 SCC MED S7 SCC SD± S7 SCC MED S14 SCC SD± S14
MIX
ATB
8,30E+06 6,31E+06 1,09E+06 1,55E+06 6,71E+05 1,16E+06
6,53E+06 6,22E+06 5,20E+05 5,12E+05 2,19E+06 2,71E+06












SCC D0 SCC D7 SCC D14
SCC - MEDIUM VALUES
MIX MIX SD+ MIX SD- ATB ATB SD+ ATB SD-
Figure 4.1 -  Preliminary Study Results. Overall mean values and SD at day 0,7,14.
As for bacteriological assay, no bacterial growth was detected at day 14 in 60% of 
quarters. Two out of four cases of S.aureus treated with MIX showed a complete 
resolution of the disease, while one case suggested the presence of biofilm 
formation without host immune response.
Results are shown in Table 4. 
Case SCC day 0 SCC day 7 SCC day 14 Bacteriological assay day 0 Bacteriological assay day 14
1 12.741.000 395.000 5.010.000 Staphylococcus aureus Staphylococcus aureus
2 100.000 25.000 10.000 Staphylococcus aureus Staphylococcus aureus
3 2.524.000 63.000 60.000 Staphylococcus aureus No bacterial growth
4 650.000 577.000 599.000 Staphylococcus aureus No bacterial growth




Interesting results collected in the preliminary study suggested to try to evaluate the 
eventual synergistic mechanism of action by separating the different active 
components. For this reason an advanced study was performed, in order to 
estimate the single effect of OO and PC, both in comparison with MIX, under an 
antibiotic control.
In addition, the partial efficacy of MIX against S.aureus suggested to investigate 
different MIX concentrations and longer duration treatment. This point is 
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An advanced study was performed between October 2013 and May 2014, and total 
of 80 animals were enrolled. The ATB, PC, OO and MIX performances were 
assessed. MIX showed the best results, suggesting a possible synergistic rapid 
activity operated by PC and OO, and between therapy and host immune system.
5.2 Introduction 
Results collected from the preliminary trial suggested an evaluation of single MIX 
components. In order to get comparable results, only one concentration of PC and 
only one concentration of OO were prepared. PC, OO and MIX were 
administrated in 5 mL filled-up syringes each, within two days from infection 
detecting, for a total of four doses each (2 after morning milking and 2 after 
evening milking). MIX was prepared with a half PC dose and a half OO dose, as 
further described. Results showed a MIX activity far beyond the sum of PC and 
OO activities, leading to the belief  of  a synergistic action of  two component. 
5.3 Materials and methods
5.3.1. Experimental design
After data computation from the preliminary study and collection of promising 
results, an advanced study was performed between October 2013 and May 2014.
Farm. The advanced experiment was carried out in a farm managed in a cubicle 
yard and divided into three different lactation groups. Herd size was of 900 cows in 
lactation, following a twice-daily milking regimen. This herd was characterized by 
high efficiency in the overall sanitary cattle management and usually free of 
contagious pathogens. As in the previous study, cows suffering from mastitis were 
identified at milking time by the farmer. Mastitis diagnosis was subsequently 
confirmed by the veterinarian enrolled in the study for examining the cows for 
inclusion in the trial and for data gathering.
Mastitis Diagnosis. In this second study, in addition to what established in the 
previous experiment about mastistis diagnosis, clinical and instrumental data have 
been collected.
Animals. A total of 80 animals were enrolled in this advanced study. Cows that 
fulfilled the inclusion criteria were randomly allocated into 4 groups: (1) ATB 
(control) group (20 animals), which was treated with intramammary antibiotic, 
chosen as further described; (2) PC group (20 animals), which was treated with 
platelet concentrate, prepared as further described; (3) OO group (20 animals), 
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which was treated with ozonated oil, prepared as further described; (4) MIX group 
(20 animals), which was treated with a blending of platelet concentrate with 
ozonated oil, prepared as further described. 
Each animal was enrolled only once.
5.3.2. Preparation of  therapies
5.3.2.1. Preparation of  platelet concentrate (PC)
Collection of Blood and Double Centrifugation Method for PC collection was 
performed as described in the preliminary study.
Half the amount of PC obtained for each donor was aliquoted in 10 mL ready-to-
use doses that were stored in syringes. Each syringe has been filled up with 5 mL of 
PC. The second half of total amount of PC was kept under the horizontal laminar 
flow hood in aseptic conditions for MIX preparation, as further described. The PC 
syringes were then frozen at −196°C in liquid nitrogen and thawed at 25°C to allow 
the release of platelet-derived factors, through thermal shock. Platelet count on a 
sample of each preparation has been performed to guarantee the total platelet 
breakdown and release of platelet-derived factors. In addition, the PC was 
subjected to bacteriological examination to verify its sterility.
Syringes containing the PC dose were kept frozen at −20°C until use.
5.3.2.2. Preparation of  ozonated oil
OO was prepared as described in the preliminary study. 
Half the amount of OO was aliquoted in 10 mL ready-to-use doses that were 
stored in syringes. Each syringe has been filled up with 5 mL of OO. Syringes 
containing the OO dose were then frozen and kept at −20°C until use.
The second half of total amount of OO was kept under the horizontal laminar 
flow hood in aseptic conditions for MIX preparation, as further described.
5.3.2.3. Preparation of  mix
The blending of PC platelet concentrate with OO ozonated oil was prepared using 
the  second half of total amount of PC kept under the horizontal laminar flow 
hood in aseptic conditions. The PC obtained for each donor was aliquoted in 10 
mL ready-to-use doses that were stored in syringes. Each syringe has been filled up 
with 2,5 mL of PC and then added with 2,5 mL of OO, previously prepared and 
kept in sterile environment. The MIX syringes were then frozen at −196°C in liquid 
nitrogen and thawed at 25°C to allow the release of platelet-derived factors. The 
MIX was subjected to bacteriological examination to verify its sterility. Moreover, 
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platelet count on a sample of each preparation has been performed to guarantee 
the total platelet breakdown and release of  platelet-derived factors.
Syringes containing the MIX dose were kept frozen at −20°C until use.
5.3.3. Indicators of  udder inflammation 
Clinical data were collected ad d 0, d 1, d 2, d 3 from day of inflammation and the 
following parameters were recorded:
S - SWELLING of inflamed area, expressed on a clinical scale of evaluation based 
on: S=0 no swelling, S=1 localized swelling at the teat area of the inflamed quarter, 
S=2  localized swelling at the inflamed quarter, S=3 spreading out of the swelling 
into the whole udder.
PT - PAIN TO TOUCH of inflamed area, expressed on a clinical scale of 
evaluation based on: S=0 no pain, S=1 moderate animal reaction to touch, S=2 
visible animal anxiety and hostility to touch, presence of complaints during the 
milking, S=3 important animal repulsion, opposition to milking, kicking.
RT - RECTAL TEMPERATURE expressed in °C.
MQ - MILK QUALITY, expressed on a scale of evaluation based on: MQ=0 not 
altered milk, MQ=1 presence of chunks, flakes or clots in the milk, MQ=2 milk is 
visibly skimmed or similar to whey, MQ=3 presence of  blood or color alteration.
MDP - MILK DAILY PRODUCTION, as indicated by the measurement 
instrument applied to the milking system and summarized for a daily value.
SCC - Somatic cell count was performed starting at d 0, and then at d 3, d 7 and d 
10 of treatment. Somatic cell counts were assessed by ISZLER (Istituto 
Zooprofilattico Sperimentale della Lombardia e dell’Emilia Romagna).
Bacteriological Analysis. Quarter milk samples for bacteriological assays were 
collected at d 0 and performed as described in the preliminary study.
5.3.4. Intramammary administration of  therapies 
All herd milking procedures included pre-milking cleaning of the teats with 
detergent and single-use paper towels and teat dipping at the end of milking with 
an approved teat disinfectant. All cows were treated after milking as hereafter 
described. After thawing, the syringe in which PC, or OO, or MIX was stored was 
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connected to a sterile disposable teat cannula to help the intramammary inoculation 
of the contents through the teat canal. The antibiotic for local use, chosen on the 
basis of an antibiogram test, was inoculated using the same procedure, according to 
manufacturer indications. Following inoculation, the udder was gently rubbed with 
upward movement of  the hands to distribute the product. 
As for the advanced study, five milliliters of PC alone or five milliliters of OO or 
five milliliters of MIX was administrated for 2 consecutive days, depending on the 
treatment group. Antibiotic only was administrated for 3 or 5 consecutive days, 
according to manufacturer indications.
After these treatments, teat dipping was performed.
5.3.5. Classification of  outcomes 
Treatment outcomes were assessed by clinical and laboratory evaluations. Clinical 
improvement was defined as the return of quarter and milk secretion to normal. It 
was assessed by visual observation of milk composition and palpation of the 
udder. Good improvement of an udder quarter was defined as having clinically 
progressed and showing, at the time of last examination, an SCC value decreasing 
under 300.000 cells/mL, in addition to S=0, PT=0, MQ=0, RT<39°C. 
5.3.6. Statistical analysis
The collection efficiency of platelets for each PC and subsequently for each MIX 
was performed as in the preliminary trial.
5.4 Results
5.4.1. Platelet collection efficiency
The platelet collection efficiency for the PC obtained by the double centrifugation 
protocol was examined as shown in the preliminary trial.
5.4.2. SCC and bacteriological assay
At time 0, the average value of SCC was above 1,5 × 106 cells/ mL. For the 
purpose, single value detection above 1,5 × 106 cells/mL is here considered not 
meaningful. In fact, such value is itself predisposing to a self-instigating tissue 
damage. Prompt SCC fall under such a value is considered indicative of negative 
loop arrest and inversion, and necessary to reach the required improvement.
The allocation of the enrolled quarters into the 4 different experimental groups 
was performed randomly at the treatment start before the results of the 
bacteriological assays. The distribution of the enrolled quarters positive for 
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bacterial growth was random and not significantly different among the treatment 
groups.
5.4.3. Treatments
Results of the treatments with ATB, PC, OO and MIX are reported in Table , 
which shows 
Different clinical and instrumental parameters are described separately.
5.4.3.1. Swelling
Data are reported in Figure 5.4.1. 
The initial medium range was comprised between 2 and 2.5 for all groups. 
PC, OO and MIX showed a faster decrease of swelling at day 1, being assessed 
under S=1 from day 2.
ATB showed a slower swelling reduction, but from day 2 reached the beneath 1 





d 0 d 1 d 2 d 3
SWELLING
ATB PC OO MIX







localized swelling at the teat area of the inflamed quarter
localized swelling at the inflamed quarter
spreading out of the swelling into the whole udder
Figure 5.4.1. Mean Swelling values at day 0-1-2-3 for each congruous group ATB, PC, OO, MIX.
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5.4.3.2. Pain to Touch
Data are reported in Figure 5.4.2. 
The initial medium range was comprised between 1.2 and 1.8 for ATB, PC, and 
MIX groups, being MIX the worse value. OO group started from a lower mean 
value (0.4).
MIX showed the faster decreasing of pain to touch at day 1, being assessed on S=0 
from day 2.
ATB and PC showed a slower linear swelling reduction, but PC alone reached S=0 
at day 3.





d 0 d 1 d 2 d 3
PAIN TO TOUCH
ATB PC OO MIX
Mean Pain to Touch values at days  0-1-2-3 for each congruous group 
ATB, PC, OO, MIX. 






moderate animal reaction to touch
visible animal anxiety and hostility to touch, presence of complaints during the milking
important animal repulsion, opposition to milking, kicking




Data are reported in Figure 5.4.3. 
The initial medium range was similar for PC, OO and MIX groups, being 
comprised between 0.8 and 1.0. ATB group started from a higher mean value (1.6).
MIX showed the best performance, staying unchanged during day 0 and starting  a 
fast decreasing at day 1. MIX showed a modest worsening from day 2, remaining 
clearly under the other groups yet.
PC and OO showed a similar progression, with a slight worsening during day 0 and 
a slow recovering from day 1. Final value at day 3 was between 0.6 and 0.8.
ATB showed the worst performance, with a significant regress during day 0, a 2.8 
value at day 1 and a following progressive slow reduction: it reached at day 3 a value 





d 0 d 1 d 2 d 3
MILK QUALITY
ATB PC OO MIX
Mean Milk Quality values at days  0-1-2-3 for each congruous group 
ATB, PC, OO, MIX. 






presence of chunks, flakes or clots in the milk
milk is visibly skimmed or similar to whey
presence of blood or color alteration




Data are reported in Figure 5.4.4. 
The initial medium range was similar for all groups, being comprised between 
39.0°C and 40.0°C. MIX showed the worse initial value (39.9°C) and OO the best 
(39.0°C).
MIX showed the best performance, with a significant improvement during day 0 
(from 39.9°C to 38.9°C) and a linear progression towards 38.3°C at day 3.
ATB and PC showed a similar progression, with an interesting improvement during 
day 0, but staying assessed over 39.0°C at day 1, and a slight progression towards 
day3. Final value at day 3 was 38.9°C for both.






d 0 d 1 d 2 d 3
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d 0 d 1 d 2 d 3
RT - MIX
Figure 5.4.4. Mean Rectal Temperature values at day 0-1-2-3 for each congruous group ATB, PC, 
OO, MIX. Arrows show SD.
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5.4.3.5. Milk Daily Production
Data are reported in Figure 5.4.5. 
The initial medium range was similar for all groups, being comprised between 18 L 
and 25 L. All groups showed an initial decrease in milk production.
PC, OO and MIX showed a similar progression, with an interesting improvement 
from day 1, and reaching final values at day 3 between 24 L and 32 L.
ATB showed the worst performance, with a critical decrease at day 1. Improvement 







































d 0 d 1 d 2 d 3
MDP - Mean Values
ATB PC OO MIX
Figure 5.4.5. Mean Milk Daily Production values at day 0-1-2-3 for each congruous group ATB, 
PC, OO, MIX. Arrows show SD.
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5.4.3.6. Somatic Cells Count
Data are reported in Figure 5.4.6. All data equal or above 1,5 × 106 cells/mL were 
shown at 1,5 × 106 cells/mL.
The initial value was then the same for all groups, being over 1,5 × 106 cells/mL. 
MIX showed the best performance, with a significant improvement during the first 
three days (from >1,5 × 106 cells/mL to 1,1 × 106 cells/mL) and a linear 
progression towards 2,8 × 105 cells/mL at day 10.
ATB, PC and OO showed no improvement during day 0. PC showed a clear 
recovery between day 3 and day 10, assessing the final value under 4,0 × 105 cells/
mL at day 10. ATM  showed no improvement regarding the mean values. A slight 
improvement is reported by its SD value. OO performed in the middle between PC 







































d 0 d 3 d 7 d 10
MED - CS
MED ATB MED PC MED OO MED MIX




The distribution of the enrolled quarters positive for bacterial growth was random 




ATB % ATB 
n.
PC % PC 
n.
OO % OO 
n.







15 33,33% 5 33,33% 5 0,00% 0 33,33% 5
25 20,00% 5 20,00% 5 20,00% 5 40,00% 10
25 20,00% 5 40,00% 10 36,00% 9 4,00% 1
2 0,00% 0 0,00% 0 100,00% 2 0,00% 0
13 40,00% 5 0,00% 0 30,00% 4 30,00% 4
Table 5.4.7. Bacterial assay distribution for each congruous group ATB, PC, OO, MIX. 
Percentages and total amount of  cases within the same groups.
Pathogens were essentially environmental noncontagious microorganisms, 
according to the choice of this second trial herd, which is characterized by high 
efficiency in the overall sanitary cattle management.
The regular pathogens distribution among different groups allows a consistent 







Bovine mastitis is a public health issue and its control is fundamental to avoid 
serious consequences in the sanitary field and in food industry. 
Mastitis usually occurs primarily in response to intramammary bacterial infection, 
but also to intramammary mycoplasmal, fungal, or algal infections. Mechanical 
trauma, thermal trauma, and chemical insult lead the gland to intramammary 
infection. Occurrence of mastitis depends on the interaction of host, agent, and 
environmental factors.
The worsening of tissue damage operated by the presence of a high congestion of 
neutrophils, cytokines and bacteria establishes a negative cycle, leading to the 
increasing of microbial aggression, decreasing milk production and additionally 
arising of  mammary tissue damage.
These interacting mechanisms are very complex to understand and represent. The 
breakdown of this intricate negative loop is very hard and its reversing requires a 
great and synergistic effort.
For these reasons, prevention should be the first approach to the problem: new 
predictive protocols and containment means, based on the updated evidence of 
interaction among environmental factors, host immune system and evolution of 
bacterial aggression, need to be deployed and shared.
In occurrence, early diagnosis and therapy prompt effectiveness are fundamental to 
control losses.
Tissue damage is here considered a key factor in understanding the great 
complexity of this problem and, as far as known, tissue protection and 
regeneration operated by cathelicidins and other AMPs has been accounted for.
On the other end, bacteria behavior and their evolution in biofilm structures have 
become an issue for further consideration of the relevance of clinical and 
instrumental parameters usually considered to measure the state of inflammation. 
In the matter, SCC data alone has become an unreliable variable, considering the 
nasty occurrence of sessile bacteria that are out of sight for the host immune 
system, and are responsible for undetected infections and recurrent relapses. It is 
reported that the presence of biofilm associated genes likely reduced infectivity in 
the short term but had the opposite effect in late adherence, allowing longer 
bacterial persistence in the mammary gland (Cucarella, 2004). 
This first approach takes into consideration evident acute clinical mastitis and 
gathers new findings from the literature with experimental results. 
As might be expected considering the size of the trial, only a certain concentration 
was designed, administered and evaluated. A deeper comprehension of the 
complementary activity of all mix components could be assessed after gauging a 
broad range of  different concentrations and shot volumes.
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6.1. Significance of  collected data
The collected data have been assessed a conceivable significance.
Somatic Cells Count, Rectal Temperature, and Swelling are considered as 
parameters related to a general activation of host immune system, subsequent to 
bacteria aggression. 
On the other side, Pain to Touch, Milk Quality, and Milk Daily Production are 
considered as tissue damage indicators.
According to the declared relation between immune cells congestion and tissue 
worsening, the two parameter groups are not completely independent, as might be 
evident from collected results. In order to reach a final assay, and a better results 
comparison, a unique scale of evaluation is proposed, assigning a value comprised 
between [-2,+2] according to the inclination changes of  the correlated graph line.
Advanced 
Trial


































d1 d7 d10 d1 d2 d3 d1 d2 d3 d1 d2 d3 d1 d2 d3 d1 d2 d3 overall overall overall
0 0 0 2 0 1 1 2 1 1 1 1 -2 1 0 -2 -2 -2 7 -4 3
0 2 2 2 1 0 2 1 1 1 1 1 -1 1 1 -1 1 1 11 5 16
0 1 1 0 0 0 2 1 1 0 1 1 -1 1 0 -1 1 1 6 3 9
2 2 2 2 2 2 2 2 1 2 2 2 0 2 1 -1 2 2 17 12 29
Table 6.1. Functional activity global evaluation chart for each congruous group ATB, PC, OO, 
MIX. 
Treatment - Advanced Trial
TIME (Day)
SCC - Somatic Cells Count (d3, d7, d10)
RT - Rectal Temperature
S - Swelling
PT - Pain to Touch
MQ - Milk Quality
MDP - Milk Daily Production
ATB PC (5ml × 4 doses) OO (5ml × 4 doses) MIX (5ml × 4 doses)
d1 d2 d3 d1 d2 d3 d1 d2 d3 d1 d2 d3
0 0 0 0 2 2 0 1 1 2 2 2
2 0 1 2 1 0 0 0 0 2 2 2
1 2 1 2 1 1 2 1 1 2 2 1
1 1 1 1 1 1 0 1 1 2 2 2
-2 1 0 -1 1 1 -1 1 0 0 2 1
-2 -2 -2 -1 1 1 -1 1 1 -1 2 2
Total score per day 0 2 1 3 7 6 0 5 4 7 12 10
Table 6.2. Time depending global evaluation chart for each congruous group ATB, PC, OO, 
MIX. Promptness is estimated equalizing SCC days of detection (0-3-7-10) to other parameters 
days of  detection (0-1-2-3).
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In addition, the same data is represented in an inverted chart, in order to endorse 
time-depending effectiveness of  results.
According to these charts, a possible role for different components on tissue 
regeneration and pathogens aggression is further evaluated.
6.2. Antibiotic results (ATB): lack of  tissue protection
In the study, antibiotic results sum to an overall score of 3 points. In regards to 
bacteria aggression and consequential host immune response, the subtotal reached 
by antibiotic is 7 points, while the tissue damage scores a negative -4 points. This is 
in accordance to literature (Cucarella, 2004): antibiotic is single-target drug and 
doesn’t provide any protection to the tissue involved in the inflammatory process. 
Unfortunately, tissue damage plays an active role in the general worsening of the 
inflammation and it can’t be underestimated. This is the first reason for ATB lack 
of  effectiveness.
In addition, as for usual MICs, ATB is mainly reliable against planktonic bacteria 
and it is too often ineffective against sessile communities of bacteria, which can 
display a decreased growth and establish persisters communities, allowing further 
subclinical consequences.
Considering the importance of the time variable, ATB showed 3/6 positive results 
on day 1 and 3/6 positive results on day 2. However, the total score was 0 (zero) on 
day 1 and 2 (two) on day 2, giving evidence of a general lack of synergy of the 
remedy, mostly due to the lack of  tissue protection.
During the trial, ATB was not able to arrest the negative loop bacteria aggression-
host immune response-tissue damage, nor to reverse it.
6.3. Platelet concentrate results (PC): tissue regeneration and host immune response
PC showed interesting positive results both in its synergistic contribution to host 
immune response and for its regenerative value for the tissues. As explained, time is 
a key point on overall problem resolution. PC showed 3/6 positive results on day 1 
and 6/6 positive results on day 2, enhancing a complete restoration of the tissue 
integrity. 
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Total score of PC was 3 on day 1 and 7 on day 2: PC showed a prompt 
effectiveness and a synergistic approach, gaining a total score of 16 points, thus 
performing the best result after MIX.
Through both tissue regeneration and host immune response support, PC seemed 
able to stop and reverse the inflammation negative loop and its dangerous 
consequences on the secreting gland. 
PC seems to show a synergistic action deploying at the same time its antimicrobial 
activity, its immunomodulatory role and its wound healing contribution. This 
synergy is particularly made possible by PC ability to exploit different features in 
milk or in whey, hence only when these are really needed, thus avoiding superfluous 
and counter-productive efforts. 
Likely, as previously reported, PC alone is not able to face biofilm persisters.
4.4. Ozonated oil results (OO): biofilm breakdown, mild host immune response 
enhancement, possible tissue protection
OO positive results could be mainly related to the effectiveness of its assault to 
both planktonic and biofilm bacteria. In addition, its mild host immune response 
enhancement and its regenerative activity on tissues led to a total score of 9 points, 
better than ATB. OO showed only 1/6 positive results on day 1 but 5/6 positive 
results on day 2, leading to the belief  that the positive cycle was settled. 
As might be expected, OO shows a synergistic activity, but without the required 
promptness. Total score of  OO was 0 on day 1 and 5 on day 2.
We hypothesize that OO plays a role in tissue protection: possibly OO upholsters 
the damaged tissue, adhering to epithelial cells and protecting them from host 
immune cells congestion.
Moreover, if the tissue is already covered by bacterial biofilm, OO covers the 
biofilm itself and within the typical tissue temperatures range, it releases gaseous 
ozone. Thus, ozone, being in contact with biological fluids, degenerates into its 
usual metabolites. Among these, H2O2 enters the biofilm protection, assaults and 
decomposes the bacterial membrane, killing the pathogen community. 
Demonstrated OO efficacy against both planktonic and biofilm growing 
Staphylococcus aureus (Al-Saadi, 2015) and other bacterial biofilm (Bialoszewski, 
2011) conveys a possible specific role of  OO into the MIX. 
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4.5. MIX synergistic results: possible biofilm aggression and functional integrity 
restoration
MIX showed 4/6 positive results on day 1 and 6/6 positive results on day 2, 
enhancing a complete restoration of  the tissue integrity. 
Total score of MIX was 7 on day 1 and 12 on day 2: MIX showed a prompt 
effectiveness and a synergistic approach, gaining a total score of 29 points, thus 
performing the best result of  all.
Through both tissue regeneration and host immune response support, MIX was 
able to stop and reverse the inflammation negative loop, besides its dangerous 
consequences on the secreting gland. Moreover it boosted a positive cycle restoring 
the udder functional integrity and enhancing the natural protective mechanisms.
The better MIX performance root might lie in the promptness of the beginning of 
the healing process: it seems that MIX is able to induce valuable and fast-paced 
synergistic activities together with host immune system and tissue protection 
mechanisms. Our understanding is that if the above mentioned positive cycle gets 
generated within the first 12 hours (time lapse between two consecutive milkings) 
since the early infection diagnosis, the recovery chances are exponentially higher.
Accordingly, a chronic mastitis detection protocol must be in place in such a way 
that the chronicities are eliminated (not only contained), acute occurrings are 
prevented, while, at the same time, the contagious pathogens are eradicated, as 
proven possible in the second trial herd.
In addition, as it occurred in the preliminary trial, in two out of four cases of 
S.aureus treated with MIX no pathogen growth was detected at day 14. A gauge of 
the broad range of  different concentrations and shot volumes should be tested.
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4.6. Possible further research
Possible further research could explore:
- administration of different AMPs concentrations and different amounts of PC 
for each MIX dose;
- administration of different ozone concentrations and different amounts of OO 
for each MIX dose;
- administration of  different MIX treatment durations;
- study of  the results in relation to specific pathogens typically growing in biofilm;
- study of the results in relation to the relapse rate and a possible persisters 
detection;
- study of  the combined components teratogenicity, already tested separately;






Bovine mastitis is a public health issue and its control is fundamental to avoid 
serious consequences. Prevention should be the first approach to the problem: new 
predictive protocols and containment means need to be deployed and shared. 
However feasible effective treatments need to be available.
The results of this clinical application point to a promising direction of 
investigation. 
In comparison with other therapies based on either a single component or a 
control group with antibiotic, the blending of platelet concentrate with oxygen/
ozone mix in oil vehicle accomplished the best outcomes in resolving the mastitic 
occurrence, downgrading and fixing the symptoms, and enhancing animal general 
conditions.








1. Al-Rayahi IA, Sanyi RH. The overlapping roles of antimicrobial 
peptides and complement in recruitment and activation of tumor-
associated inflammatory cells. Front Immunol. 2015 Jan 22;6:2.  
Collection 2015.
2. Al-Saadi H, Potapova I, Rochford ET, Moriarty TF, Messmer P. 
Ozonated saline shows activity against planktonic and biofilm 
growing Staphylococcus aureus in vitro: a potential irrigant for 
infected wounds. Int Wound J. 2015 Jan 14. doi: 10.1111/iwj.12412. 
[Epub ahead of  print]
3. Amable PR, Carias RB, Teixeira MV, da Cruz Pacheco I, Corrêa do 
Amaral RJ, Granjeiro JM, Borojevic R. Platelet-rich plasma preparation 
for regenerative medicine: optimization and quantification of 
cytokines and growth factors. Stem Cell Res Ther. 2013 Jun 7;4(3):67. 
doi: 10.1186/scrt218.
4. Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous 
platelets as a source of proteins for healing and tissue regeneration. 
Thromb Haemost. 2004 Jan;91(1):4-15.
5. Argüelles D, Carmona JU, Pastor J, Iborra A, Viñals L, Martínez P, Bach 
E, Prades M. Evaluation of single and double centrifugation tube 
methods for concentrating equine platelets. Res Vet Sci. 2006 Oct;81
(2):237-45.
6. Bannerman DD, Chockalingam A, Paape MJ, Hope JC. The bovine 
innate immune response during experimentally-induced 
Pseudomonas aeruginosa mastitis. Vet Immunol Immunopathol. 2005 
Sep 15;107(3-4):201-15.
7. Beecher C, Daly M, Berry DP, Klostermann K, Flynn J, Meaney W, Hill C, 
McCarthy TV, Ross RP, Giblin L. Administration of a live culture of 
Lactococcus lactis DPC 3147 into the bovine mammary gland 
stimulates the local host immune response, particularly IL-1beta 
and IL-8 gene expression. J Dairy Res. 2009 Aug;76(3):340-8. doi: 
10.1017/S0022029909004154. Epub 2009 May 18.
8. Bialoszewski D, Pietruczuk-Padzik A, Kalicinska A, Bocian E, 
Czajkowska M, Bukowska B, Tyski S. Activity of ozonated water and 
89
ozone against Staphylococcus aureus and Pseudomonas aeruginosa 
biofilms. Med Sci Monit. 2011 Nov;17(11):BR339-344.
9. Bocci V, Aldinucci C. Biochemical modifications induced in human 
blood by oxygenation-ozonation. J Biochem Mol Toxicol. 2006;20(3):
133-8.
10. Bocci V, Zanardi I, Borrelli E, Travagli V. Reliable and effective 
oxygen-ozone therapy at a crossroads with ozonated saline infusion 
and ozone rectal insufflation. J Pharm Pharmacol. 2012 Apr;64(4):
482-9. doi: 10.1111/j.2042-7158.2011.01427.x. Epub 2011 Dec 30.
11. Bocci V. How a calculated oxidative stress can yield multiple 
therapeutic effects. Free Radic Res. 2012 Sep;46(9):1068-75. doi: 
10.3109/10715762.2012.693609. Epub 2012 May 28.
12. Bocci V. Is it true that ozone is always toxic? The end of a dogma. 
Toxicol Appl Pharmacol. 2006 Nov 1;216(3):493-504. Epub 2006 Jun 27.
13. Broeckx S, Zimmerman M, Crocetti S, Suls M, Mariën T, Ferguson SJ, 
Chiers K, Duchateau L, Franco-Obregón A, Wuertz K, Spaas JH. 
Regenerative therapies for equine degenerative joint disease: a 
preliminary study. PLoS One. 2014 Jan 20;9(1):e85917. doi: 10.1371/
journal.pone.0085917. eCollection 2014.
14. Capuco AV, Bright SA, Pankey JW, Wood DL, Miller RH, Bitman J. 
Increased susceptibility to intramammary infection following 
removal of  teat canal keratin. J Dairy Sci. 1992 Aug;75(8):2126-30.
15. Carter CA, Jolly DG, Worden CE Sr, Hendren DG, Kane CJ. Platelet-
rich plasma gel promotes differentiation and regeneration during 
equine wound healing. Exp Mol Pathol. 2003 Jun;74(3):244-55.
16. Clutterbuck AL, Woods EJ, Knottenbelt DC, Clegg PD, Cochrane CA, 
Percival SL. Biofilms and their relevance to veterinary medicine. 2007 
Mar 31;121(1-2):1-17. Epub 2007 Jan 9.
17. Costerton JW. Introduction to biofilm. Int J Antimicrob Agents.   1999 
May;11(3-4):217-21; discussion 237-9.
90
18. Cucarella C, Tormo MA, Ubeda C, Trotonda MP, Monzón M, Peris C, 
Amorena B, Lasa I, Penadés JR. Role of biofilm-associated protein 
bap in the pathogenesis of bovine Staphylococcus aureus. Infect 
Immun. 2004 Apr;72(4):2177-85.
19. da Costa Krewer C, Santos Amanso E, Veneroni Gouveia G, de Lima 
Souza R, da Costa MM, Aparecido Mota R. Resistance to 
antimicrobials and biofilm formation in Staphylococcus spp. 
isolated from bovine mastitis in the Northeast of Brazil. Trop Anim 
Health Prod. 2014 Dec 30. [Epub ahead of  print]
20. Fabres-Klein M, Caizer Santos M, Contelli Klein R, Nunes de Souza G, de 
Oliveira Barros Ribon A. An association between milk and slime 
increases biofilm production by bovine Staphylococcus aureus. 
BMC Vet Res. 2015 Jan 16;11(1):3. [Epub ahead of  print]
21. Fontes B, Cattani Heimbecker AM, de Souza Brito G, Costa SF, van der 
Heijden IM, Levin AS, Rasslan S. Effect of low-dose gaseous ozone on 
pathogenic bacteria. BMC Infect Dis. 2012 Dec 18;12:358. doi: 
10.1186/1471-2334-12-358.
22. Giacometti A, Cirioni O, Gov Y, Ghiselli R, Del Prete MS, Mocchegiani F, 
Saba V, Orlando F, Scalise G, Balaban N, Dell'Acqua G. RNA III 
inhibiting peptide inhibits in vivo biofilm formation by drug-
resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2003 
Jun;47(6):1979-83.
23. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the 
natural environment to infectious diseases. Nat Rev Microbiol. 2004 
Feb;2(2):95-108.
24. Harmon RJ. Physiology of mastitis and factors affecting somatic cell 
counts. J Dairy Sci. 1994 Jul;77(7):2103-12.
25. Hensen SM, Pavicić MJ, Lohuis JA, Poutrel B. Use of bovine primary 
mammary epithelial cells for the comparison of adherence and 
invasion ability of Staphylococcus aureus strains. J Dairy Sci. 2000 
Mar;83(3):418-29.
91
26. Joo HS, Otto M. Molecular basis of in vivo biofilm formation by 
bacterial pathogens. Chem Biol. 2012 Dec 21;19(12):1503-13. doi: 
10.1016/j.chembiol.2012.10.022.
27. Kim JH, Park C, Park HM. Curative effect of autologous platelet-rich 
plasma on a large cutaneous lesion in a dog. Vet Dermatol. 2009 Apr;
20(2):123-6. doi: 10.1111/j.1365-3164.2008.00711.x. Epub 2009 Jan 21.
28. Kościuczuk EM, Lisowski P, Jarczak J, Krzyżewski J, Zwierzchowski L, 
Bagnicka E. Expression patterns of β-defensin and cathelicidin 
genes in parenchyma of bovine mammary gland infected with 
coagulase-positive or coagulase-negative Staphylococci. BMC Vet 
Res. 2014 Oct 6;10:246. doi: 10.1186/s12917-014-0246-z.
29. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides 
have multiple roles in immune defense. Trends Immunol. 2009 Mar;30
(3):131-41.Epub 2009 Feb 13. 
30. Lange-Consiglio A, Spelta C, Garlappi R, Luini M, Cremonesi F. 
Intramammary administration of platelet concentrate as an 
unconventional therapy in bovine mastitis: first clinical application. 
J Dairy Sci. 2014 Oct;97(10):6223-30. doi: 10.3168/jds.2014-7999. Epub 
2014 Aug 6.
31. Lewis K. Riddle of biofilm resistance. Antimicrob Agents Chemother. 
2001 Apr;45(4):999-1007.
32. Mack D, Riedewald J, Rohde H, Magnus T, Feucht HH, Elsner HA, Laufs 
R, Rupp ME. Essential functional role of the polysaccharide 
intercellular adhesin of Staphylococcus epidermidis in 
hemagglutination. Infect Immun.  1999 Feb;67(2):1004-8.
33. Marusi A., Ubaldi A., Fusari A., Marasi G. Lipohydroperoxides in the 
treatment of mastitis in dairy cows. XI Congresso Internazionale della 
Federazione Mediterranea Sanitá e Produzione Ruminanti. 2003 
May.
34. Melchior MB, Fink-Gremmels J, Gaastra W. Comparative assessment of 
the antimicrobial susceptibility of Staphylococcus aureus isolates 
from bovine mastitis in biofilm versus planktonic culture. J Vet Med 
B Infect Dis Vet Public Health. 2006 Sep;53(7):326-32. (2006-1).
92
35. Melchior MB, Vaarkamp H, Fink-Gremmels J. Biofilms: a role in 
recurrent mastitis infections? Vet J. 2006 May;171(3):398-407. (2006-2).
36. Moureu S, Violleau F, Ali Haimoud-Lekhal D, Calmon A. Ozonation of 
sunflower oils: Impact of experimental conditions on the 
composition and the antibacterial activity of ozonized oils. Chem 
Phys Lipids. 2015 Feb;186:79-85. doi: 10.1016/j.chemphyslip.2015.01.004. 
Epub 2015 Jan 23.
37. Ogata A, Nagahata H. Intramammary application of ozone therapy 
to acute clinical mastitis in dairy cows. J Vet Med Sci. 2000 Jul;62(7):
681-6.
38. Oviedo-Boyso J, Valdez-Alarcón JJ, Cajero-Juárez M, Ochoa-Zarzosa A, 
López-Meza JE, Bravo-Patiño A, Baizabal-Aguirre VM. Innate immune 
response of bovine mammary gland to pathogenic bacteria 
responsible for mastitis. J Infect. 2007 Apr;54(4):399-409. Epub 2006 
Aug 1.
39. Roosen S, Exner K, Paul S, Schröder JM, Kalm E, Looft C. Bovine beta-
defensins: identification and characterization of novel bovine beta-
defensin genes and their expression in mammary gland tissue. 
Mamm Genome. 2004 Oct;15(10):834-42.
40. Roosen S, Exner K, Paul S, Schröder JM, Kalm E, Looft C. Bovine beta-
defensins: identification and characterization of novel bovine beta-
defensin genes and their expression in mammary gland tissue. 
Mamm Genome. 2004 Oct;15(10):834-42.
41. Sechi LA, Lezcano I, Nunez N, Espim M, Duprè I, Pinna A, Molicotti P, 
Fadda G, Zanetti S. Antibacterial activity of ozonized sunflower oil 
(Oleozon). J Appl Microbiol. 2001 Feb;90(2):279-84
42. Shinozuka Y, Hirata H, Ishibashi I, Okawa Y, Kasuga A, Takagi M, Taura 
Y. Therapeutic efficacy of mammary irrigation regimen in dairy 
cattle diagnosed with acute coliform mastitis. J Vet Med Sci. 2009 
Mar;71(3):269-73.
43. Smolenski GA, Wieliczko RJ, Pryor SM, Broadhurst MK, Wheeler TT, 
Haigh BJ. The abundance of milk cathelicidin proteins during 
93
bovine mastitis. Vet Immunol Immunopathol. 2011 Sep 15;143(1-2):
125-30. doi: 10.1016/j.vetimm.2011.06.034. Epub 2011 Jul 2.
44. Sordillo LM, Streicher KL. Mammary gland immunity and mastitis 
susceptibility. J Mammary Gland Biol Neoplasia.  2002 Apr;7(2):135-46.
45. Tomasinsig L, De Conti G, Skerlavaj B, Piccinini R, Mazzilli M, D'Este F, 
Tossi A, Zanetti M. Broad-spectrum activity against bacterial 
mastitis pathogens and activation of mammary epithelial cells 
support a protective role of neutrophil cathelicidins in bovine 
mastitis. Infect Immun. 2010 Apr;78(4):1781-8.
46. Valacchi G, Zanardi I, Lim Y, Belmonte G, Miracco C, Sticozzi C, Bocci 
V, Travagli V. Ozonated oils as functional dermatological matrices: 
effects on the wound healing process using SKH1 mice. Int J Pharm. 
2013 Dec 15;458(1):65-73. doi: 10.1016/j.ijpharm.2013.09.039. Epub 
2013 Oct 19.
47. Weibrich G, Kleis WK, Hitzler WE, Hafner G. Comparison of the 
platelet concentrate collection system with the plasma-rich-in-
growth-factors kit to produce platelet-rich plasma: a technical 
report. Int J Oral Maxillofac Implants. 2005 Jan-Feb;20(1):118-23.
48. Whelehan CJ, Barry-Reidy A, Meade KG, Eckersall PD, Chapwanya A, 
Narciandi F, Lloyd AT, O'Farrelly C1 Characterisation and expression 
profile of the bovine cathelicidin gene repertoire in mammary 
tissue. BMC Genomics. 2014 Feb 13;15:128. 
49. Wuertz S, Okabe S, Hausner M. Microbial communities and their 
interactions in biofilm systems: an overview. Water Sci Technol.  
2004;49(11-12):327-36.
50. Zanardi I, Burgassi S, Paccagnini E, Gentile M, Bocci V, Travagli V. What 
is the best strategy for enhancing the effects of topically applied 
ozonated oils in cutaneous infections? Biomed Res Int. 
2013;2013:702949. doi: 10.1155/2013/702949. Epub 2013 Oct 27.
51. Zhao X, Lacasse P. Mammary tissue damage during bovine mastitis: 
causes and control. J Anim Sci.2008 Mar; 86(13 Suppl):57-65. Epub 
2007 Sep 4.
94
52. Zimmermann R, Arnold D, Strasser E, Ringwald J, Schlegel A, Wiltfang J, 
Eckstein R. Sample preparation technique and white cell content 
influence the detectable levels of growth factors in platelet 





Cellule staminali mesenchimali 
dell’amnios equino per il 




Ippologia, Anno 22, n. 3, Settembre 2011
97
98
9. Cellule staminali mesenchimali dell’amnios equino 
per il trattamento delle tendinopatie del cavallo 
sportivo: prima segnalazione
AUTHORS: Anna Lange Consiglio1, Stefano Tassan2, Bruna Corradetti3, Davide 
Bizzaro3, Andrea Bignotti1, Fausto Cremonesi1 
1 Università degli Studi di Milano, Ospedale Grandi Animali, Azienda “Polo Veterinario” di 
Lodi, Sezione di Riproduzione, Lodi Italia 
2 Libero professionista 
3 Università Politecnica Marche, Dipartimento Biochimica Biologia e Genetica, Ancona Italia
9.1 Abstract
Regenerative medicine is an emerging and multidisciplinary field which draws on 
biology, medicine and genetic manipulation for the development of strategies 
aimed at maintaining, enhancing or restoring the function of tissues or organs that 
have been compromised by disease or injury. Because of their ability to 
differentiate into different cell lines, stem cells undoubtedly play a key role in 
developing such strategies. The embryonic cells are totipotent, but their isolation 
involves the destruction of the embryo and the application is limited from their 
oncogenic potential. Adult stem cells (i.e. from bone marrow, BM) have a limited 
potential compared to embryonic stem cells in terms of both in vitro proliferation 
ability and differentiation capacity, and do not appear to noticeably improve long-
term functionality. Stem/progenitor cells derived from extra-fetal sources may 
represent attractive alternative candidates with the potential to circumvent many of 
these limitations, opening new perspectives for developmental biology and 
regenerative medicine. The aims of this work were to provide, for the first time, an 
isolation protocol for horse amnion-derived cells, to investigate the biological 
properties of these cells and to assess whether horse amnion-derived cells can be 
tolerated and exert beneficial effects in vivo when allogenically transplanted into 
horses with tendon injuries.
Our results have shown that these cells have high prolificacy and plasticity, 
differentiating in vitro toward mesodermic and ectodermic lineages, and own ability 
to be frozen without loss of  their characteristics. 
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Through cell transplantation studies in vivo, we found that the transplanted equine 
amnion-derived cells were well-tolerated by horses, and all of the clinical findings 
reported provided compelling evidence to support the exertion of beneficial effects 
by the injected cells.The possibility of administering an immediate intralesional 
treatment which is available before any ultrastructural change is observed within 
the injured tendon, together with the plasticity effect of amniotic MSCs, represent 
the major features of interest for this novel biotechnological approach to equine 
tendinopathies.
9.2 Introduction
Il cavallo atleta è continuamente sottoposto a sollecitazioni meccaniche che spesso 
possono determinare lesioni all’apparato muscolo-scheletrico, in particolare tendini 
e legamenti, che costituiscono la più comune causa di ritiro dei soggetti sportivi 
dall’attività agonistica (Lam et al., 2007). Per queste lesioni muscolo-tendinee le 
terapie tradizionali conservative mediante, per esempio, iniezioni intralesionali di 
steroidi (Kapetanos 1982), di acido ialuronico (Foland et al., 1992) o di 
glicosaminoglicani polisolfati (PSGAG) (Marr et al., 1993), nonché terapie 
chirurgiche quali lo splitting transcutaneo accompagnato da desmotomia della 
briglia radiale, associate a riposo dell’animale per diversi mesi, conseguono nella 
formazione di tessuto cicatriziale con matrice connettivale povera e fibrille 
collagene con diametri ridotti che ne compromettono la guarigione (Woo et al., 
1999). Infatti, in seguito a lesioni tendinee, il tessuto cicatriziale che si forma nel 
focolaio di rottura rappresenta una causa di calo di prestazioni e di aumento del 
rischio di recidiva che ammonta al 56% per i cavalli da salto e al 66% per quelli da 
corsa (Dyson 2004).
Poiché è noto che il tessuto cicatriziale non consente il ripristino di una condizione 
anatomo-funzionale prossima a quella precedente il trauma, nel corso di questi 
ultimi anni sono state sviluppate numerose strategie terapeutiche finalizzate ad 
accelerare i tempi e, soprattutto, la qualità dei processi riparativi tendinei. In 
quest’ottica, del tutto innovativo e promettente è il recente ricorso, anche in 
medicina veterinaria, alla terapia rigenerativa, nuovo emergente campo 
multidisciplinare, che sfrutta la biologia e la manipolazione cellulare per lo sviluppo 
di strategie atte a ripristinare la funzione di organi o tessuti compromessi da eventi 
patologici.
La terapia cellulare è basata sulla capacità delle cellule staminali mesenchimali 
(MSCs) ottenute da midollo osseo (BM) o tessuto adiposo, di differenziare in 
diverse linee cellulari. In medicina veterinaria, approcci terapeutici per trattare danni 
ai tessuti muscolo-scheletrici sono stati sviluppati usando MSCs multipotenti 
100
(Smith et al., 2003; Pacini et al., 2007; Crovace et al., 2007; Fortier e Smith, 2008; 
Guest 2008).
Si ipotizza che le MSCs impiantate in una lesione tendinea possano influire sulla 
rigenerazione tissutale secondo due meccanismi: differenziandosi in tenociti e 
secernendo matrice extracellulare tendinea, oppure, secernendo fattori di crescita 
che inducano le cellule impiantate o quelle residenti a produrre tale matrice 
(Murphy et al., 2003; Caplan e Dennis 2006). I risultati ottenuti da diverse prove di 
applicazione delle MSCs per la rigenerazione di tessuti danneggiati di varia natura 
sono positivi, sia dal punto di vista della ricostituzione della struttura sia del 
recupero della funzionalità. Diversi studi hanno dimostrato che, in seguito ad 
inoculazione di MSC da BM in lesioni tendinee del tendine flessore superficiale 
delle falangi, in tempi relativamente brevi (40-100 giorni) si è verificata la completa 
ricostituzione dell’architettura e della struttura del tessuto, valutata mediante tecnica 
ultrasonografica, istologica ed immunoistochimica (Smith et al., 2003; Koch et al., 
2008; Lacitignola et al., 2008; Crovace et al., 2010).
Nonostante l’incremento della terapia cellulare per trattare problemi di natura 
ortopedica nell’equino, molte problematiche rimangono senza risposta 
relativamente alla fonte ottimale di cellule mesenchimali, ai tempi ed alle modalità di 
trattamento in base al tipo di lesione, alla valutazione della sicurezza delle terapie in 
termini di potenziale tumorigenico ed all’efficacia del trattamento (Berg et al., 2009).
Il BM è stato considerato, per lungo tempo, la principale fonte di MSCs adulte. In 
numerosi studi è stato dimostrato come l’inoculo di cellule provenienti da BM in 
tendini anche gravemente danneggiati producesse una significativa rigenerazione in 
luogo di una riparazione cicatriziale (Caplan 2007). Per queste loro attitudini, l’uso 
di cellule staminali mesenchimali isolate da BM o talvolta, in modo più empirico, 
l’impiego di BM tal quale, è stato introdotto tra le terapie delle tendinopatie e delle 
desmopatie del cavallo (Smith et al., 2003; Crovace et al., 2007; Pacini et al., 
2007;Wilke et al., 2007; Fortier e Smith 2008; Guest 2008). Il BM tal quale contiene, 
però, anche derivati e precursori ossei e cellule adipose che potrebbero essere 
deleteri per la guarigione innescando la formazione di mineralizzazioni distrofiche o 
metaplasie nella sede di inoculo. Inoltre, è riportato in letteratura che le cellule 
derivanti da BM mostrano una limitata capacità di proliferazione (circa 32 giorni 
per l’espansione fra l’isolamento e l’impianto) e differenziamento (Guest et al., 
2010) che aumenta con l’età del donatore ed il numero di passaggi in vitro 
(Digirolamo et al., 1999; Guillot et al., 2007) e non danno miglioramenti funzionali a 
lungo termine (Paris e Stout, 2010). Infine, la raccolta di BM richiede una 
procedura invasiva che è stata associata occasionalmente nell’equino a 
pneumopericarditi (Durando et al., 2006). Altra fonte di MSCs è rappresentata dal 
tessuto adiposo, ma alcuni ricercatori hanno evidenziato che queste cellule 
posseggono un minor potenziale osteogenico e condrogenico (Winter et al., 2003; 
Muschler et al., 2004; Im et al., 2005).
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Le cellule provenienti dagli annessi fetali potrebbero rappresentare una valida 
alternativa per superare alcune di queste limitazioni, aprendo nuove prospettive per 
lo sviluppo della medicina rigenerativa. In medicina umana, la membrana amniotica 
isolata dalla placenta a termine è una fonte particolarmente attraente di cellule 
staminali mesenchimali perché è solitamente eliminata alla nascita, il suo utilizzo 
non comporta conflitti etici e permette un recupero molto efficiente di MSCs senza 
richiedere procedure invasive. Il fatto che la placenta sia fondamentale per il 
mantenimento della tolleranza materno-fetale durante la gravidanza suggerisce, 
inoltre, che le cellule presenti nel tessuto placentare possano avere caratteristiche 
immuno-modulatorie che riducono i rischi del rigetto immunologico delle cellule 
staminali trapiantate da parte del ricevente (Evangelista et al., 2008). Infatti, la 
membrana amniotica umana e le cellule epiteliali amniotiche isolate da essa hanno 
mostrato la capacità di sopravvivere per lungo tempo in animali 
immunocompetenti quali conigli (Avila et al., 2001), ratti (Kubo et al., 2001), 
porcellini d’India (Yuge et al., 2004) e scimmie (Sankar e Muthusa- my, 2003). 
Recenti studi hanno anche dimostrato che cellule mesenchimali di amnios umano 
possono fortemente inibire la proliferazione dei linfociti T (Magatti et al., 2008) e 
mostrare bassa immunogenicità (Bailo et al., 2004). Inoltre, è stato riportato che tali 
cellule posseggono l’abilità di differenziarsi in più linee cellulari (Ilancheran et al., 
2007; Evangelista et al., 2008) ed avere funzioni anti-infiammatorie (Sarugaser et al., 
2005).
In medicina veterinaria, la membrana amniotica in toto è stata usata in terapie 
cliniche per la ricostruzione della superficie oculare in cavalli (Ollivier et al., 2006; 
Plummer 2009) e cani (Arcelli et al., 2009) poiché è una struttura avascolare, pro- 
muove la ri-epitelizzazione, decresce infiammazione e fibrosi (Solomon et al., 2005) 
e modula l’angiogenesi (Dua et al., 2004). Considerando che il processo di 
guarigione richiede fattori di crescita che stimolano l’angiogenesi, la mitogenesi e la 
formazione di matrice, le cellule derivanti dall’amnios potrebbero rappresentare un 
prezioso strumento per la terapia cellulare in ambito veterinario.
Lo scopo di questa sperimentazione è stato la messa a punto di un protocollo per 
l’isolamento di cellule mesenchimali dalla membrana amniotica e la 
caratterizzazione delle presunte cellule staminali sulla base della loro capacità 
proliferativa e differenziativa in senso osteogenico, adipogenico, condrogenico e 
neurogenico, anche in seguito a crioconservazione. Inoltre, per la prima volta, un 
ulteriore obiettivo di questo studio è stato l’impiego di cellule mesenchimali 
allogeniche di derivazione amniotica per il trattamento delle patologie dell’apparato 
muscolo-scheletrico nel cavallo.
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9.3 Materials and methods
Tutti i reagenti impiegati in questa sperimentazione, se non diversamente indicato, 
sono stati acquistati dalla Sigma Aldrich, Milano, Italia.
Raccolta della membrana allanto-amniotica Per questo studio sono stati 
lavorati cinque campioni di membrana amniotica prelevati al momento del parto. I 
campioni sono stati posti a 4°C in tampone fosfato salino privo di calcio e 
magnesio (PBS, Euroclone, Milano, Italia), supplementato con 100 U/ml 
penicillina, 100 μg/ml streptomicina e 0,25 μg/ml amfotericina B e processati 
entro 12 ore dal prelievo. La membrana amniotica, sottile e trasparente, è stata 
separata meccanicamente dall’allantoide vascolarizzata (Fig. 1) e sottoposta a 
digestione enzimatica.
Isolamento di cellule amniotiche mesenchimali I frammenti di ogni campione 
di amnios sono stati incubati per 9 minuti a 37°C in PBS contenente 2,4 U/ml 
dispasi (Becton Dickinson and Company, Milano, Italia). Dopo un periodo di 5-10 
minuti a tem- peratura ambiente in High Glucose - Dulbecco’s Modified Eagle’s 
Medium (HG-DMEM; Euroclone), addizionato con 10% di siero fetale bovino 
(FBS, Fetal Bovine Serum) e 2 mM L-glutammina, i frammenti sono stati digeriti 
con 0,93 mg/ml collagenasi tipo I e 20 μg/ml DNAsi (Roche, Mannheim, 
Germany) per circa 3 ore a 37°C. Il prodotto della digestione è stato filtrato 
utilizzando un filtro da 100 μm. Il filtrato è stato centrifugato a 200xg per 10 minuti 
per raccogliere le cellule mesenchimali isolate. Queste cellule sono state denominate 
cellule mesenchimali amniotiche (AMCs). Il numero delle cellule vitali isolate è 
stato contato mediante saggio di esclusione con il colorante Trypan blue, usando la 
camera di Bürker.
Coltura, espansione e conta cellulare Successivamente all’isolamento, le AMCs 
sono state seminate alla densità di 1x105 cell/cm2 e le colture cellulari sono state 
mantenute con HG- DMEM addizionato con 10% FBS, 10 ng/ml epidermal 
growth factor (EGF), 100 U/ml penicillina, 100 μg/ml streptomicina, 0,25 μg/ml 
amfotericina B e 2 mM L-glutammina. Le colture cellulari sono state mantenute in 
incubatore ad un’atmosfera al 5% CO2 e 90% umidità, ed alla temperatura di 
38,5°C per gli esperimenti descritti in seguito. Il terreno di coltura è stato cambiato 
per la prima volta dopo 72 ore dalla semina per eliminare le cellule non aderenti. Il 
mantenimento delle colture cellulari ha previsto la rimozione del terreno di coltura 
due volte la settimana. Al raggiungimento di una confluenza pari a circa l’80% della 
superficie della fiasca a passaggio 0 (P0) la coltura primaria è stata espansa, 
staccando le cellule dal fondo della fiasca con 0,05% tripsina/0,02% EDTA in 
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tampone fosfato (Euroclone) a 37°C per 2-3 minuti. Dopo la conta, la sospensione 
cellulare è stata ridistribuita in fiasche di coltura più ampie in rapporto 1:2 (P1) 
seminando circa 1x104 cell/cm2 al fine di mantenere ed espandere la coltura fino al 
decimo passaggio.
Analisi della proliferazione cellulare Doubling Time (DT) Per l’analisi del DT è 
stata utilizzata la metodica della conta seriale, cioè le cellule sono state contate a 
passaggi successivi da P1 a P10. Per questo scopo, le AMCs sono state seminate alla 
densità di 3x103 cell/cm2 ed il cambio di terreno è stato eseguito ogni tre giorni 
sino al raggiungimento di circa l’80% di confluenza, momento in cui le cellule sono 
state tripsinizzate, contate e seminate alla stessa densità.
Il DT è stato ottenuto a ciascun passaggio accordandosi alle formule CD = log 
(Nf/Ni)/log2, e DT = CT/CD, dove CD rappresenta il fattore di duplicazione 
cellulare, Nf è il numero finale di cellule a confluenza, Ni è il numero iniziale di 
cellule seminate, CT rappresenta il tempo di mantenimento della coltura.
Analisi delle unità formanti colonie fibroblastoidi (CFU-F) Per il test delle CFU-F, le 
AMCs sono state seminate, subito dopo il loro isolamento (P0) a densità differente 
(100, 250, 500 e 1000 cell/cm2) e mantenute in incubatore a 38,5°C, in 
un’atmosfera con il 5% CO2 e 90% umidità, per 2 settimane in terreno HG-
DMEM arricchito come descritto precedentemente. Le colonie sono state fissate in 
formalina al 4%, colorate con 1% di Blu di Metilene (Serva, Heidelberg, Germania) 
in tampone borato 10mM  (pH 8,8; Fluka, BioChemika, Buchs, Svizzera) a 
temperatura ambiente e lavate con acqua distillata per due volte. Le colonie 
comprendenti un numero di cellule nucleate maggiore di 16-20 sono state contate 
utilizzando un microscopio rovesciato Olympus BX71.
Differenziamenti in vitro
Lo studio prevedeva di analizzare il potenziale plastico delle cellule isolate, 
mediante induzione del differenziamento osteogenico, adipogenico, condrogenico e 
neurogenico.
Per tale studio, le cellule isolate da amnios sono state espanse e a P3 sono state 
seminate alla densità di 3x103 cellule/cm2 per il trattamento differenziativo e ad una 
densità di 1x103 cellule/cm2 per il controllo. Per i primi 3-4 giorni, le cellule sono 
state incubate con il terreno utilizzato per la loro espansione (HG-DMEM 
arricchito) in modo da permetterne l’adesione ed il raggiungimento della 
confluenza, momento in cui sono stati avviati i trattamenti differenziativi.
Differenziamento osteogenico
Per il differenziamento osteogenico, le colture cellulari sono state incubate in HG-
DMEM addizionato con 10% FBS, 100 U/ml penicillina, 100 μg/ml streptomicina, 
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0,25 μg/ml amfotericina B, 2 mM L- glutammina, 10 mM β-glicerofosfato, 0,1 μM 
desa- metasone, 250 μM acido ascorbico.
Il differenziamento osteogenico è stato condotto incubando le cellule per 3 
settimane a 38,5°C in un’atmosfera con il 5% CO2. Per il controllo è stato 
utilizzato il terreno di espansione cellulare di base per il mantenimento delle cellule 
amniotiche in coltura. Al 21° giorno, l’osteogenesi è stata valutata con la 
convenzionale colorazione von Kossa usando 1% di nitrato d’argento e 5% di 
tiosolfato di sodio per la determinazione dei depositi di calcio.
Differenziamento adipogenico
Per indurre il differenziamento adipogenico, le cellule sono state stimolate con tre 
cicli di induzione/mantenimento. Ogni ciclo prevedeva una coltura di 3 giorni con 
un terreno di induzione specifico per l’adipogenesi ed un altro periodo di 3 giorni 
con un terreno di mantenimento.
Il terreno di induzione era costituito da HG- DMEM, supplementato con il 10% 
FBS, 100 U/ml penicillina, 100 μg/ml streptomicina, 0,25 μg/ml amfotericina B, 2 
mM L-glutammina, 10 μg/ml insulina, 150 μM indometacina, 1 μM desametasone 
e 500 μM 3-isobutil-metil-xantina (IBMX). Il terreno di mantenimento era 
costituito da HG-DMEM, supplementato con il 10% FBS e 10 μg/ml insulina. Le 
cellule di controllo sono state coltivate per lo stesso periodo di tempo unicamente 
nel terreno di mantenimento. Dopo 3 settimane, il trattamento differenziativo è 
stato bloccato e l’adipogenesi è stata analizzata usando la colorazione 
convenzionale Oil red O (0,1% di Oil red O in 60% di isopropanolo) per 
visualizzare le gocce lipidiche.
Differenziamento condrogenico
Il differenziamento condrogenico è stato indotto incubando le cellule in 
monostrato per 2-3 settimane in DMEM low-glucose (LG-DMEM, Euroclone), 
supplementato con 100 nM desametasone, 50 μg/ml acido-L-ascorbico-2-fosfato, 1 
mM sodio piruvato (BDH Chemicals Ltd., Poole, UK), 40 μg/ml prolina, ITS 
(insulina 5 μg/ml, transferrina 5 μg/ml, selenito di sodio 5 ng/ml) e 5 ng/ml TGF-
β3 (Pe- provet, DBA Italia). Le cellule di controllo sono state coltivate per lo stesso 
periodo di tempo nel terreno di crescita standard per le cellule amniotiche (HG-
DMEM supplementato). Dopo 3 settimane, la presenza di matrice metacromatica è 
stata dimostrata dalla colorazione con Alcian Blue pH 2,5.
Differenziamento neurogenico
Il differenziamento neurogenico è stato eseguito con una pre-induzione di 24 ore in 
un terreno costituito da HG-DMEM addizionato con 20% FBS e 1 mM β-
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mercaptoetanolo (BME) (Mitchell et al., 2003). Successivamente, l’induzione 
neurogenica è stata effettuata con un terreno costituito da HG- DMEM 
supplementato con 2% FBS, 2% DMSO e 200 μM  idrossianisolo butilato (BHA) 
per 3 giorni. Le cellule di controllo sono state mantenute per lo stesso periodo di 
tempo nel terreno di coltura standard delle cellule amniotiche. Il differenziamento 
neurogenico è stato valutato attraverso la morfologia delle cellule e la colorazione di 
Nissl (0,1% Cresyl violetto) che mostra l’incremento di corpi tigroidi.
Analisi dei marker di espressione attraverso RT-PCR Mediante RT-PCR, è 
stata indagata sia l’espressione di marker specifici (CD34, CD29, CD44, CD166, 
CD105, MHC I e MHC II) caratterizzanti le AMCs indifferenziate a P1 e P5, sia 
l’espressione di marker specifici espressi dalle cellule differenziate ottenute dopo 
specifica induzione.
L’RNA totale è stato estratto a P1 e P5 dalle AMCs indifferenziate usando 
TRIZOL® Reagent (Invitrogen Carlsbag, CA, USA) seguito da un trattamento con 
DNasi accordandosi alle specifiche tecniche del produttore. La concentrazione e la 
purezza di RNA sono state misurate usando lo spettrofotometro NanoDrop 
(NanoDrop ND1000). Il cDNA è stato sintetizzato dall’RNA totale usando il kit 
iScript retrotranscription kit (Bio-Rad Laboratories, Hercules, CA, USA). La PCR 
convenzionale è stata effettuata in un volume finale di 25 μl con DreamTaq DNA 
Polymerase (Fermentas GmbH, St. Leon Rot, Germany). I primer oligonucleotidici 
specifici per l’equino sono stati disegnati tramite il software PerlPrimer v.1.1.17, 
basandosi sulle sequenze disponibili presso l’NCBI per la specie Equus caballus o su 
sequenze consenso costruite mediante multi-allineamento di geni omologhi di 
interesse nei mammiferi. Le sequenze oligonucleotidiche sono state disegnate a 
cavallo tra esoni, con lo scopo di evitare l’amplificazione del DNA genomico.
Per gli esperimenti di differenziamento, l’RNA totale è stato estratto da cellule 
indifferenziate (cellule di controllo) e da cellule indotte ai differenziamenti. L’analisi 
della RT-PCR è stata effettuata come precedentemente d e s c r i t t o . 
Tessuti di equino adulto (osseo, adiposo, cartilagineo e midollo spinale) sono 
stati impiegati come controllo positivo per analizzare l’espressione dei marker 
osteogenici (osteocalcina [BGLAP] ed osteopontina [OPN]), adipogenici 
(peroxisome proliferator actived receptor-γ [PPAR-γ] e adiponectina [ADIPQ]), 
condrogenici (collagene tipo 2α1 [COL2A1] ed aggrecano [ACAN]) e neurogenici 
(Nestina [NES] e Proteina Acida Glio Fibrillare [GFAP]).
I primer sono stati utilizzati ad una concentrazione finale pari a 200 nM. Il 
GAPDH è stato utilizzato come gene di riferimento.
Immunocitochimica
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Sono stati valutati gli antigeni Oct-4,TRA 1-60 e SSEA-4, a P3, in quanto marker di 
pluripotenza tipici delle cellule staminali embrionali (ESCs). Gli anticorpi sono stati 
scelti sulla base dei risultati ottenuti da Hoynowski et al. (2007). Gli anticorpi 
primari sono stati acquistati dalla ditta Abcam, (Cambridge, UK), mentre quelli 
secondari sono stati forniti da Invitrogen.
Per l’immunocitochimica le cellule sono state fissate in 3,7% paraformaldeide per 
15 minuti e lavate tre volte in PBS. Per valutare la presenza dell’antigene Oct-4, le 
cellule sono state permeabilizzate in 0,4% Triton-X100 diluito in PBS per 10 minuti 
a temperatura ambiente. Dopo tre lavaggi con PBS, tutte le cellule sono state 
bloccate in PBS addizionato con il 2% di albumina sierica bovina (BSA) per 4 ore a 
4°C, e sono state, quindi, incubate con gli anticorpi primari per 12 ore a 4°C. 
Successivamente, sono stati effettuati tre lavaggi e le cellule sono state incubate con 
gli anticorpi secondari coniugati con il fluoroforo AlexaFluor-488 (Invitrogen, 
diluizione 1:250) per 1 ora. Infine, per la colorazione nucleare, l’Hoechst 33342 (1 
mg/ml) è stato diluito 1:100 in PBS e caricato sui campioni per 15 minuti.Tutte le 
analisi sono state basate su cellule di controllo incubate con isotipi specifici IgGs 
per stabilire il segnale di background. Le immagini sono state visualizzate attraverso 
il microscopio Olympus BX 51.
Istologia dell’allantoamnios
Opportuni campioni di allantoamnios sono stati fissati in 10% formalina a 
temperatura ambiente per 24 ore, inclusi in paraffina e tagliati con microtomo 
(Leica Instruments GmbH) per ottenere sezioni dello spessore di 5-7 μm. I vetrini 
sono stati colorati con Ematossilina/Eosina col metodo di Mallory.
Crioconservazione
Le cellule sono state congelate a P0 in HG- DMEM con il 50% di FBS ed il 10% di 
DMSO per 6 mesi a -80°C. Dopo scongelamento alcune cellule sono state usate 
per lo studio del doubling time, mentre altre cellule sono state espanse fino a P3 
per gli studi di immunocitochimica e per valutare l’espressione dei marker specifici 
di mesenchimalità e di differenziamento multilineare. I risultati sono stati 
confrontati con quelli delle cellule fresche.
Casi clinici
In questo studio sono stati impiegati 3 cavalli ai quali è stata diagnosticata una 
lesione spontanea a livello delle strutture teno-legamentose degli arti. Nello 
specifico sono riportati i seguenti casi: il primo cavallo (caso 1) era affetto da una 
lesione traumatica acuta del tendine flessore superficiale del dito (SDFT) 
coinvolgente l’80% della sezione trasversale del tendine (Fig. 10, caso 1 A, B); nel 
secondo caso (caso 2) è stata individuata una lesione severa di 0,58 cm2 nel 
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medesimo tendine (Fig. 10, caso 2 A, B); il terzo caso era rappresentato da un 
cavallo con una lesione acuta del legamento accessorio del tendine flessore 
profondo (AL-DDFT) la cui area danneggiata è stata quantificata in 2,32 cm2 (Fig. 
10, caso 3 A, B).
Impianto delle MSCs all’interno della struttura teno-legamentosa Previo consenso informato 
dei proprietari, 1 milione di cellule mesenchimali allogeniche a P3 diluite in 100 μl 
di plasma autologo sono state inoculate per via intradermica in alcuni cavalli con 
anamnesi conosciuta, per valutare eventuali reazioni avverse. L’osservazione è 
durata 6 mesi. In seguito, nelle lesioni dei tre casi clinici precedentemente descritti, 
sono state impiantate aliquote di 1 milione di AMCs allogeniche sempre a P3, 
diluite in 800 μl di plasma autologo. La procedura prevedeva la tricotomia della 
regione in cui era presente la lesione, in modo da poter effettuare un’ecografia di 
controllo prima di procedere all’impianto. I soggetti sono stati sedati con 
Detomidina (0,01 mg/kg) e successivamente si è proceduto alla preparazione del 
campo chirurgico previa anestesia tronculare, o cerchiante, prossimale rispetto al 
sito di lesione impiegando una soluzione di Mepivacaina al 2%. La sonda 
dell’ecografo è stata inserita all’interno di una guaina sterile o all’interno di un 
guanto sterile e l’area veniva cosparsa di alcool a 90% per permettere la diffusione 
delle onde ultrasonore. Le iniezioni sono state eseguite sotto controllo ecografico. I 
tendini flessori superficiali delle falangi (SDFT) sono stati iniettati con tecnica 
longitudinale (preferita in questi casi dall’operatore) con un ago 20 gauge e 70 mm, 
in direzione prossimale-distale. Le lesioni a carico di tutte le altre strutture sono 
state eseguite con tecnica trasversale usando un ago 21 gauge e 40 mm, inserito 
lateralmente.
L’arto è stato poi fasciato con cotone garzato sterile e fasce elastiche (Vetrap®). 
Tale fasciatura è stata mantenuta per 48 h ed i cavalli sono stati confinati in box, 
prima di consentire 15 minuti di passo a mano per 15 giorni, aumentati a 30 minuti 
per un medesimo periodo. Non sono stati mai somministrati antibiotici o farmaci 
anti-infiammatori non steroidei (FANS).
9.3 Results
Raccolta delle membrane amniotiche ed isolamento di AMCs Dalla porzione 
lavorata di ciascun amnios equino a termine sono state generalmente isolate circa 
25x106 di AMCs. La vitalità iniziale è stata pari al 75%.Tutte le cellule isolate sono 
state seminate e durante la coltura si sono selezionate cellule in base alla loro 
capacità di aderire alla piastra. Le AMCs hanno mostrato una morfologia fibroblast- 
like (Fig. 2A). Le colonie cellulari, osservate ai primi stadi di coltura, hanno avuto la 
capacità di formare cluster (Fig. 2B).
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Dopo scongelamento (a P0), la vitalità delle cellule è stata dell’80% per le AMCs 
che hanno conservato la loro forma fibroblast-like.
Analisi della proliferazione cellulare
Doubling Time
La capacità proliferativa delle AMCs è diminuita a partire dal P8 (p<0,05), ma è 
stata molto intensa tra P4 e P6. Il valore medio di DT è stato di 1,17±0,15 giorni 
(Fig. 3).
Dopo scongelamento il DT medio osservato è stato di 1,88 ± 0,51 giorni.
Analisi delle unità formanti colonie fibroblastoidi Nelle AMCs è stato osservato un 
incremento statisticamente significativo (p<0,05) della frequenza di CFU-F 
all’aumentare della densità di semina (Tabella 1). Un esempio di colonia è 
rappresentato nella Fig. 4.
Differenziamenti in vitro
È stato valutato il potenziale multidifferenziativo delle AMCs (Fig. 5).
Differenziamento osteogenico
Dopo 10 giorni di induzione il differenziamento osteogenico delle AMCs è stato 
confermato dalla colorazione Von Kossa, che ha evidenziato i depositi di calcio. Le 
cellule, inoltre, hanno modificato la propria morfologia aumentando anche le 
proprie dimensioni. Il controllo è risultato, invece, negativo alla colorazione non 
mostrando matrice mineralizzata. L’analisi dell’espressione dei marker osteogenici 
BGLAP e OPN attraverso RT-PCR ha confermato l’induzione osteogenica.
Differenziamento adipogenico
Le AMCs hanno mostrato la capacità di differenziare nella linea adipogenica, come 
dimostrato dal risultato positivo della colorazione con Red Oil O effettuata dopo 3 
settimane di coltura nel terreno adipogenico. Le cellule mantenute nel terreno 
standard non hanno mostrato depositi lipidici e, quindi, la colorazione è risultata 
negativa. L’analisi dell’espressione dei marker adipogenici PPAR-γ e ADIPQ 
attraverso RT-PCR ha confermato l’induzione adipogenica. Le cellule indotte al 
differenziamento hanno rivelato un’aumentata espressione di PPAR-γ e 
adiponectina rispetto al controllo. Il tessuto adiposo è stato usato come controllo 
positivo di espressione dei marker adipogenici.
Differenziamento condrogenico
Le AMCs hanno mostrato la capacità di differenziare nella linea condrogenica, 
come è risultato dalla colorazione con Alcian Blue. Il controllo ha dato esito 
negativo alla colorazione, come atteso. L’analisi dell’espressione dei marker 
condrogenici, COL2A1 e ACAN attraverso RT-PCR ha confermato l’avvenuta 
induzione. Le cellule indotte al differenziamento hanno mostrato un’aumentata 
espressione di COL2A1 e ACAN rispetto al controllo, che non ha mostrato 
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l’espressione dei marker. Il tessuto cartilagineo è stato usato come controllo 
positivo di espressione dei marker condrogenici.
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FIGURA 3 - DT a differenti passaggi durante la coltura cellulare delle AMCs.
Legenda: asterischi all’interno del grafico indicano differenze statisticamente signi-
ficative (P<0,05) rispetto a P1 per le cellule fresche.
rurgico previa anestesia tronculare, o cerchiante,
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FIGURA 2 - (A) Monostrato di AMCs, 10X e (B) AMCs con un piccolo cluster,
20X. Scale bar 20 microns
FIGURA 4 - Colonia cellulare (CFU-F, 20x).
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osteogenici BGLAP e OPN attraverso RT-PCR ha
confermato l’induzione osteogenica.
Differenziamento adipogenico
Le AMCs hann  mostrato la capacità di differen-
ziare nella linea adipogenica, come dimostrato dal
risultato positivo della colorazione con Red Oil O
effettuata dopo 3 settimane di coltura nel terreno
adipogenico. Le cellule mantenute nel terreno
standard non hanno mostrato depositi lipidici e,
quindi, la colorazione è risultata negativa. L’analisi
dell’espressione dei marker adipogenici PPAR-γ e
ADIPQ attraverso RT-PCR ha confermato l’indu-
zione adipogenica. Le cellule indotte al differenzia-
mento hanno rivelato un’aumentata espressione
di PPAR-γ e adiponectina rispetto al controllo. Il
tessuto adiposo è stato usato come controllo po-
sitivo di espressione dei marker adipogenici.
Differenziamento condrogenico
Le AMCs hann  mostrato la capacità i diffe-
renziare nella linea condrogenica, come è risul-
TABELLA 1
CFU-F per le AMCs a P0





Legenda: lettere diverse all’interno della stessa colonna indicano differenze stati-
sticamente significative per P<0,05.
FIGURA 5 - Differenziamenti nelle linee mesodermiche ed ectodermica confermate da colorazioni morfologiche ed
espressione genica dei geni specifici delle linee cellulari di induzione.
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Differenziamento neurogenico 
Dopo 3 giorni di induzione, il differenziamento neurogenico è stato confermato 
non solo dalla morfologia assunta dalle cellule in piastra, ma anche dalla positività 
alla colorazione di Nissl. Le AMCs hanno mostrato la tipica morfologia dei neuroni 
con processi axon-like e dendrite-like e la presenza dei processi primitivi tipici, 
come quelli osservati nei neuroni. L’espressione del gene GFAP ha indicato, però, 
che in queste condizioni di coltura le cellule amniotiche probabilmente sono state 
indotte a differenziare in cellule gliali per la mancata espressione della nestina 
(NES).
Il GAPDH è stato impiegato come gene riferimento. Le cellule scongelate sono 
state in grado di differenziarsi verso le stesse linee testate per le cellule fresche 
isolate (dati non mostrati).
Analisi dei marker di espressione attraverso RT-PCR L’analisi RT-PCR ha 
permesso di evidenziare, a differenti passaggi (a P1 e P5), la presenza degli RNA 
messaggeri di marker specifici per le MSCs
(CD29, CD44, CD166, CD105) e l’assenza del marker ematopoietico (CD34) (Fig. 
6).Tuttavia, le cellule hanno cominciato ad esprimere quest’ultimo marker a P5 (dati 
non mostrati). Le AMCs hanno espresso l’antigene di immunoistocompatibilità I 
(MHC-I) sino a P5, mentre non si è manifestata espressione dell’antigene di 
immunoistocompatibilità II (MHC-II) a P1, che si è espresso al passaggio P5. Il 
GAPDH è stato usato come gene di riferimento. Nei campioni congelati è stata os- 
servata una ridotta espressione del CD105 rispetto alle cellule fresche e l’assenza di 
espres- sione del CD166 (Fig. 6).
Immunocitochimica
È stata indagata l’espressione dei marker di pluripotenza: Oct-4, SSEA-4 e TRA 
1-60. Le AMCs hanno rivelato gli antigeni studiati, come mostrato nella Fig. 7.
Oct-4 è espresso nel citoplasma e nel nucleo mentre SSEA-4 e TRA 1-60 sono 
espressi sulla superficie cellulare come riportato in Fig. 7. L’espressione di TRA 
1-60 è risultata molto debole. La presenza combinata degli antigeni Oct-4, SSEA-4 
e TRA 1-60 attribuisce alle cellule amniotiche un fenotipo primitivo.
Gli stessi risultati sono stati ottenuti dopo scongelamento (dati non mostrati).
Istologia dell’allantoamnios
L’amnios e l’allantoide delle membrane fetali a termine sono caratterizzati ciascuno 
da uno strato epiteliale e da uno strato mesenchimale (Fig. 8). L’amnios è un unico 
tessuto privo di vasi sanguigni, costituito da cellule epiteliali cuboidali nello strato 
epiteliale (Fig. 9A) e da cellule stromali nello strato mesenchimale (Fig. 9B). Le 
cellule amniotiche epiteliali, sul versante esterno dell’amnios, sono a diretto 
contatto con il liquido amniotico.
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FIGURA 6 - Analisi con RT-PCR per l’espressione di specifici marker di mesenchi-
malità (CD105, CD29, CD166, CD44 e CD34) e di immunogenicità (MHC-I e MHC-
II) su AMCs prima e dopo crioconservazione. Il GAPDH è stato usato come gene
di riferimento.
tato dalla colorazione con Alcian Blue. Il con-
trollo ha dato esito negativo alla colorazione,
come atteso.
L’analisi dell’espressione dei marker condrogeni-
ci, COL2A1 e ACAN attraverso RT-PCR ha confer-
mato l’avvenuta induzione. Le cellule indotte al
differenziamento hanno mostrato un’aumentata
espressione di COL2A1 e ACAN rispetto al con-
trollo, che non ha mostrato l’espressione dei
marker. Il tessuto cartilagineo è stato usato co-
me controllo positivo di espressione dei marker
condrogenici.
Differenziamento neurogenico
Dopo 3 giorni di induzione, il differenziamento
neurogenico è stato confermato non solo dalla
morfologia assunta dalle cellule in piastra, ma an-
che dalla positività alla colorazione di Nissl. Le
AMCs hanno mostrato la tipica morfologia dei
neuroni con processi axon-like e dendrite-like e la
presenza dei processi primitivi tipici, come quelli
osservati nei neuroni. L’espressione del gene GFAP
ha indicato, però, che in queste condizioni di col-
tura le cellule amniotiche probabilmente sono sta-
te indotte a differenziare in cellule gliali per la
mancata espressione della nestina (NES).
Il GAPDH è stato impiegato come gene riferimento.
Le cellule scongelate sono state in grado di diffe-
renziarsi verso le stesse linee testate per le cellu-
le fresche isolate (dati non mostrati).
Analisi dei marker di espressione
attraverso RT-PCR
L’analisi RT-PCR ha permesso di evidenziare, a
differenti passaggi (a P1 e P5), la presenza degli
RNA messaggeri di marker specifici per le MSCs
(CD29, CD44, CD166, CD105) e l’assenza del
marker ematopoietico (CD34) (Fig. 6). Tuttavia, le
cellule hanno cominciato ad esprimere quest’ul-
timo marker a P5 (dati non mostrati). Le AMCs
hanno espresso l’antigene di immunoistocompa-
tibilità I (MHC-I) sino a P5, mentre non si è mani-
festata espressione dell’antigene di immunoisto-
compatibilità II (MHC-II) a P1, che si è espresso al
passaggio P5. Il GAPDH è stato usato come gene
di riferimento. Nei campioni congelati è stata os-
servata una ridotta espressione del CD105 ri-
spetto alle cellule fresche e l’assenza di espres-
sione del CD166 (Fig. 6).
Immunocitochimica
È stata indagata l’espressione dei marker di pluri-
potenza: Oct-4, SSEA-4 e TRA 1-60. Le AMCs han-
no rivelato gli antigeni studiati, come mostrato
nella Fig. 7.
Oct-4 è espresso nel citoplasma e nel nucleo
mentre SSEA-4 e TRA 1-60 sono espressi sulla su-
perficie cellulare come riportato in Fig. 7. L’espres-
sione di TRA 1-60 è risultata molto debole. La
presenza combinata degli antigeni Oct-4, SSEA-4 e
TRA 1-60 attribuisce alle cellule amniotiche un fe-
notipo primitivo.
Gli stessi risultati sono stati ottenuti dopo scon-
gelamento (dati non mostrati).
Istologia dell’allantoamnios
L’amnios e l’allantoide delle membrane fetali a ter-
mine sono caratterizzati ciascuno da uno strato
epiteliale e da uno strato mesenchimale (Fig. 8).
L’amnios è un unico tessuto privo di vasi sangui-
gni, costituito da cellule epiteliali cuboidali nello
strato epiteliale (Fig. 9A) e da cellule stromali nel-
lo strato mesenchimale (Fig. 9B). Le cellule amnio-
tiche epiteliali, sul versante esterno dell’amnios,
sono a diretto contatto con il liquido amniotico.
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FIGURA 7 - Presenza degli antigeni associati alla pluripotenza (Oct-4, SSEA-4 e
TRA-1-60) nelle cellule mesenchimali amniotiche equine. 20X. Scala: 20 micron.
FIGURA 8 - Morfologia delle membrane fetali equine a
termine (colorazione con ematossilina-eosina). (A) fo-
glietto amniotico epiteliale; (B) foglietto amniotico me-
senchimale; (C) foglietto allantoideo mesenchimale; (D)
foglietto allantoideo epiteliale. La regione di contatto tra
amnios e allantoide è mostrata dalla freccia. Si può osser-
vare la presenza di un vaso sanguigno nella parte allantoi-
dea della membrana.
FIGURA 6 - Analisi con RT-PCR per l’espressione di specifici marker di mesenchi-
malità (CD105, CD29, CD166, CD44 e CD34) e di immunogenicità (MHC-I e MHC-
II) su AMCs prima e dopo crioconservazione. Il GAPDH è stato usato come gene
di riferimento.
tato dalla colorazione con Alcian Blue. Il con-
trollo ha dato esito negativo alla colorazione,
come atteso.
L’analisi dell’espressione dei marker condrogeni-
ci, COL2A1 e ACAN attraverso RT-PCR ha confer-
mato l’avvenuta induzione. Le cellule indotte al
differenziamento hanno mostrato un’aumentata
espressione di COL2A1 e ACAN rispetto al con-
trollo, che non ha mostrato l’espressione dei
marker. Il tessuto cartilagineo è stato usato co-
me controllo positivo di espressione dei marker
condrogenici.
Differenziamento neurogenico
Dopo 3 giorni di induzione, il differenziamento
neurogenico è stato confermato non solo dalla
morfologia assunta dalle cellule in piastra, ma an-
che dalla positività alla colorazione di Nissl. Le
AMCs hanno mostrato la tipica morfologia dei
neuroni con processi axon-like e dendrite-like e la
presenza dei processi primitivi tipici, come quelli
osservati nei neuroni. L’espressione del gene GFAP
ha indicato, però, che in queste condizioni di col-
tura le cellule amniotiche probabilmente sono sta-
te indotte a differenziare in cellule gliali per la
mancata espressione della nestina (NES).
Il GAPDH è stato impiegato come gene riferimento.
Le cellule scongelate sono state in grado di diffe-
renziarsi verso le stesse linee testate per le cellu-
le fresche isolate (dati non mostrati).
Analisi dei marker di espressione
attraverso RT-PCR
L’analisi RT-PCR ha permesso di evidenziare, a
differenti passaggi (a P1 e P5), la presenza degli
RNA messaggeri di marker specifici per le MSCs
(CD29, CD44, CD166, CD105) e l’assenza del
marker ematopoietico (CD34) (Fig. 6). Tuttavia, le
cellule hanno cominciato ad esprimere quest’ul-
timo marker a P5 (dati non mostrati). Le AMCs
hanno espresso l’antigene di immunoistocompa-
tibilità I (MHC-I) sino a P5, mentre non si è mani-
festata espressione dell’antigene di immunoisto-
compatibilità II (MHC-II) a P1, che si è espresso al
passaggio P5. Il GAPDH è stato usato come gene
di riferimento. Nei campioni congelati è stata os-
servata una ridotta espressione del CD105 ri-
spetto alle cellule fresche e l’assenza di espres-
sione del CD166 (Fig. 6).
Immunocitochimica
È stata indagata l’espressione dei marker di pluri-
potenza: Oct-4, SSEA-4 e TRA 1-60. Le AMCs han-
no rivelato gli antigeni studiati, come mostrato
nella Fig. 7.
Oct-4 è espresso nel citoplasma e nel nucleo
mentre SSEA-4 e TRA 1-60 sono espressi sulla su-
perficie cellulare come riportato in Fig. 7. L’espres-
sione di TRA 1-60 è risultata molto debole. La
presenza combinata degli antigeni Oct-4, SSEA-4 e
TRA 1-60 attribuisce alle cellule amniotiche un fe-
notipo primitivo.
Gli stessi risultati sono stati ottenuti dopo scon-
gelamento (dati non mostrati).
Istologia dell’allantoamnios
L’amnios e l’allantoide delle membrane fetali a ter-
mine sono caratterizzati ciascuno da uno strato
epiteliale e da uno strato mesenchimale (Fig. 8).
L’amnios è un unico tessuto privo di vasi sangui-
gni, costituito da cellule epiteliali cuboidali nello
strato epiteliale (Fig. 9A)  da cellule stromali nel-
lo strato mesenchimale (Fig. 9B). Le cellule amnio-
tiche epiteliali, sul versante esterno dell’amnios,
sono a diretto contatto con il liquido amniotico.
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FIGURA 7 - Presenza degli antigeni associati alla pluripotenza (Oct-4, SSEA-4 e
TRA-1-60) nelle cellule mesenchimali amniotiche equine. 20X. Scala: 20 micron.
FIGURA 8 - Morfologia delle membrane fetali equine a
termine (colorazione con ematossilina-eosina). (A) fo-
glietto amniotico epiteliale; (B) foglietto amniotico me-
senchimale; (C) foglietto allantoideo mesenchimale; (D)
foglietto allantoideo epiteliale. La regione di contatto tra
amnios e allantoide è mostrata dalla freccia. Si può osser-
vare la presenza di un vaso sanguigno nella parte allantoi-
dea della membrana.
FIGURA 10 - Tre casi di lesioni tendinee prima e dopo trapianto di cellule mesenchimali allogeniche di derivazione amniotica.
Caso 1: lesione traumatica acuta del tendine flessore superficiale del dito (SDFT). Le freccie mostrano un’ampia area anecogena nell’ecografia in
sezione trasversale (A) e longitudinale (B). Le frecce in C e D mostrano un’omogenea area ecogenica rispettivamente nell’immagine ecografica
trasversale e longitudinale nella stessa lesione dopo 50 giorni dall’impianto.
Caso 2: lesio e sev ra del SDFT. Le frecce indicano un’area anecoica nell’ecografia in sezione trasvers le (A) e long tudinale (B), ed una leggera
area ipoecoica rispettivamente nella sezione trasversale (C) e longitudinale (D) della stessa lesione dopo 50 giorni dall’impianto.
Case 3: Lesione acuta del legamento accessorio del tendine flessore profondo (AL-DDFT). Le frecce mostrano un’area ipoecoica nell’ecografia in se-
zione trasversale (A) e longitudinale (B) e un’area ecogenica in sezione trasversale (C) e longitudinale (D) rilevabile dopo 50 giorni dall’impianto.
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Impianto delle MSCs nella
struttura teno-legamentosa
A seguito delle iniezioni intradermiche, effettuate
per valutare eventuali reazioni avverse, non si so-
no verificate alterazioni, quindi, dopo questa fase si
è proceduto agli impianti intralesionali.
I soggetti hanno ben tollerato gli impianti intrale-
sionali di cellule mesenchimali allogeniche isolate
da amnios equino. Non si sono verificate reazioni
algiche o infiammatorie. Si è verificata, inoltre, già
dai primi giorni, una sostanziale riduzione di volu-
me, una diminuita algia alla palpazione del tratto
i teressato ed un  significativa riduz o e del gra-
do di zoppia. Ad un primo controllo ecografico a
15 giorni si è evidenziata, in tutti i casi, una preco-
ce riduzione dell’area totale di sezione (T-CSA).
Specificatamente, nel caso 1 l’area anecoica rap-
presentativa della lesione è migliorata marcata-
mente. L’aspetto ecogenico e l’architettura tissu-
tale nella sezione longitudinale dell’ecografia rive-
lano un chiaro processo di evoluzione dopo un
periodo di 70 giorni (Fig. 10, caso 1 C, D).
Nel secondo caso la lesione anecoica che misura-
va 0,58 cm2 si è ridotta in n’area ipoe oica di
0,18 cm2 unitamente ad un aspetto soddisfacente
dell’architettura delle fibre in scansione longitudi-
nale dopo i primi 60 giorni (Fig. 10, caso 2 C, D).
Nel terzo caso un’acuta e severa lesione di 2,32
cm2 del legamento accessorio del tendine flessore
profondo delle falangi (AL-DDFT) presentava un
aspetto ecografico strutturato ed organizzato a
circa 60 giorni (Fig. 10, caso 3 C, D).
Inoltre, un follow up è stato condotto, dopo la ri-
presa dell’attività agonistica, in tutti i casi fino a 12
mesi dopo il trattamento e non sono state osser-
vate recidive.
FIGURA 9 - Sezione istologica della membrana amnioti-
ca con la regione epiteliale (A) e mesenchimale (B).
Im anto delle MSCs nella struttura teno-legamentosa A seguito delle 
iniezioni intradermiche, effettuate per valutare eventuali re zioni avv rs , non si so- 
no verificate alterazioni, quindi, dopo questa fase si è proceduto agli impianti 
intralesionali. I soggetti hanno ben tollerato gli i pianti intralesionali di cellule 
mesenchimali allogeniche isolate da amnios equino. Non si sono verificate reazioni 
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algiche o infiammatorie. Si è verificata, inoltre, giá dai primi giorni, una sostanziale 
riduzione di volume, una diminuita algia alla palpazione del tratto interessato ed una 
significativa riduzione del grado di zoppia. Ad un primo controllo ecografico a 15 
giorni si è evidenziata, in tutti i casi, una precoce riduzione dell’area totale di 
sezione (T-CSA). Specificatamente, nel caso 1 l’area anecoica rappresentativa della 
lesione è migliorata marcatamente. L’aspetto ecogenico e l’architettura tissutale 
nella sezione longitudinale dell’ecografia rivelano un chiaro processo di evoluzione 
dopo un periodo di 70 giorni (Fig. 10, caso 1 C, D).
Nel secondo caso la lesione anecoica che misurava 0,58 cm2 si è ridotta in un’area 
ipoecoica di 0,18 cm2 unitamente ad un aspetto soddisfacente dell’architettura delle 
fibre in scansione longitudinale dopo i primi 60 giorni (Fig. 10, caso 2 C, D). Nel 
terzo caso un’acuta e severa lesione di 2,32 cm2 del legamento accessorio del 
tendine flessore profondo delle falangi (AL-DDFT) presentava un aspetto 
ecografico strutturato ed organizzato a circa 60 giorni (Fig. 10, caso 3 C, D).
Inoltre, un follow up è stato condotto, dopo la ripresa dell’attività agonistica, in 
tutti i casi fino a 12 mesi dopo il trattamento e non sono state osservate recidive.
FIGURA 10 - Tre casi di lesioni tendinee prima e dopo trapianto di cellule mesenchimali allogeniche di derivazione amniotica.
Caso 1: lesione traumatica acuta del tendine flessore superficiale del dito (SDFT). Le freccie mostrano un’ampia area anecogena nell’ecografia in
sezione trasversale (A) e longitudinale (B). Le frecce in C e D mostrano un’omogenea area ecogenica rispettivamente nell’immagine ecografica
trasversale e longitudinale nella stessa lesione dopo 50 giorni dall’impianto.
Caso 2: lesione severa del SDFT. Le frecce indicano un’area anecoica nell’ecografia in sezione trasversale (A) e longitudinale (B), ed una leggera
area ipoecoica rispettivamente nella sezione trasversale (C) e longitudinale (D) della stessa lesione dopo 50 giorni dall’impianto.
Case 3: Lesione acuta del legamento accessorio del tendine flessore profondo (AL-DDFT). Le frecce mostrano un’area ipoecoica nell’ecografia in se-
zione trasversale (A) e longitudinale (B) e un’area ecogenica in sezione trasversale (C) e longitudinale (D) rilevabile dopo 50 giorni dall’impianto.
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Impianto delle MSCs nella
struttura teno-legamentosa
A seguito delle iniezioni intradermiche, effettuate
per valutare eventuali reazioni avverse, non si so-
no verificate alterazioni, quindi, dopo questa fase si
è proceduto agli impianti intralesionali.
I soggetti hanno ben tollerato gli impianti intrale-
sionali di cellule mesenchimali allogeniche isolate
da amnios equino. Non si sono verificate reazioni
algiche o infiammatorie. Si è verificata, inoltre, già
dai primi giorni, una sostanziale riduzione di volu-
me, una diminuita algia alla palpazione del tratto
interessato ed una significativa riduzione del gra-
do di zoppia. Ad un primo ontrollo ecografico a
15 giorni si è evidenziata, in tutti i casi, una preco-
ce riduzione dell’area totale di sezione (T-CSA).
Specificatamente, nel caso 1 l’area anecoica rap-
presentativa della lesione è migliorata marcata-
mente. L’aspetto ecogenico e l’architettura tissu-
tale nella sezione longitudinale dell’ecografia rive-
lano un hiaro processo di evoluzione dopo un
periodo di 70 giorni (Fig. 10, caso 1 C, D).
Nel secondo caso la lesione anecoica che misura-
va 0,58 cm2 si è ridotta in un’area ipoecoica di
0,18 cm2 unitamente ad un aspetto soddisfacente
dell’architettura delle fibre in scansione longitudi-
nale dopo i primi 60 giorni (Fig. 10, caso 2 C, D).
Nel terzo caso un’acuta e severa lesione di 2,32
cm2 del legamento accessorio del tendine flessore
profondo delle falangi (AL-DDFT) presentava un
aspetto ecografico strutturato ed organizzato a
circa 60 giorni (Fig. 10, caso 3 C, D).
Inoltre, un follow up è stato condotto, dopo la ri-
presa dell’attività agonistica, in tutti i casi fino a 12
mesi dopo il tra tam nto e non s no state osser-
vate recidive.
FIGURA 9 - Sezione istologica della membrana amnioti-
ca con la regione epiteliale (A) e mesenchimale (B).
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condrogenico e neurogenico, anche in seguito a
crioconservazione. Inoltre, per la prima volta, un
ulteriore obiettivo di questo studio è stato l’im-
piego di cellule mesenchimali allogeniche di deri-
vazione amniotica per il trattamento delle patolo-
gie dell’apparato muscolo-scheletrico nel cavallo.
MATERIALI E METODI
Tutti i reagenti impiegati in questa sperimentazio-
ne, se non diversamente indicato, sono stati acqui-
stati dalla Sigma Aldrich, Milano, Italia.
Raccolta della membrana
allanto-amniotica
Per questo studio sono stati lavorati cinque cam-
pioni di membrana amniotica prelevati al momen-
to del parto. I campioni sono stati posti a 4°C in
tampone fosfato salino privo di calcio e magnesio
(PBS, Euroclone, Milano, Italia), supplementato con
100 U/ml penicillina, 100 µg/ml streptomicina e
0,25 µg/ml amfotericina B e processati entro 12
ore dal prelievo.
La membrana amniotica, sottile e trasparente, è sta-
ta separata meccanicamente dall’allantoide vascola-
rizzata (Fig. 1) e sottoposta a digestione enzimatica.
Isolamento di cellule amniotiche
mesenchimali 
I frammenti di ogni campione di amnios sono stati
incubati per 9 minuti a 37°C in PBS contenente 2,4
U/ml dispasi (Becton Dickinson and Company, Mi-
lano, Italia). Dopo un periodo di 5-10 minuti a tem-
peratura ambiente in High Glucose - Dulbecco’s
Modified Eagle’s Medium (HG-DMEM; Euroclone),
addizionato con 10% di siero fetale bovino (FBS,
Fetal Bovine Serum) e 2 mM L-glutammina, i fram-
menti sono stati digeriti con 0,93 mg/ml collagena-
si tipo I e 20 µg/ml DNAsi (Roche, Mannheim,
Germany) per circa 3 ore a 37°C. Il prodotto del-
la digestione è stato filtrato utilizzando un filtro da
100 µm. Il filtrato è stato centrifugato a 200xg per
10 minuti per raccogliere le cellule mesenchimali
isolate. Queste cellule sono state denominate cel-
lule mesenchimali amniotiche (AMCs).
Il numero delle cellule vitali isolate è stato conta-
to mediante saggio di esclusione con il colorante
Trypan blue, usando la camera di Bürker. 
Coltura, espansione 
e conta cellulare
Successivamente all’isolamento, le AMCs sono
state seminate alla densità di 1x105 cell/cm2 e le
colture cellulari sono state mantenute con HG-
DMEM addizionato con 10% FBS, 10 ng/ml epi-
dermal growth factor (EGF), 100 U/ml penicillina,
100 µg/ml streptomicina, 0,25 µg/ml amfotericina
B e 2 mM L-glutammina.
Le colture cellulari sono state mantenute in incu-
batore ad un’atmosfera al 5% CO2 e 90% umidi-
tà, ed alla temperatura di 38,5°C per gli esperi-
menti descritti in seguito. Il terreno di coltura è
stato cambiato per la prima volta dopo 72 ore
dalla semina per eliminare le cellule non aderen-
ti. Il mantenimento delle colture cellulari ha pre-
visto la rimozione del terreno di coltura due vol-
te la settimana. 
Al raggiungimento di una confluenza pari a circa
l’80% della superficie della fiasca a passaggio 0 (P0)
la coltura primaria è stata espansa, staccando le
cellule dal fondo della fiasca con 0,05% tripsi-
na/0,02% EDTA in tampone fosfato (Euroclone) a
37°C per 2-3 minuti. 
Dopo la conta, la sospensione cellulare è stata ri-
distribuita in fiasche di coltura più ampie in rap-
porto 1:2 (P1) seminando circa 1x104 cell/cm2 al





Per l’analisi del DT è stata utilizzata la metodica
della conta seriale, cioè le cellule sono state con-
tate a passaggi successivi da P1 a P10. Per questo
scopo, le AMCs sono state seminate alla densità di
3x103 cell/cm2 ed il cambio di terreno è stato ese-
guito ogni tre giorni sino al raggiungimento di cir-
ca l’80% di confluenza, momento in cui le cellule
sono state tripsinizzate, contate e seminate alla
stessa densità.
Il DT è stato ottenuto a ciascun passaggio accor-
dandosi alle formule CD = log (Nf/Ni)/log2, e DT
= CT/CD, dove CD rappresenta il fattore di dupli-
cazione cellulare, Nf è il numero finale di cellule a
confluenza, Ni è il numero iniziale di cellule semi-
nate, CT rappresenta il tempo di mantenimento
della coltura.
Analisi delle unità formanti colonie
fibroblastoidi (CFU-F)
Per il test delle CFU-F, le AMCs sono state semi-
nate, subito dopo il loro isolamento (P0) a densi-
FIGURA 1 - La membrana amniotica è separata meccani-
camente dalla sovrastante membrana allantoidea. La frec-
cia indica il punto di sovrapposizione delle membrane.
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osteogenici BGLAP e OPN attraverso RT-PCR ha
confermato l’induzione osteogenica.
Differenziamento adipogenico
Le AMCs hanno mostrato la capacità di differen-
ziare nella linea adipogenica, come dimostrato dal
risultato positivo della colorazione con Red Oil O
effettuata dopo 3 settimane di coltura nel terreno
adipogenico. Le cellule mantenute nel terreno
standard non hanno mostrato depositi lipidici e,
quindi, la colorazione è risultata negativa. L’analisi
dell’espressione dei marker adipogenici PPAR-γ e
ADIPQ attraverso RT-PCR ha confermato l’indu-
zione adipogenica. Le cellule indotte al differenzia-
mento hanno rivelato un’aumentata espressione
di PPAR-γ e adiponectina rispetto al controllo. Il
tessuto adiposo è stato usato come controllo po-
sitivo di espressione dei marker adipogenici.
Differenziamento condrogenico
Le AMCs hanno mostrato la capacità di diffe-
renziare nella linea condrogenica, come è risul-
TABELLA 1
CFU-F per le AMCs a P0





Legenda: lettere diverse all’interno della stessa colonna indicano differenze stati-
sticamente significative per P<0,05.
FIGURA 5 - Differenziamenti nelle linee mesodermiche ed ectodermica confermate da colorazioni morfologiche ed
espressione genica dei geni specifici delle linee cellulari di induzione.
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9.4 Discussion
Terapie basate sul trapianto cellulare sono emerse come un nuovo potenziale 
approccio negli ultimi anni in svariati settori della medicina rigenerativa. Le MSCs 
possono essere isolate da molteplici tessuti e possiedono proprietà differenti, in 
base alla fonte di origine ed al loro grado di differenziamento. Le MSCs ottenute 
dal BM sono le più studiate e conosciute, come dimostrano i lavori scientifici 
dell’ultimo decennio (Digirolamo et al., 1999; Gronthos et al., 2003; Vidal et al., 
2011). Per tale motivo, esse sono anche le più utilizzate per la terapia rigenerativa 
tissutale ed, in particolare, in medicina veterinaria, per trattare le patologie 
dell’apparato muscolo-scheletrico e del sistema ematopoietico.
Le problematiche relative al prelievo ed alle caratteristiche delle cellule 
mesenchimali isolate da BM hanno portato, però, alla necessità di individuare nuove 
fonti di cellule staminali.
La recente scoperta in campo umano dell’esistenza di MSCs in annessi fetali, di 
facile accesso e privi di controversie etico-morali, rende queste cellule interessanti 
agli occhi dell’intera comunità scientifica e questo vale soprattutto per il fatto che 
questa popolazione cellulare si colloca in una posizione ontogenetica intermedia tra 
le ESCs e le cellule staminali adulte (Bajada et al., 2008; Siegel et al., 2007). Infatti, le 
cellule isolate da queste fonti, in campo umano, sono caratterizzate da 
proliferazione più rapida, una maggiore espansione in vitro, dall’espressione 
dell’enzima telomerasi (Mitchell et al., 2003) e da un notevole potenziale 
differenziativo, rispecchiando, quindi, i criteri di staminalità definiti dal Comitato 
delle cellule staminali.
È con questi obiettivi che è stato affrontato questo studio, nel quale, per la prima 
volta nella specie equina, la membrana amniotica a termine, che solitamente è 
scartata ed è di facile raccolta, è stata da noi considerata come una fonte alternativa 
di cellule con proprietà staminali in campo medico-veterinario. In medicina 
veterinaria, la membrana amniotica è usata in terapia clinica per la ricostruzione 
della superficie oculare come membrana in toto, ma a parte quest’uso non sono mai 
state ottenute cellule amniotiche dall’amnios equino per possibile uso terapeutico. 
In seguito a digestione enzimatica del tessuto amniotico, sono state isolate cellule 
amniotiche equine di natura mesenchimale che sono state espanse in coltura per 10 
passaggi, sono state caratterizzate, differenziate e, dopo inoculo nei siti di lesione, 
valutate per la loro potenzialità rigenerativa. Essendo questa una prima indagine 
conoscitiva su quest’invoglio fetale, è stato effettuato uno studio dettagliato relativo 
alla morfologia di questa membrana ed alla caratterizzazione delle sue cellule.
Dallo studio istologico è emerso che la membrana amniotica equina è composta da 
uno strato epiteliale e da uno stroma avascolare nel quale è presente una rete di 
cellule mesenchimali fibroblastoidi. Nelle nostre condizioni, dopo digestione, la 
vitalità iniziale delle cellule isolate è stata più alta del 75%, che è considerata un 
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ottimo valore della qualità a lungo termine di queste cellule sia in vista 
dell’efficienza di semina sia per la crescita cellulare. Durante le fasi di coltura, le 
cellule che sono rimaste adese alle piastre sono state espanse fino al passaggio P10 
ed i nostri risultati hanno dimostrato la presenza di un gruppo di cellule capaci di 
aderire tenacemente al substrato colturale e di proliferare intensamente in vitro.
Le cellule amniotiche equine, in generale, hanno dimostrato un’alta capacità 
proliferativa fino al 6°- 8° passaggio. Dopo questo periodo, la proliferazione è 
diminuita, anche se il DT si è attestato, comunque, a valori non superiori alle 48 
ore. Comunque, una robusta proliferazione fino al passaggio P6 è stata riportata 
anche da altri autori per le cellule amniotiche umane (Soncini et al., 2007; Miki et al., 
2010).
Le AMCs mantenute in coltura in alta densità hanno sviluppato strutture sferoidali 
senza mostrare inibizione da contatto. Queste strutture sferoidali si sono sviluppate 
tridimensionalmente al di sopra del monostrato e sono state descritte nella coltura 
delle ESCs (Miki e Strom, 2006) ed individuate anche da Carlin et al., (2006) nella 
coltura delle cellule della matrice del cordone di suino. Miki et al. (2005) hanno 
suggerito che il monostrato di cellule amniotiche, adese alla piastra di coltura, 
potrebbe giocare il ruolo di monostrato cellulare di sostegno autologo servendo 
come substrato per l’adesione del cluster o per fornire fattori che potrebbero 
indurre o mantenere indifferenziate le cellule amniotiche che costituiscono le 
strutture sferoidali.
Le cellule amniotiche in vitro hanno mostrato anche l’abilità di formare cloni, 
popolazioni omogenee di cellule generate da un unico capostipite. Questa 
caratteristica, definita clonogenicità, è un attributo essenziale delle cellule staminali le 
quali, contrariamente a quanto avviene con cellule differenziate, sono in grado di 
ripristinare in tempi brevi una popolazione di cellule uguali tra loro anche quando 
seminate a diluizioni estremamente elevate. La frequenza di formazione delle CFU-
F è aumentata con l’incrementare della densità di semina indicando l’esistenza di 
qualche segnale paracrino, fra le cellule amniotiche, che avrebbe potenziato la 
formazione delle CFU-F nella coltura primaria a P0 (Sarugaser et al., 2005).
Le cellule amniotiche equine hanno rivelato il caratteristico modello di espressione 
degli antigeni delle MSCs espanse in coltura. L’analisi è stata eseguita mediante RT-
PCR basata su un pannello di primer oligonucleotidici specificatamente disegnati 
sulla sequenza genica di questa specie. Il pannello di marker realizzato rappresenta 
un utile strumento nella ricerca delle cellule staminali equine, poiché molti 
anticorpi, marker di staminalità descritti nelle altre specie, mostrano poca o nulla 
reattività nella specie equina, rendendo così difficoltoso il loro utilizzo in questo 
campo. Queste cellule hanno manifestato positività ai più comuni marker che 
definiscono le MSCs: CD29, CD44, CD105, CD166 e MHC-I ma non MHC-II. La 
natura non ematopoietica delle cellule staminali è stata suggerita dalla mancata 
espressione del marker CD34 che ha iniziato ad esprimersi a P5. Quest’ultimo dato 
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potrebbe essere un’evidenza che le cellule amniotiche hanno un potenziale 
angiogenico così come è stato riportato in medicina umana da Alviano et al. (2007). 
A P5 anche il marker MHC-II ha iniziato ad essere espresso mentre il marker 
CD105 non era più espresso. La scarsa stabilità dei marker di superficie potrebbe 
indicare fenomeni epigenetici associati con la coltura cellulare che potrebbero 
influenzare le presunte cellule staminali amniotiche. Ulteriori caratterizzazioni di 
queste cellule saranno necessarie per comprendere meglio questi cambiamenti.
È importante sottolineare come l’assenza di espressione del marker MHC-II, 
almeno fino al quinto passaggio, renda queste cellule ipo-immunogene e, quindi, 
possibilmente utilizzabili nei passaggi precoci per terapie cellulari di tipo allogenico. 
In aggiunta ai caratteristici marker di superficie, le cellule amniotiche hanno 
mostrato immunopositività a Oct-4, TRA-1-60 e SSEA-4. Questi marker sono 
tipici delle ESCs, ma rilevati anche in altre popolazioni cellulari derivanti da annessi 
fetali quali il cordone ombelicale (Carlin et al., 2006; Hoynowsky et al., 2007), la 
membrana amniotica ed il liquido amniotico umani (Miki et al., 2005; Portmann-
Lanz et al., 2006; De Coppi et al., 2007; Ilancheran et al., 2007; Kim et al., 
2007;Wolbank et al., 2007). È stato ipotizzato che la presenza di popolazioni 
cellulari con tali caratteristiche possa essere messa in relazione ad uno stato di 
“primitività” del tessuto stesso e ad uno stadio cellulare privo di differenziamento, 
ma caratterizzato da pluripotenza (Miki et al., 2005; Portmann-Lanz et al., 2006; De 
Coppi et al., 2007; Kim et al., 2007; Ilancheran et al., 2007;Wolbank et al., 2007). Le 
nostre positività potrebbero ricalcare queste ipotesi. Lo studio del differenziamento 
in vitro suggerisce che queste cellule hanno fenotipo pluripotente, come supportato 
dalle differenziazioni nelle linee mesodermica ed ectodermica. In particolare, da 
questo lavoro emerge la capacità di queste cellule amniotiche di differenziarsi nelle 
linee osteogenica, adipogenica e condrogenica, come riportato da In’t Anker et al. 
(2004) per l’amnios umano, ma anche in cellule della linea gliale come mostrato da 
Miki et al. (2005) sempre in campo umano, dove il 95% delle cellule stromali 
amniotiche ha espresso immunolocalizzazione di GFAP. Osservando i dati relativi 
al potenziale proliferativo e differenziativo delle cellule amniotiche mesenchimali, si 
può pensare che questa membrana possa offrire vantaggi come una straordinaria 
fonte di presunte cellule staminali disponibili per i futuri sforzi nell’ambito della 
terapia cellulare. È per queste caratteristiche che ci è sembrato di notevole interesse 
un primo studio di queste cellule in vivo, per capirne gli eventuali meccanismi 
riparativi. Gli effetti benefici di queste cellule in questo test iniziale sottolineano il 
loro potenziale applicativo nella medicina rigenerativa veterinaria.
Attraverso studi di trapianto cellulare in vivo, abbiamo osservato che il trapianto 
allologo di cellule mesenchimali derivanti da amnios è ben tollerato dal cavallo e 
che tutti i dati clinici (riduzione dello spessore nelle dimensioni del tendine; 
sensibilità alla palpazione, misure delle aree delle sezioni trasversali nell’ecografia) 
forniscono completa evidenza nel supportare l’azione benefica delle cellule 
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iniettate. L’evoluzione ecografica riportata per l’architettura di tendini e legamenti è 
simile a quella che è stata precedentemente riportata dopo applicazione di altre 
colture cellulari multipotenti mesenchimali ed autologhe (Richardson et al., 2007). 
La possibilità di inoculo terapeutico immediato nelle lesioni di cellule che sono 
prontamente disponibili prima che ogni cambiamento ultrastrutturale avvenga, e 
l’effetto plastico dimostrato da queste cellule, rappresentano i maggiori aspetti di 
interesse di questo nuovo approccio biotecnologico nel campo delle tendinopatie 
nei cavalli. Ovviamente, questo studio non è stato un trial pre-clinico, ma un’analisi 
di scoperte preliminari ottenute con le cellule di derivazione amniotica nella specie 
equina. Inoltre, un punto debole di questo studio è la mancanza di un gruppo di 
controllo e di una valutazione istologica, quindi, ulteriori studi applicati ad un 
maggior numero di animali saranno necessari per confermare questi risultati.
Infine, abbiamo dimostrato che le cellule amniotiche equine possono essere 
congelate, conservate e recuperate senza la perdita della loro integrità funzionale in 
termini di morfologia, presenza di specifici marker e potenziale differenziativo, 
sebbene la capacità proliferativa sia stata più bassa di quella osservata nelle cellule 
fresche. Da questo punto di vista i protocolli di crioconservazione dovrebbero 
essere migliorati al fine di permettere la creazione di un servizio di banca cellulare.
9.6 Conclusions
Questo studio è il primo a documentare le caratteristiche di presunte cellule 
staminali isolate dalla membrana amniotica equina ed il loro uso in vivo. Questi 
risultati ci conducono a sviluppare protocolli d’isolamento che possano essere utili 
in futuro per ottimizzare la raccolta e l’espansione di queste cellule ai fini del loro 
utilizzo e ad ipotizzare la costituzione di riserve crio-preservate utilizzabili in 
medicina rigenerativa.
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10.1 Introduction
The employment of pre-puberal animals as oocyte donors gives the potential to 
shorten the generation interval and raise the genetic improvement rate by means of 
embryo transfer reproductive technology. Several studies in this field have shown 
that prepuberal oocytes can resume and complete the meiotic process after in vitro 
maturation (IVM) but lack competence to develop into normal embryos due to 
incomplete or retarded cytoplasmic maturation (Salamone et al. 2001). The 
ooplasm, indeed, plays a key role in the development of early bovine embryos as is 
evident in the biochemical discrepancies between the ooplasms of calf and adult 
oocytes: the altered synthesis and the different phosphorylation status of calf 
oocyte protein kinases can be considered as an example of the cytoplasmic 
dysfunction of these young oocytes (Taneja et al. 2000). Among the several options 
developed to allow the recovery of non-competent oocytes, the cytoplasmic 
transfer from in vitro and/or in vivo matured oocytes to a non-competent oocyte, 
has been proposed. This integration can be performed either by transferring small 
volumes of cytoplasm or by electro-fusion of two demi-oocytes, one bearing the 
carioplasm and the other the ooplasm, but, based on these techniques, no more 
than 50% of competent cytoplasm can be integrated. A further approach can be 
the replacement of the whole cytoplasm by means of germinal vesicle (GV) 
transfer: this procedure allows the GV of a non-competent oocyte to mature and 
terminate the first meiotic cycle within an ooplasm of a competent oocyte. In this 
work we perform the reconstruction of calf oocyte through its germinal vesicle 
transfer into the ooplasm of an adult bovine oocyte matured in vitro. The 
reconstructed oocyte is then subjected to the further steps of in vitro fertilization 
(IVF) and in vitro embryo culture (IVC).
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10.2 Materials and methods
Retrival of GV stage oocytes and in vitro matured oocytes. This procedure is based 
on the use of two distinct oocyte populations: adult bovine oocytes collected after 
slaughtering and assigned to IVM for 24 hours and calf oocytes collected at the 
GV stage. Four week old donor calves underwent a four day ovarian stimulation 
protocol by gonadotropin administration and oocytes were retrived by laparotomy 
under general anesthesia. Oocyte collections from calves were performed on the 
day when adult oocytes ended the IVM step. The mean collection rate (ratio 
between the number of aspirated follicles and the number of oocytes collected) 
was 87%. For the micromanipulation processing, both oocyte populations were 
decumulated by ialuronidase treatment (300 IU/ml) before germinal transfer could 
be performed.
GV transfer and calf oocyte reconstruction. GV stage calf oocytes and adult 
bovine oocytes at metaphase II stage were treated with cytochalasin and Hoechst 
33342 (5μg/ml), in order to make the plasma membrane more suitable to be 
micromanipulated and to locate the nucleus. The GV of each calf oocyte was 
transferred into the perivitelline space of an in vitro matured and enucleated adult 
bovine oocyte (Fig. 1). The fusion between the carioplasts and the ooplasms was 
performed in an electrofusion chamber in a suitable medium (0.3 M Mannitol, 0.1 
mM CaCl2 and 0.05 mM MgSO4 in H2O) with a double pulse (2KV/cm DC for 
30μs at 0.1 sec intervals).
Maturation, fertilization and embryo culture. After fusing, the reconstructed 
oocytes at the GV stage were allocated to IVM for 18–20 hours with the aim of 
completing the first meiotic division (Fig. 2). Afterwards, upon attainment of the 
metaphase II stage, the reconstructed oocytes were assigned to IVF and IVC (Fig. 
3).
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but, based on these techniques, no more than 50% of competent cytoplasm can be
integrated. A further approach can be the replacement of the whole cytoplasm by means of
germinal vesicle (GV) transfer: this procedure allows the GVof a non-competent oocyte to
mature and terminate the first meiotic cycle within an ooplasm of a competent oocyte. In
this work we perform the reconstruction of calf oocyte through its germinal vesicle transfer
into the ooplasm of an adult bovine oocyte matured in vitro. The reconstructed oocyte is
then subjected to the further steps of in vitro fertilization (IVF) and in vitro embryo culture
(IVC).
Materials and methods
Retrival of GV stage oocytes and in vitro matured oocytes. This procedure is based on the
use of two distinct oocyte populations: adult bovine oocytes collected after slaughtering and
assigned to IVM for 24 hours and calf oocytes collected at the GV stage. Four week old
donor calves underwent a four day ovarian stimulation protocol by gonadotropin
administration and oocytes were retrived by laparotomy under general anesthesia. Oocyte
collections from calves were performed on the day when adult oocytes ended the IVM step.
The mean collection rate (ratio between the number of aspirated follicles and the number of
oocytes collected) was 87%. For the micromanipulation processing, both oocyte
populations were decumulated by ialuronidase treatment (300 IU/ml) before germinal
transfer could be performed.
GV transfer and calf oocyte reconstruction. GV stage calf oocytes and adult bovine
oocytes at metaphase II stage were treated with cytochalasin and Hoechst 33342 (5µg/ml),
in order to make the plasma membrane more suitable to be micromanipulated and to locate
the nucleus. The GVof each calf oocyte was transferred into the perivitelline space of an in
vitro matured and enucleated adult bovine oocyte (Fig. 1). The fusion between the
carioplasts and the ooplasms was performed in an electrofusion chamber in a suitable
medium (0.3 M Mannitol, 0.1 mM CaCl2 and 0.05 mM MgSO4 in H2O) with a double
pulse (2KV/cm DC for 30µs at 0.1 sec intervals).
Maturation, fertilization and embryo culture. After fusing, the reconstructed oocytes at
the GV stage were allocated to IVM for 18–20 hours with the aim of completing the first
meiotic division (Fig. 2). Afterwards, upon attainment of the metaphase II stage, the
reconstructed oocytes were assigned to IVF and IVC (Fig. 3).
Fig. 1 Calf oocyte following GV
transfer. Original magnification
40×
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Parthenogenesis and IVM assessment of prepuberal oocytes. To set up the electrofusing
technique, oocytes were reconstructed, as described above, starting from ooplasms and GVs
collected from adult bovine oocytes which underwent all the IVM/IVF/IVC steps in order
to study some of the micromanipulation parameters such as the partenogenetic activation
and the polispermic rate after IVF. A further batch of prepuberal oocytes, assigned to IVM
just after collection, served as the control group.
Results
In the present study the percentage of oocytes reconstructed after GV transfer and
electrofusion was 76.34%. The maturation rate of the reconstructed prepuberal oocytes was
56%, the same as that observed in the case of the reconstructed adult oocytes, but
significantly different (p≤0.05) from the maturation rate of the control adult oocytes (80%)
and of the control prepuberal oocytes (37%). The cleavage rate observed for both
reconstructed oocyte populations was 40% and lower than that reported, on average, for
adult bovine oocytes (60%). Neither parthenogenetic or polispermic events were detected.
Fig. 2 Reconstructed calf oocyte
showing a polar body after at-
tainment of first meiotic division.
Original magnification 40×
Fig. 3 Two cell embryo from in
vitro fertilization of reconstructed
calf oocyte. Original
magnification 40×
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10.4 Discussion
Several, albeit differing data concerning the maturation and cleavage rates of calf 
oocytes, relatively to the donor age and to the experimental conditions adopted, are 
present in the scientific literature. In this preliminary work we demonstrated that 
our nuclear transfer technique is effective, that calf oocytes that have undergone 
GV transfer mature in vitro and can be fertilized, even if the maturation and the 
cleavage rates are still lower than those of adult bovine oocytes. A reason for this 
could be the lack of the selection of the calf oocytes used in the juvenile IVM/
IVF/IVC program as almost all of the oocytes collected, excluding the damaged 
ones, were used regardless of their quality, due to the scarcity and value of the 
oocytes retrivable from the calves. Another reason could be the absence of contact 
with the cumulus cells, necessary elements either for the maturation or the 
competence of embryonic development, that the oocytes are removed from by the 
micromanipulation step.
Our data are of interest for investigating the relationship between the ooplasm and 
carioplasm following electrofusion in view of the production of embryos from 
calves by standard in vitro procedures and could represent a way to enhance, in 
vitro, the competence toward embryo development of  juvenile calf  oocytes.
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